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1 INTRODUCTION 
 
1.1 Epidemiology of cancer 
There are several approaches for the definition of cancer. Cancer is defined by the 
American Cancer Society (ACS) as a „group of diseases characterized by uncontrolled cell 
proliferation, loss of function and spread of abnormal cells, which can lead to death“ 
(www.cancer.org). The World Health Organisation (WHO) defines cancer as „a generic 
term for a group of more than 100 diseases that can affect any part of the body and one 
feature of cancer is the rapid creation of abnormal cells which grow beyond their usual 
boundaries“ (www.who.int/cancer). The National Cancer Institute (NCI) describes cancer 
as „a term for diseases in which abnormal cells divide without control and can invade 
nearby tissues“ (www.cancer.gov). The NCI also differentiates between the main types of 
cancer. Carcinoma originates in the skin or in tissues that cover intestinal organs, 
Sarcoma begins in connective or supportive tissue and Leukemia starts in blood forming 
tissue. Another main cancer types are Lymphoma and multiple myeloma which originate 
in cells of the immune system. Central nervous system cancers begin in brain or spinal 
cord tissues (NCI 2011). 
Cancer is one of the major causes of death worldwide, second after cardiovascular 
disease in developed countries and third after cardiovascular and diarrheal diseases in 
developing countries (Garcia et al., 2007). Each year cancer is diagnosed in about 11 
million people worldwide and was responsible for over 7.9 million deaths in 2008 (WHO) 
and so the search for new therapeutics to treat this disease, remains an important target 
in research. 
Two different definitions are used to describe the occurrence of cancer in a population. 
The term incidence describes the number of new cases per 100 000 people per year and 
the term mortality defines the number of deaths per 100 000 people per year. Incidence 
and mortality do not necessarily correlate.  
Regarding incidence the most common cancers in women worldwide are breast, cervix 
and colorectal cancer. Breast cancer also has the highest mortality in women followed by 
lung, cervix and colorectal cancer. In men the most frequent cancer types are lung, 
prostate and colorectal cancer. Regarding mortality the most common cancers in men 
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worldwide are lung, stomach, liver and colorectal cancer. Thus, colorectal cancer is the 
third most frequent cancer type in both men and women, and the fourth most frequent 
cause of death worldwide (Fig. 1). 
 
Fig. 1: Incidence and mortality of the most common cancer types in women and men worldwide 
(Globocan 2011) 
 
In 2010 in Austria 48.1% of the women died due to cardiovascular diseases. The second 
common cause of death in women is cancer with 22.9%. Cardiovascular diseases are also 
in men the most common cause of death in Austria with 37.4%, followed by cancer with 
28.5% (Fig. 2). 
 
 
                                         Fig. 2: Cause of deaths in men and women in Austria                          
                                                            (adapted from: Statistik Austria, 2010) 
 
The distribution of cancer incidence and death in Austria is similar to the data worldwide. 
Regarding incidence and mortality, the most common cancers in women in Austria are 
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breast cancer, colorectal and lung cancer. In men prostate cancer, lung and colorectal 
cancer occur most frequently and exhibit the highest mortality as well (Fig. 3). 
 
Fig. 3: Incidence and mortality of the most common cancer types in women and men in Austria 
 
(Globocan 2011) 
 
1.2 Epidemiology of colorectal cancer 
Cancer originating in the colon or rectum is classified as colon cancer, rectal cancer or 
colorectal cancer.  
Almost 60% of the cases of colorectal cancer occur in developed countries with the 
highest incidence in Western Europe, Australia and New Zealand. The lowest incidence 
for this cancer type is in Africa with the exception of South Africa. The incidence rates as 
well as the mortality rates are higher in men than in women Fig. 4). 
The incidence of colorectal cancer increases in some countries historically at low risk like 
Spain and countries in Eastern Asia and Eastern Europe (Center et al., 2009). The reasons 
for this trend are probably the changes in the dietary pattern, increased obesity and also 
an increased prevalence for smoking (Jemal et al., 2011). In other countries like the 
United States or Australia the high incidence and mortality of colorectal cancer is 
stabilizing or declining (Center et al., 2009) as a result of increased awareness, early 
detection due to colorectal cancer screening programs and improved treatment (Edwards 
et al., 2010).  
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Fig. 4: Incidence and mortality of the colorectal cancer in women and men worldwide 
(Globocan 2011) 
 
The risk factors of colorectal cancer include obesity, physical inactivity, smoking and 
consumption of high amounts of red and processed meat as well as excessive 
consumption of alcohol (Ferrari et al., 2007; Boyle et al., 2008; Jemal et al., 2011).  
Each year approximately 5000 malignant tumors in the colon or rectum are diagnosed in 
Austria, representing 13% of all diagnosed cancers and about 2200 people die each year 
from colorectal cancer in Austria.  
Incidence, as well as mortality, is higher in Austrian men than in Austrian women. In the 
last decade both, the incidence and the mortality of colorectal cancer, decreased (Fig. 5) 
(Statistik Austria, 2011). This is probably the result of preventive actions like screening 
and the removal of precancerous lesions.  
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Fig. 5: Incidence and mortality of colorectal cancer in men and women in Austria 
(adapted from: Statistik Austria, 2010) 
 
1.3 Development of cancer – carcinogenesis 
Normal cells are under the constant influence of several signals regulating the behaviour 
of the cell. Cancer is characterised by dysregulation of these intercellular signalling 
mechanisms (Schulte-Hermann 2004). The term carcinogenesis describes the multistage 
process of development from a normal cell to a malignant cancer cell. This complex 
successive transformation involves changes at genetic and cellular levels to acquire the 
malignant characteristics (Fig. 6) (Stratton et al., 2009). 
 
 
 
Fig. 6: Carcinogenesis 
(Weinberg 2008) 
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Initiation – Promotion – Progression 
Carcinogenesis is known to follow a specific order described in the three stage model of 
carcinogenesis as follows: 
 
Initiation: Initiation is the first step of carcinogenesis. This rare and irreversible event 
occurs rapidly and only in proliferating cells. The outcome of initiation is a mostly genetic 
alteration that confers an advantage in proliferation compared to normal cells in the 
presence of tumor promotors and is passed on to the daughter cells. Initiation can occur 
spontaneously or due to replication mistakes or DNA lesions. The frequency for initiation 
is increased by DNA damaging exogenous agents such as chemicals like aflatoxin, 
polycyclic aromatic hydrocarbons, nitrosamine or arsenic, physical impacts like X-rays or 
UV-light and biological carcinogens such as human papilloma virus (HPV) or hepatitis B 
and C viruses. All these different agents can lead to damage in DNA, chromosomes or the 
genome (Reddy et al., 2003). Usually these defects are repaired by efficient DNA repair 
systems. As initiation is not reversible, mutations will be transmitted to the daughter 
cells. Often genes regulating cell growth and differentiation are affected by mutations, 
but initiation alone does not lead to tumor development (Schulte-Hermann 2004). 
 
Promotion: Promotion is the second step of carcinogenesis which needs to be maintained 
over a long period of time. It is considered to be a not gene-toxic and reversible process. 
When promotion stops, regression of neoplasia can be seen. Promoters can either 
activate growth signaling pathways or can lead to a decrease in apoptosis (Reddy et al., 
2003). Exogenous tumor promoters are over-nutrition, chronic inflammation or different 
environmental substances. Hormones such as estrogen and androgen, prostaglandins and 
growth factors like TGF-α are examples for endogenous tumor-promoting factors 
(Schulte-Hermann 2004). 
As initiation is an irreversible process, the occurrence of promotion after a long period 
after initiation, supports initiated cell growth and leads to cancer. But as promotion is a 
reversible process it does not necessarily lead to cancer when a long period of time lies 
between individual promoting events. Promotion alone is not able to achieve malignant 
transformation of initiated cells and produces mainly benign tumors (Fig. 7) (Kufe et al., 
2003). 
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                                                    Fig. 7: The interaction of initiation and promotion            
                                                                                (Kufe et al., 2003) 
 
Progression: The transition from a benign to a malignant tumor and the third stage of 
carcinogenesis is called tumor progression (Fig. 8) (Reddy et al., 2003). This stage is 
characterized by accumulation of further mutations, alterations in genes or in the repair 
mechanism of the cells. Genetic instability which can promote further mutations is 
essential for progression. The mutations affect different oncogenes and tumor suppressor 
genes. Oncogenes encode proteins that control cell proliferation and/or apoptosis (Croce 
2008) and promote cell growth. Tumor suppressor genes reduce the probability of the 
appearance of a tumor (Schulte-Hermann 2004; Weinberg 2007).  
 
 
 
Fig. 8: The multistage concept of carcinogenesis 
(modified from: http://www.hakeem-sy.com) 
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1.4 Hallmarks of cancer 
The hallmarks of cancer described by Hanahan and Weinberg consist of six biological 
capabilities acquired during the multistep development of human tumors (Hanahan and 
Weinberg 2011). These capabilities, needed to transform a normal cell into a cancer cell, 
include sustaining proliferative signalling, insensitivity to antigrowth signals, the ability to 
resist apoptosis, limitless replicative potential, sustained angiogenesis and tissue invasion 
and metastasis (Hanahan and Weinberg 2000) (Fig. 9). 
 
Fig. 9: The hallmarks of cancer 
(Hanahan and Weinberg 2000) 
 
1.4.1 Sustained proliferative signaling 
In normal cells the production and release of growth promoting signals is controlled 
carefully, but cancer cells are able to deregulate these signals of growth factors typically 
involving intracellular tyrosine kinase receptor domains (Hanahan and Weinberg 2011). 
But cancer cells can also acquire this capability to sustain proliferation in some alternative 
ways and may produce growth factors themselves (Bhowmick et al. 2004) or send signals 
to stimulate normal cells which supply the cancer cells with growth factors (Cheng et al., 
2008; Hanahan and Weinberg 2011). 
 
1.4.2 Evading growth suppressors 
In addition, cancer cells have to lose sensitivity to signals negatively regulating cell 
proliferation depending on inactivation of tumor suppressor genes in cancer cells 
(Hanahan and Weinberg 2011). One typical tumor suppressor encodes the 
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retinoblastoma associated protein which blocks proliferation and its signaling pathway 
(Hanahan and Weinberg 2000). Cancer cells often have a defect in the retinoblastoma 
pathway resulting in continuous cell proliferation. A second typical tumor suppressor is 
TP53 which receives the inputs from signals within the cell and can stop further cell cycle 
progression or trigger apoptosis. This tumor suppressor can be defect in tumor cells as 
well (Hanahan and Weinberg 2011). 
 
1.4.3 Resisting cell death 
Cell death or apoptosis is defined as programmed cell death and intracellular apoptotic 
signals lead to specific cell morphology characteristics and death of cells. Tumor cells 
evolve different strategies to limit or circumvent apoptosis e.g. by loss of function of the 
tumor suppressor TP53, by increasing the levels of anti-apoptotic proteins like BCL 2 or 
BCL-XL or by decreasing the levels of the pro-apoptotic proteins BAX or BIM (Hanahan 
and Weinberg 2011). 
 
1.4.4 Inducing angiogenesis 
Angiogenesis is defined as the formation of new blood vessels and is important for 
nutrient and oxygen supply to the tumor. During tumor progression angiogenesis is an 
essential step as soon as tumors exceed a diameter approximately 2mm. Activation is 
achieved by different stimulators of angiogenesis like vascular endothelial growth factor-
A (VEGF-A) or members of the fibroblast growth factor (FGF) family that are chronically 
upregulated in tumors (Baeriswyl and Christofori 2009; Hanahan and Weinberg 2000). 
The new blood vessels, produced within tumors, show abnormal characteristics like 
enlargement of vessels, aberrant blood flow, leakiness and excessive vessel branching 
(Nagy et al., 2010; Baluk et al., 2005). Angiogenesis also serves the tumor to metastasize, 
when single cancer cells enter the blood vessels and start a secondary tumor in another 
part of the body (Hanahan and Weinberg 2000). 
 
1.4.5 Enabling replicative immortality 
Cancer cells depend on an unlimited replicative potential in order to form big tumors 
(Hanahan and Weinberg 2000). Most established cancer cell lines have the ability to 
proliferate in culture without evidence of senescence or crisis (Hanahan and Weinberg 
2011). There is evidence that the induction of telomerase, which prevents the 
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chromosomal ends from shortening during replication, is involved in the capability for 
unlimited proliferation (Blasco 2005; Hanahan and Weinberg 2011). 
 
1.4.6 Activating invasion and metastasis 
Carcinomas from epithelial tissues develop alterations in their attachment to other cells 
and to the extracellular matrix resulting in higher pathological grades of malignancy. The 
best described alteration is the loss of E-cadherin by carcinoma cells. E-cadherin is a key 
cell-to-cell adhesion molecule and plays an essential role in the maintenance of 
intercellular contacts within epithelia (Hanahan and Weinberg 2011). The decline of E-
cadherin is known to potentiate invasion and metastasis (Berx and van Roy 2009). 
Development of metastasis causes 90% of human cancer deaths (Sporn 1996; Hanahan 
and Weinberg 2000). 
 
1.4.7 Enabling characteristics and emerging hallmarks of cancer 
The acquisition of these six hallmarks is made possible by chromosomal abnormalities 
leading to genetic instability and local chronic inflammation maintained by innate 
immune cells.  
In the last decade more research evidence suggested two additional hallmarks of cancer. 
The first emerging hallmark is the capability to reprogram the cellular energy metabolism 
in order to support the proliferation most efficiently. The second emerging hallmark is the 
evasion of immune destruction by T- and B-lymphocytes, natural killer cells and 
macrophages (Fig. 10) (Hanahan and Weinberg 2011).  
                                 
Fig. 10: The emerging hallmarks of cancer    
             (Hanahan and Weinberg 2011) 
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1.5 Carcinogenesis of colorectal cancer 
1.5.1 Anatomy of the colon 
The gastrointestinal tract consists of the upper and the lower part. The upper 
gastrointestinal tract consists of the mouth, the pharynx, the esophagus and the stomach. 
The lower gastrointestinal tract includes the small intestine, consisting of the duodenum, 
the jejunum and the ileum and the large intestine, consisting of the cecum, the colon, the 
rectum and the anal canal (Fig. 11). In mammals, the colon consists of the ascending 
colon, the transverse colon, the descending colon and the sigmoid colon. The ascending 
colon is the part of the colon from the cecum to the hepatic flexure where the transverse 
colon begins and leads into the descending colon at the splenic flexure. The part from the 
splenic flexure to the beginning of the sigmoid colon is called descending colon, where 
the stool is stored. The last part of the large intestine after the descending colon to the 
rectum is the sigmoid colon. The main function of the large intestine is storing waste, 
absorbing some fat-soluble vitamins, reclaiming water and maintaining the water 
balance. (http://hopkinscoloncancercenter.org). 
.  
Fig. 11: Anatomy of the large intestine 
(http://www.britannica.com/EBchecked/topic/330544/large-intestine) 
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1.5.2 Histopathology of the colon 
The gastrointestinal tract has a general histology consisting of 5 different layers. The inner 
layer surrounding the lumen of the gastrointestinal tract is the mucosa, an epithelial layer 
responsible for digestion and absorption of the nutrients. The second layer is the 
muscularis mucosa and the third layer is the submucosa. The submucosa consists of large 
mesenchymal cells and is rich in vessels and immune cells. The forth layer is called 
muscularis propria which consists of smooth muscle cells and moves the content of the 
colon. The outer fifth layer is the serosa (Thomson and Shaffer, 1994).  
The epithelium of the colon is rapidly renewing itself every four to six days. Stem cells at 
the bottom of the crypts are dividing continuously by a coordinated process of cell 
proliferation and differentiation. The new cells migrate towards the luminal surface 
where they undergo apoptosis (Fig. 12). A loss of the proliferation control in the crypt is 
the cause for colorectal cancer.  
 
Fig. 12: Depiction of colorectal stem cells and crypts 
(http://hopkinscoloncancercenter.org) 
 
1.5.3 Development of colorectal cancer 
Malignant transformations which lead to colorectal cancer occur mostly in the mucosa, 
where colorectal cancer usually starts as a benign polyp. Most of these hyperplastic 
polyps remain benign showing almost normal histopathology. However, these 
hyperplastic areas have an unusual high division rate leading to a thicker epithelia over 
time and to alterations in the morphology of the cells which is called dysplastic cells or 
adenoma. The higher the degree of dysplasia in an adenoma the higher is the risk of 
developing into a malignant carcinoma. 95% of colorectal cancers develop from 
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adenomas in this way. Polyps that grow into the colonic lumen on a stalk can be removed 
by colonoscopy to prevent progression to malign adenocarcinomas. They invade 
surrounding colon tissue and grow into the wall of the colon. In advanced stages the 
cancer cells metastasize and spread to other organs, mainly the liver (Fig. 13). 
(http://hopkinscoloncancercenter.org; Weinberg 2007). 
 
Fig. 13: Benign to malignant tumor progression 
(http://hopkinscoloncancercenter.org) 
About 10% of colorectal tumors occur in the transverse colon, 15% in the descending 
colon, 25% in the sigmoid colon, 30% in the ascending colon and about 20% in the rectum 
(http://hopkinscoloncancercenter.org). 
 
1.5.3.1 Hereditary colorectal cancer 
The tendency to develop colorectal cancers can be inherited (Kinzler and Vogelstein 
1996). Although about 60% of colorectal cancers are sporadic, there are different 
inherited conditions with a significant high risk of colorectal cancer (Fig. 14) like FAP, 
HNPCC, MAP and Hamartomatous Polyposis Syndromes. 
 
Fig. 14: Incidence of types of colorectal cancer 
(modified from: http://hopkinscoloncancercenter.org) 
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1.5.3.1.1 Hereditary non polyposis colorectal cancer (HNPCC) 
The Hereditary Non Polyposis Colorectal Cancer (HNPCC) is also known as the Lynch 
syndrome or the cancer family syndrome and is the most common form of inherited 
colorectal cancer responsible for about 5% of all colorectal carcinomas (Lynch et al., 
1996). Patients with HNPCC carry mutations in DNA mismatch repair genes (MMR) 
involved in growth regulation like TGF-β. In contrast to FAP patients, people with HNPCC 
do not develop many of polyps, but carcinogenesis progresses rapidly. These patients 
have an 80% risk to develop colorectal cancer in their life (Hisamuddin and Yang 2004, 
http://hopkinscoloncancer center.org). 
 
1.5.3.1.2 Familial adenomatous polyposis (FAP) 
Familial Adenomatous Polyposis (FAP), also called familial polyposis or Gardner’s 
syndrome, is a dominantly inherited disease that is characterized by the formation of 
hundreds of adenomatous polyps (Fig. 15) caused by a mutation on the APC gene (Groden 
et al., 1991; Stratte 2005) and is responsible for less than 1% of all colorectal cancers (see 
also chapter 1.5.5.1). 
          
Fig. 15: Comparison of the colon of a FAP patient (1) and a healthy colon (2) 
            (Weinberg 2007) 
 
1.5.3.1.3 MYH associated polyposis (MAP) 
The MYH Associated Polyposis (MAP) is a hereditary condition leading to the formation of 
multiple adenomatous polyps and an increased risk to develop colorectal cancer. The 
MYH gene is located on the short arm of the chromosome 1 and the MYH protein is 
essential for DNA damage repair (Jass 2005; Lipton and Tomlinson 2006). 
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1.5.3.1.4 Hamartomatous polyposis syndromes 
The Hamartomatous Polyposis Syndromes are a heterogeneous group of inherited 
disorders forming hamartomatous polyps leading to an increased risk for colorectal 
cancer. These group include syndromes like Juvenile Polyposis syndrome, Peutz Jeghers 
syndrome, Cowdens syndrome (Schreibmann 2005) with mutations in e.g. the PTEN or 
SMAD4 gene responsible for less than 1% of all colorectal tumors (Hisamuddin and Yang 
2004). 
 
1.5.3.2 Inflammation and colorectal cancer 
Inflammation is known to be an important tumor promotor. There is clear evidence about 
a connection between inflammatory diseases of the colon such as Morbus Crohn or 
ulcerative colitis and colorectal tumors. Colorectal cancers associated with inflammatory 
diseases seem to be based on an early mutation in p53 and fewer mutations in APC and 
K-Ras genes compared to sporadic tumors (Ilyas et al., 1999). 
 
1.5.3.2.1 Morbus Crohn 
Morbus Crohn is a chronic inflammatory disease of the intestinal tract. It is assumed to be 
an autoimmune disease, but the cause of this condition is still not known. Levels of TNF-α, 
interleukin-2 and interferon-γ are elevated due to chronic inflammation and patients 
suffering from Morbus Crohn have an increased risk to develop cancer (Freeman 2008). 
 
1.5.3.2.2 Ulcerative colitis 
Ulcerative colitis is a chronic inflammatory disease of the large intestine that is 
characterized by ulcers in the colon. The cause of this disease is not known as well, but 
patients suffering from this condition have an increased cancer risk (NDDIC 2011). 
 
1.5.3.3 Nutrition and colorectal cancer 
The incidence of cancer in developed countries as well as in developing countries is still 
increasing as a result of aging population on the one hand and different life style factors 
on the other hand (Jemal et al., 2011). As stated before, cancer can be caused by internal 
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factors such as immune conditions or inherited mutations, but only 5-10% of all cancers 
can be related to genetic defects, whereas all others are resulting from different lifestyle 
factors (Fig.16) (Anand et al., 2008) such as smoking, excessive alcohol consumption, 
infections, physical inactivity, obesity or an unbalanced diet. It is reported that 20-25% of 
all cancer related deaths are due to smoking, 15-20% are due to infection and almost 35% 
are due to the diet (Anand et al., 2008; Boyle and Levin 2008; Giovannucci and Wu 2006). 
Regarding colorectal cancer an unbalanced diet is reported to account for 80% of all cases 
(Reddy et al., 2003). 
The risk to develop colorectal cancer is closely related to an unbalanced diet and 
overnutrition. For obese men with an BMI higher than 30 a 2-fold and in obese women a 
1,5-fold increased risk of colorectal cancer was reported and the risk is reduced in 
physically active persons (McTiernan et al., 1998). There is also evidence, that the intake 
of red meat, processed meat or meat cooked at high temperatures, is related to a higher 
risk to develop colorectal cancer (Larsson and Wolk 2006). In meat prepared at high 
temperatures, heterocyclic amines and polycyclic aromatic hydrocarbons are produced 
and processed meat contains N-nitroso compounds, which are also known to be 
carcinogenic. The intake of red meat is associated with an increased risk of adenoma in 
the descending and sigmoid colon linked to two heterocyclic amines, 2-amino-3,8-
dimethylimidazo[4,5]quinoxaline and 2-amino-1-methyl-6-phenyl imidazo[4,5]pyridine as 
well as benzo(a)pyrene (Shina et al., 2005). Another risk factor is the consumption of high 
fat diets. Fatty acid hydroperoxides from unsaturated fatty acids are also assumed to be a 
risk factor of colorectal cancer (Jurek et al., 2005). 
 
  Fig. 16: The role of genes and environment in the development of cancer       
      (modified from: Anand et al., 2008) 
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In order to reduce the cancer risk a stop of smoking, exercise, reduction of the intake of 
alcohol and red meat, combined with an increased intake of fruits, vegetables and whole 
grains and regular medicinal check-ups are highly recommended (Anand et al., 2008). 
 
1.5.4 Staging of Colorectal Cancer 
Staging describes the extent of local growth and invasion of a cancer. Staging information 
is important to plan the treatment and serves as a prognostic factor. Tumors are classified 
according to evidence of invasion and tumor spread on which the aggressiveness of 
colorectal tumors are based. The size of the tumor is usually not of high importance for 
the outcome, but there is a close correlation between advanced stage and mortality. 
There are different systems for cancer classification. The first one established by Dr. 
Cuthbert Dukes has been modified and is now called the Astler-Coller modification of the 
Dukes’ classification (MAC) (Schölmerich 2005) (Fig. 17). 
 
Carcinoma in situ 
May be referred to a high grade dysplasia – an intramucosal 
carcinoma that does not penetrate the mucosae muscularis 
Stage A 
Tumors that invade through the mucosa muscularis into the 
submucosa but do not reach the muscularis propria 
Stage B1 Tumors that invade into the muscularis propria 
Stage B2 
Tumors that completely penetrate the smooth muscle layer into the 
serosa 
Stage C 
Tumors that encompass any degree of invasion but are defined by 
regional lymph node involvement 
Stage C1 
Tumors that invade the muscularis propria with fewer than four 
positive nodes 
Stage C2 
Tumors that completely penetrate the smooth muscle layer into the 
serosa with four or more involved nodes 
Stage D Lesions with distant metastases 
    
Fig. 17: Dukes’ classification (Astler-Coller modification) 
(http://hopkinscoloncancercenter.org) 
 
Nowadays the TNM classification of malignant tumors (Fig. 18) developed by the 
American Joint Committee on Cancer (AJCC), is frequently used for staging. The TNM 
Staging System is based on the size of the tumor (T), the extent of spread to the lymph 
nodes (N), and the presence of metastasis (M) (AJCC 2011).  
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T-category describes the size of the primary tumor and invasion into nearby tissue 
TX Primary tumor cannot be evaluated 
T0 No evidence of primary tumor 
Tis Carcinoma in situ (early cancer that has not spread to nearby tissue) 
T1-T4 Size and/or extent of the primary tumor 
N-category describes regional lymph node involvement 
NX Regional lymph nodes cannot be evaluated 
N0 No regional lymph node involvement 
N1-N3 Involvement of regional lymph nodes (number and extent of spread) 
M-category describes presence of Metastasis 
M0 No distant metastasis 
M1 Distant metastasis 
     
Fig. 18: TNM classification of malignant tumors 
(AJCC 2011) 
 
After determination of the T, N and M stage, an overall stage of I, II, III and IV is assigned 
as well. Stage I cancers are defined as the least advanced and have the best prognosis. 
Higher stage cancers are more advanced and most stage IV tumors are inoperable (AJCC 
2011). 
TNM Classification Dukes‘ Classification 
Stages T N M  
Stage 0 Tis N0 M0  
Stage I 
T1 N0 M0 A 
T2 N0 M0 B1 
Stage II 
T3 N0 M0 B2 
T4 N0 M0 B2 
Stage III 
T1, T2 N1 or N2 M0 C1 
T3, T4 N1 or N2 M0 C2 
Stage IV Any T Any N M1 D 
 
Fig. 19: Comparison of the TNM classification with the Dukes’ classification 
(http://hopkinscoloncancercenter.org) 
 
1.5.5 Genetic alterations in colorectal cancer 
Vogelstein and Fearon described a series of mutations responsible for colorectal 
carcinogenesis. They defined a preferred sequence of accumulation for these mutations 
regarding the histological changes of tumor progression (Vogelstein et al., 1988). They 
determined a loss of heterozygosity (LOH) in the long arm of chromosome 5 in many early 
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adenomas. The region on chromosome 5 affected by this loss of the normal function of 
one allele is carrying the APC (adenomatous polyposis coli) gene, a tumor suppressor 
gene. In larger adenomas a high rate of LOH on the long arm of chromosome 18 was 
proven and 50% of the carcinomas show additionally a loss of heterozygosity on the short 
arm of chromosome 17 which carries p53. A mutated K-ras oncogene was also detectable 
in about 50% of the adenomas (Fig. 20) (Vogelstein et al., 1988). These findings 
established the acceptance that the genetic modifications during carcinogenesis involve 
the activation of one proto-oncogen and the inactivation of at least three tumor 
suppressor genes, of which APC is always the first to be altered (Vogelstein et al., 1988; 
Weinberg 2007). 
 
Fig. 20: Genetic alterations during the colorectal cancer progression 
(modified from: Weinberg 2007) 
The prominent mutated genes responsible for development of colorectal cancer are 
adenomatous polyposis coli (APC) gene, K-RAS, p53, “Deleted in Colorectal Cancer” (DCC) 
gene and genes involved in TGF-ß response (Kinzler and Vogelstein 1996). 
 
1.5.5.1 Adenomatous polyposis coli (APC) gene  
The adenomatous polyposis coli (APC) gene, a tumor suppressor gene, is located on the 
long arm of chromosome 5 and plays an essential role in the early development of 
colorectal cancer. The APC protein helps to control proliferation and movements of cells 
and ensures that the chromosome number in cells is correct. β-catenin level is controlled 
by a complex containing the APC protein involved in the Wnt-pathway that induces rapid 
degradation of the protein. The most common and first mutation in colorectal cancer is 
the inactivation of APC which must be followed by other mutations to become malignant. 
In most colorectal cancers both alleles of the APC gene are inactivated (Nagase 1993). 
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APC is not expressed in the crypts of the colon but its level increases with the cells 
migrating upwards. Mutation of APC leads to an accumulation of β-catenin in the cells 
and the cells keep proliferating but do not differentiate while migrating upwards the 
crypt. When further migration becomes impossible due to the increased proliferation 
they develop an adenomatous polyp (Weinberg 2007). 
 
 
Fig. 21: The biology of colonic crypts and APC/ β-catenin 
(Weinberg 2007) 
 
In people carrying an APC inactivating mutation, the risk to suffer from colorectal cancer 
at the age of 40 is almost 100% (Markowitz and Bertagnolli 2009). The loss of APC 
functions seems to be the initiating mutation common to most human colorectal 
carcinomas. 
 
1.5.5.2 Kirsten – Ras (K-Ras) gene 
Members of the Ras family are GTPases and serve as key effectors of growth factors (Ross 
et al., 2001). Ras is involved in three important pathways: The Ras/Raf pathway controls 
cell proliferation, differentiation and apoptosis, the Ras/PI3kinase pathway modulates 
mainly apoptosis and the Ras/Ral pathway regulates membrane transport, cell migration, 
cell proliferation and apoptosis (Castagnola et al., 2005; Alberts 2002; Camonis et al., 
2005).  
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Ras is activated when GTP is bound to the protein and inactive when GDP is bound (Fig. 
22). Three different Ras genes (Kirsten-, Harvey- and Neuroblastoma-Ras) are known, but 
K-Ras is most frequently mutated in cancer. In approximately 10% of adenomas smaller 
than 1cm, about 50% of larger adenomas and even more of the colorectal carcinomas K-
Ras mutation have been determined resulting in the hyperactivation of Ras (Bos et al., 
1987; Vogelstein et al., 1988). This Ras mutation is not the initiating event in tumors, but 
its occurrence after APC mutation promotes carcinogenesis (Ross et al., 2001; Fearon and 
Vogelstein 1990; Weitz 2004). 
 
                                                               
Fig. 22: The regulation of Ras activity 
(Alberts 2002) 
 
1.5.5.3 p53 gene 
One of the most important tumor suppressor genes is p53 which is located on the short 
arm of chromosome 17 and obviously mutated and deleted in 70% of all sporadic 
colorectal cancers (Ilyas et al., 1999). p53 plays an important role in inducing cell cycle 
arrest, apoptosis and in inhibiting angiogenesis. DNA damage sensors like ATM activate 
p53 leading to a temporary cell cycle arrest in G1-phase (Grady 2004). If DNA damage 
cannot be repaired, p53 activates the apoptotic machinery (Miyashita 1994).  
Mutations of p53 are often accompanied by loss of heterozygosity. This mutation is rare 
in polyps, but frequent in carcinomas suggesting that it occurs later during carcinogenesis. 
Germ line mutations of p53 lead to the Li-Fraumeni syndrome which frequently leads to 
cancer in affected persons (Bartram 2004). Mutations on p53 leading to the loss its 
function occur mostly during the transition of a benign adenoma to an invasive malignant 
adenocarcinoma. 
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1.5.5.4 Deleted in colorectal cancer (DCC) gene 
The Deleted in Colon Cancer (DCC) gene is located on the long arm of chromosome 18 
and is one of the genes lost due to LOH during carcinogenesis. This has been shown in 
approximately 13% of the early adenomas and in around 70% of carcinomas (Vogelstein 
et al., 1988). DCC cannot lead to tumor formation, but is one of many reasons to promote 
existing tumor growth and is involved in the progression of a benign adenoma to a 
malignant carcinoma (Miyaki et al., 1990). 
 
1.5.5.5 Transforming growth factor beta (TGF-β) 
The Transforming Growth Factor Beta (TGF-β) signaling pathway consists of a sequence of 
tumor suppressor genes which possesses anti-proliferative activity and can induce 
apoptosis by triggering the SMAD or the DAXX pathway (Markowitz and Roberts 1996). In 
about 30% of colorectal tumors mutations of the TGF-β-receptor or the SMAD 
transcription factors lead to a loss of function as a tumor suppressor gene. Furthermore, 
TGF-β signaling is involved in tumor progression (White 1998). 
 
Fig. 23: The transforming growth factor  (TGF-) signalling pathway 
(http://journals.cambridge.org/fulltext_content/ERM/ERM5_05/S1462399403005684sup008.htm) 
 
1.6 The cell cycle 
The cell cycle is a complex process involving numerous regulatory proteins responsible for 
proliferation, the regulation of DNA damage repair and the replication of cells. (Schafer 
1998; Alberts et al., 2002).  
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It consists of four successive phases, the G1-, S-, G2- and M-phase (Fig.19). G0-phase is a 
resting state of cells that temporarily or permanently leave the cell cycle. Cells are 
growing in G1-phase which is the first gap from the end of the previous M-phase until the 
beginning of DNA synthesis. The replication of DNA resulting in two equal copies of each 
chromosome takes place in the S-phase. Then the cells enter the G2-phase preparing for 
the entry into mitosis (Garrett 2001) (Fig. 24). During M-phase the chromosomes are 
distributed equally and the cytoplasm is divided to the daughter cells. Mitosis consists of 
six stages, the prophase, pro-metaphase, metaphase, anaphase, telophase and 
cytokinesis. In prophase the chromosomes condense and the cytoskeleton begins to 
reorganize. During pro-metaphase the condensed chromosomes connect to the 
microtubules. At metaphase the mitotic spindle is formed and during anaphase the sister 
chromatids of the chromosomes separate and migrate to the poles of the cell. During 
telophase the chromosomes at the two poles of the cell start to decondense and an 
envelope reforms around the new chromosomes (Garrett 2001). 
The activation of each phase of the cell cycle is dependent on the correct progression and 
completion of the previous phase regulated by different proteins. 
 
Fig. 24: The cell cycle and cell cycle regulation 
(modified from: Garrett 2001) 
 
1.6.1 Cell cycle regulation 
There are two classes of regulatory proteins, the cyclins and the cyclin-dependent kinases 
(CDKs), necessary for the regulation of cell cycle progression (Nigg 1995). The CDKs are 
the key regulatory proteins and cause modifications in the phosphorylation of proteins 
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important for the regulation of cell cycle events and are controlled by the cyclins (Alberts 
et al., 2002). Cyclins have no catalytic activity but are the activating regulatory domains of 
their partner cyclins. The protein levels of CDKs remain stable during cell cycle 
progression, but the protein levels of cyclins rise and fall during cell cycle as different 
cyclins are required at different time points of the cell cycle (Vermeulen et al., 2003). 
Cyclin D and E are mainly expressed in G1-phase, cyclin A in S-phase and cyclin B is 
required in M-phase. Cyclin E also plays an important role in G1- to S-phase transition and 
cyclin A in G2- to M-phase transition. Cyclin D binds to CDK4 and CDK6 and cyclin E 
activates CDK2. Cyclin A associates with CDK2 to initiate the DNA replication and with 
CDK1 regulating the entry into mitosis. Cyclin B forms complexes with CDK1 to further 
promote mitosis (Fig. 25) (Vermeulen et al., 2003; Sanchez and Dynlacht 2005). 
 
Fig. 25: Overview of some essential steps in cell cycle regulation 
(Vermeulen et al., 2003) 
Restriction points and checkpoints are the quality control of cell cycle progression. The 
restriction point is the „point of no return“ in G1-phase when the cell enters the cell cycle 
(Vermeulen et al., 2003). At checkpoints the cell cycle is arrested in response to e.g. DNA 
damage until the damage is repaired. One DNA damage checkpoint is positioned before 
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entering the S-phase (G1-S-checkpoint) and is p53 dependent. DNA damage recognized 
by different protein kinases like ATM and ATR, leads to an increase in the levels of p53, 
which stimulates different repair mechanisms and results in CDK inhibition and cell cycle 
arrest (Ko and Prives 1996; Vermeulen et al., 2003). 
As mitosis is an irreversible process, the completion of DNA replication and the absence 
of genomic lesions are crucial criteria that must be met for the cell to enter mitosis 
(Tapia-Alveal et al., 2009). Therefore the second important DNA damage checkpoint is 
positioned after DNA replication (G2-M-checkpoint). At this point of the cell cycle arrest 
can be p53 dependent or p53 independent. The entry into mitosis is prevented by the 
protein kinases Chk1 and Chk2 which phosphorylate Cdc25 and the CDK1-cyclin B 
complex will not be activated. 
Chk1 and Chk2 are the checkpoint effector kinases necessary for the cell cylce arrest at 
the G2-M-checkpoint. They get phosphorylated and activated by ATM and ATR in 
response to diverse genotoxic insults including DNA crosslinks, stalled replication forks or 
radiation damage (Stracker et al., 2009). Chk2 is expressed in all cell cylce phases (Lukas 
et al., 2001) and is activated mainly by ATM. Chk1 is largely in S and G2-phase and mainly 
activated by ATR (Bartek and Lukas 2003). 
 
 
1.6.2 Cell cycle and cancer 
Common features of tumors are genetic mutations that allow them to proliferate outside 
their normal growth restraint. In cancer cells mutations affect predominantly proto-
oncogenes and tumor suppressor genes (Vermeulen et al., 2003). A number of these 
genes are important in cell cycle checkpoints and DNA-damage recognition (Garrett 
2001). Important examples are mutations in genes affecting Cdks, cyclins and checkpoint 
proteins (McDonald and Deiry 2000). Especially mutations in checkpoint proteins are 
frequent in all types of cancer. The tumor suppressor gene p53 is able to induce cell cycle 
arrest or apoptosis and is known to be the most frequently mutated gene in human 
cancer (Vermeulen et al., 2003).  
The cell cycle is therefore an attractive target for the development of novel anti-cancer 
agents. An example of therapeutically targeting the cell cycle, are cyclin-dependent kinase 
(Cdk) inhibitors. Flavopiridol, a flavonoid isolated from the Indian plant Dysoxylum 
binectariferum Hook F., is reported to inhibit Cdk1 and Cdk2 (Raju et al., 2003). Other 
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compounds such as roscovitine and butyrolactone inhibit CDK4. Staurosporine, a 
microbial alkaloid, is an inhibitor of CDK1 (Vermeulen et al., 2003; Schwartz and Shah 
2005). 
 
1.7 Cell death 
It is possible to discriminate up to 12 pathways of cell death occurring in mammals (Fig. 
26), 10 of which are genetically programmed. The different types of cell death are: 
necrosis, apoptosis, anoikis, caspase-independent apoptosis, autophagy, Wallerian 
degeneration (WD), excitotoxicity, erythropoiesis, platelets, cornification, lens and mitotic 
catastrophe. Apoptosis, autophagy or cornication are best known among the genetically 
programmed forms of cell death, but necrosis or mitotic catastrophe which are not 
genetically programmed lead to cell death as well (Melino et al., 2005). 
 
Fig. 26: Different types of cell death 
(Melino et al., 2005) 
 
Necrosis occurs predominantly in pathological conditions and is the end point of very 
severe damage, resulting in a loss of membrane integrity, swelling and disrupture of the 
cells. The cellular contents are released into the cells environment leading to a strong 
inflammatory response (Leist and Jaattela 2001). Necrosis can be secondary to apoptosis. 
(Melino et al., 2005). 
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1.7.1 Apoptosis 
Apoptosis is a programmed cell death which occurs in response to physiological signals 
during embryonic development, in maintenance of homeostasis in multicellular 
organisms or to eliminate dysfunctional cells (Norbury and Hickson 2001). Apoptosis is 
strictly regulated and can be recognized by morphological modifications such as cellular 
shrinking, cell deformation and loss of contact to neighbouring cells. The chromatin 
condenses, marginates at the nuclear membrane and the cell membrane starts to show 
protrusions (blebs). The process of entire cell condensation and fragmentation into 
apoptotic bodies is called budding. The apoptotic bodies are engulfed by macrophages 
and removed from the tissue without causing an inflammatory response (Fig. 27) 
(Kurosaka et al., 2003; Häcker 2000; Saraste and Pulkki 2000; Elmore 2007). 
 
 
 Fig. 27: Comparison of apoptosis and necrosis  
       (modified from: Van Cruchten et al., 2002) 
 
Dysfunction of the apoptotic machinery is involved in a variety of diseases, especially in 
cancer cells the balance is shifted towards uncontrolled cell proliferation. 
 
 
Mechanisms of apoptosis: Apoptosis can be triggered through an intrinsic or an extrinsic 
pathway both leading to activation of caspases. The intrinsic pathway is initiated by death 
signals within the cell. Pro-apoptotic proteins like BAX and BAK are up-regulated, resulting 
in the release of cytochrom C from the mitochondria into the cytosol. Caspase 9, an 
initiator caspase, is activated and cleaves and activates caspase 3, an effector caspase, 
leading to apoptosis. 
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The extrinsic pathway is initiated by extracellular signals. A death-ligand binds to death-
receptors like Fas and the initiator caspase 8 is activated leading to further activation of 
caspase 3 which is followed by apoptosis (Fig. 28) (Elmore 2007). 
 
 
Fig. 28: The intrinsic and extrinsic pathway of apoptosis 
(Pai et al., 2006) 
 
Caspases are cysteine proteases with an important role in the apoptotic machinery. They 
can be divided into two groups, the initiator and the effector caspases. Caspase 3, an 
effector kinase, is only activated in cells during apoptosis (Peng et al., 2004). After 
proteolytic activation of caspase 3 from its proenzyme form, it cleaves various protein 
substrates during apoptosis such as poly(ADP-ribose) polymerase (PARP) (Shin et al., 
2000; Nicholson et al., 1995; Kaufmann et al., 1993). Caspase 6 and 7 also belong to the 
group of the effector caspases. Initiator caspases are caspase 8, 9 and 10. These caspases 
are auto-activated in a signal-dependent manner and are responsible for activation of the 
effector caspases.  
Caspase 2 has features of both groups (Zhivotovsky and Orrenius, 2005), but unlike 
initiator caspases, caspase 2 does not directly activate effector caspases (Bouchier-Hayes 
2010). The function of caspase 2 in apoptosis seems to be stimulus- and/or cell type 
specific (Bergeron et al., 1998). There is evidence for potential roles of caspase-2 in non-
apoptotic processes, including DNA repair and cell cycle regulation (Vakifahmetoglu-
Norberg and Zhivotovsky 2010). 
The BCL 2 family serves a central function in apoptosis and is divided into a pro- and an 
anti-apoptotic subfamily. Specifically, BAX and BAK are pro-apoptotic proteins and 
operate at both the mitochondria and endoplasmic reticulum to regulate the intrinsic 
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apoptotic pathway (Ruiz-Vela et al., 2005; Oltvai et al., 1993). BCL-XL and BCL 2, members 
of the anti-apoptotic sub-family and play an important role in inhibiting mitochondria-
dependent cell death pathways (Kim 2005).  
The apoptotic machinery is an important target in research for the development of new 
cancer therapeutics capable of killing continuously proliferating cells or restoring the 
normal growth rate of the cells. 
 
1.7.2 Mitotic catastrophe 
There still exists no broadly accepted definition of mitotic catastrophe (Niida et al., 2005). 
The term mitotic catastrophe is used to describe cell death that occurs during or after 
incorrect mitosis characterized by formation of large cells that contain multiple or 
polyploid nuclei, but the mechanisms of regulation and the signals involved are barely 
characterized (Portugal et al., 2010).  
It has been discussed that mitotic catastrophe is totally different from apoptosis (Fig. 29) 
(Roninson et al., 2001) because some manipulations preventing apoptosis, such as 
overexpression of BCL 2, enhance the frequency of catastrophic mitoses (Lock and 
Stribinskiene 1996; Ruth and Roninson 2000; Castedo et al., 2004). But in fact there is no 
clear line between apoptosis and mitotic catastrophe. The latter can also be accompanied 
by the release of pro-apoptotic proteins and caspase activation (Portugal et al., 2010). 
Most examples of mitotic catastrophe seem to be characterized by the activation of 
caspase 2. The treatment of human breast carcinoma cells with doxorubicin, one of the 
most effective anti-tumor drugs ever developed, induces polyploidy and cell death by 
mitotic catastrophe and activation of caspase 2 (Mansilla et al., 2006). HCT116 colon 
carcinoma cells treated with doxorubicin undergo mitotic catastrophe as well (Chan et al., 
1999; Castedo et al., 2004). 
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Fig. 29: Summary of several pathways of cell death 
(Portugal et al., 2010) 
 
Several other anti-cancer drugs as well as ionizing radiation are known to induce mitotic 
catastrophe (Portugal et al., 2010). For a long time apoptosis was considered to be the 
key mechanism of cell death in drug-treated cancer cells (Brown and Attardi 2005; Abend 
2003). But mitotic catastrophe might be the main mechanism of tumor selectivity in the 
search for new anti-tumor agents since cell death by mitotic catastrophe showed a more 
intense and longer lasting effect in vivo (Portugal et al., 2010; Roninson et al., 2001). 
Another advantage of mitotic catastrophe in treatment could be that it is not regulated 
via p53, as this protein is frequently mutated in malignant tumor cells (Ianzini et al., 2006 
and 2007). Apoptosis is regulated by wild-type p53 and frequently inactivated due to a 
non-functional p53 protein (Levesque and Eastman 2007). Another advantage is, that in 
contrast to apoptosis, mitotic catastrophe is enhanced by some changes during the 
development of the tumor (Portugal et al., 2010). 
 
1.8 Traditional medicine 
There is evidence in fossils that humans used plants as medicine at least from the Middle 
Paleolithic age (Solecki and Shanidar 1975). The best known and still used traditional 
medicines are Ayurveda, the traditional Indian medicine, and the traditional Chinese 
medicine (TCM). In the last decades there has been an increased interest in traditional 
medicine (Patwardhan et al., 2005). Ethnomedicine or traditional medicine may be 
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defined as the use of plants by humans as herbal remedies, but literally it is a broad term 
used to define any non-Western medical practice (Farnsworth 1994; Bannerman et al., 
1983). For almost 65% of the world’s population traditional medicine is their primary 
modality of health care (Farnsworth et al., 1985). 
Ethnopharmacology is a highly manifold approach to drug discovery involving the 
observation, description and experimental investigation of indigenous drugs and their 
biological activities. It is based on botany, chemistry, biochemistry and pharmacology 
(Rivier and Bruhn 1979; Fabricant and Farnsworth 2001). 
Plants are used as sources of therapeutic agents to isolate bioactive principles for direct 
use as morphine, quinine or taxol on the one hand and on the other hand to find novel 
structures as lead compounds for semisynthesis like metformin, nabilone or taxotere. 
Another option is to use plant extracts as herbal remedies like echinacea or ginkgo biloba 
(Fabricant and Farnsworth 2001). 
 
1.9 Natural products as sources of new drugs 
Plants used in traditional medicine are a rich source for novel compounds for the 
development of new drugs (Kim and Park 2002). Numerous drugs have entered the 
international pharmacopoeia via the study of traditional medicine (Fig. 30) (Patwardhan 
2009).  
  
 
Fig. 30: Drugs developed from natural sources 
(selected compounds from: da Rocha et al., 2001) 
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From 1984 to 1995 over 60% of the newly approved drugs were of natural origin. Drugs of 
natural origin have been classified into original natural products, products derived 
semisynthetically from natural products, synthetic products based on natural product 
models (Cragg et al., 1997) and natural product mimics (Newmann and Cragg 2007). The 
figures of approval of new chemical entities (NCE) demonstrate that natural products are 
still involved in about 50% of all small molecules in the years 2000 to 2006 (Fig. 31) 
(Newmann and Cragg 2007).  
 
 
Fig. 31: All new chemical entities 
(modified from: Newman and Cragg 2007) 
 
 
1.9.1 Natural products as sources of new anti-cancer therapeutics 
The chemical diversity of millions of species of plants, microorganisms and marine 
organisms is an attractive source of new therapeutic agents in cancer research (da Rocha 
et al., 2001) In the field of cancer research around 50% of the drugs in current use are of 
natural origin (see Fig. 32) (Newmann and Cragg 2007). 
      
 
Fig. 32: All available anti-cancer drugs from 1940-2006 
(modified from: Newman and Cragg 2007) 
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Especially plant species with the capacity to defend themselves against potential 
predators and inhibit other plants competing for space to grow with numerous chemical 
substances are a very rich source for new cytotoxic compounds (da Rocha et al., 2001). 
The immense variety of secondary metabolites isolated from plants has been source of 
important pharmaceutical compounds (HemaIswarya and Doble 2006). 
 
1.9.1.1 Alkaloids 
From the ancient medicinal plant Catharanthus roseus G. Don. (Apocynaceae) the very 
potent cytotoxic compounds vinblastine and vincristine were isolated (da Rocha et al., 
2001). These substances and several structural relatives like vinorelbine and vindesine are 
used for a long time to treat childhood leukaemia, testicular cancer, Hodgkin’s disease 
and several other cancers (Mann 2002; Cragg and Newman 2005).  
Another class of clinically active anti-cancer agents derived from camptothecin isolated 
from Camptotheca acuminata Decne (Nyssaceae) (Rahier et al., 2005). The effective 
derivatives are topotecan, which is used for the treatment of ovarian and small cell lung 
cancers, and irinotecan, which is used to treat colorectal cancers (Cragg and Newman 
2005). Elliptinium, a derivative of the alkaloid ellipticine, was isolated from different 
species of the Apocynaceae family and is marketed in France for the treatment of breast 
cancer (Cragg and Newman 2005). 
The most important anti-cancer drug isolated from the bark of Taxus brevifolia Nutt. is 
paclitaxel or Taxol (Fig. 33) which is used to treat refractory breast and ovarian cancers 
and non-small lung cancer and is, at present, the bestselling anticancer drug. From Taxus 
baccata L. a related chemical structure, 10-deacetylbaccatin, could be isolated which can 
be converted easily into taxol and another even more potent analogue, docetaxel or 
taxotere, which is used to treat non-small lung cancer and breast cancer (Mann 2002). 
Additionally, 23 taxanes are in preclinical development as potential anti-cancer drugs 
(Cragg and Newman 2005). 
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Fig. 33: Plant derived anti-cancer agents 
(da Rocha et al., 2001 and Cragg and Newman 2005) 
 
1.9.1.2 Lignans 
Native Americans already used extracts from the roots of Podophyllum peltatum L. 
(Podophyllaceae) to treat skin cancers. Later, the main constituent of this plant was 
identified as podophyllotoxin, which is the precursor of the podophyllins, a group of 
anticancer agents, which includes etoposide and teniposide (da Rocha et al., 2001) (Fig. 
33). Etoposide, the glycoside of the lignan podophyllotoxin, is in regular use for the 
effective treatment of testicular teratoma and small-cell lung cancer and teniposide is 
effective against acute lymphocytic leukaemia and neuroblastoma in children and against 
non-Hodgkin’s lymphomas and brain tumours in adults (Mann 2002).  
 
1.9.1.3 Flavonoids 
In different studies the intake of certain polyphenols such as flavonoids and lignans in the 
diet was correlated with low incidence of colorectal cancer (Taraphdar et al., 2001). 
Dietary flavonoids are known to be antiproliferative and may play an important role in 
cancer chemoprevention, especially for cancers of the gastrointestinal tract. Two potent 
dietary flavonoids, quercetin and genistein, induced apoptosis in colon cancer cells and 
genistein inhibits angiogenesis and cell-cycle progression (Taraphdar et al., 2001; 
HemaIswarya and Doble 2006; Richter et al., 1999; Kaindl et al., 2008). 
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Tangerine peel, with its main flavonoid tangeretin, is used in Japan in Kampo medicines 
for treatment of cancer. Tangeretin blocks cell cycle progression and inhibits cancer cell 
growth through induction of apoptosis (Taraphdar et al., 2001). Another flavonoid, 
baicalein, contained in the Japanese herbal medicine sho-saiko-to, inhibits the activity of 
topoisomerase II and induces apoptosis in different cell lines (Matsuzaki et al. 1996; 
Taraphdar et al., 2001). 
 
1.9.1.4 Xanthones 
Some prenylated xanthones possess anti-cancer activity against MCF-7 and NCI-H460 cell 
lines (Castanheiro et al., 2009) as well as against HeLa and MDA-MB-231 cancer cell lines 
(Lim et al., 2011). α-Mangostin, the best studied prenylated xanthone isolated from 
Garcinia mangostana Linn., induces cell-cycle arrest in G1 and induce apoptosis through 
the activation of intrinsic pathway in human colon cancer DLD-1 cells (Matsumoto et al., 
2005; Akao et al., 2008).  
 
An ideal anti-cancer agent should have little or no toxicity related to cell necrosis, show 
high efficacy in multiple sites with a known mechanism of action, be capable of oral 
consumption, low in cost and have a high acceptance (Rajamanickam and Agarwal 2008). 
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2 AIMS OF THE THESIS 
 
Cancer therapy is one of the most addressed issues in drug discovery and natural 
products and their structural relatives are an important source of novel anticancer agents, 
providing over 50% of the drugs in present clinical use (Newman and Cragg 2007). The 
chemical diversity of plants and the great variety of secondary metabolites are an 
attractive source of new pharmaceutical compounds (HemaIswarya and Doble 2006; da 
Rocha et al., 2001). Numerous drugs have entered the international pharmacopoeia via 
the study of ethnopharmacology and traditional medicine (Patwardhan 2009).  
As tropical plants used in traditional medicine are an interesting source for novel 
structures, Metaxya rostrata C. Presl, Stachytarpheta jamaicensis L. Vahl and Maranta 
arundinacea Pulm., which are used in traditional medicine against intestinal diseases in 
Costa Rica, were investigated. 
Therefore the aim of this study was to 
1) phytochemically investigate the tree fern Metaxya rostrata, as there is very little 
phytochemical data available. 
2) isolate and elucidate the structures of the cytotoxic principles of the herbal 
remedies Metaxya rostrata, Stachytarpheta jamaicensis and Maranta arundinacea 
using a bioactivity-guided approach.  
3) give an insight into the underlying mechanisms of action of the active compounds. 
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3 MATERIALS AND METHODS 
 
3.1 Phytochemistry 
3.1.1 Plant Material 
Three different plants, used in Costa Rican traditional medicine, were collected. Rhizomes 
and/or leaves of Stachytarpheta jamaicensis L. Vahl, Maranta arundinacea Pulm. Ex. L. 
and Metaxya rostrata C. Presl were collected and sun dried in the surroundings of La 
Gamba (8° 41’N – 83° 13’W) near Golfito, south western Costa Rica, in autumn 2009 by 
Dr. Werner Huber. The plant material was authenticated in the Herbarium of the Museo 
National in San Jose. Voucher specimens are deposited at the Herbarium of the 
Department of Pharmacognosy, University of Vienna, Austria (Fig. 34).1 
 
         Fig. 34: Voucher specimen of the plant material 
Metaxya rostrata is a tree fern, belonging to the family of the Metaxyacea. It is 
widespread in the low land forests of Central- and Southamerica and used for the 
treatment of intestinal diseases by traditional healers in Costa Rica. Maranta arundinacea 
a herb, belonging to the family of the Marantacea and Stachytarpheta jamaicensis a 
shrub, belonging to the family of the Verbenacea, both used in traditional medicine as 
well.  
                                                     
1
 I am grateful to Dr. Werner Huber (Department of Structural and Functional Botany, University of Vienna) for 
collecting and identifying the plant material. 
 
Materials and Methods 
40 
 
  
Fig. 35: Plant material 
 
3.1.2 Extraction and Fractionation 
In a previous study, the rhizomes of Metaxya rostrata were extracted by sonification with 
water. After vacuum liquid chromatography 15 fractions were obtained (Virtbauer 2007). 
Fraction 12 was not investigated in the previous work and due to the pattern of 
compounds and the moderate cytotoxic activity, this fraction was chosen for further 
separation. 
For the bioactivity-guided approach, the rhizomes and rootlets of Metaxya rostrata were 
separated. The rhizomes, rootlets and leaves of the different plants were pulverized. All 
drug material was extracted in the same manner:  
For pretesting, first extraction and fractionation steps the Accelerated Solvent Extraction 
(ASE) was used. For pretesting, 5 - 10g plant material were extracted 3 times at 40°C with 
CH2Cl2, EA, MeOH and water using ASE (Table 1). For the extraction of the active extracts 
after pretesting, 100g rootlets (for CH2Cl2- and EA-extract), 120g leaves (EA-extract) and 
300g rhizomes (MeOH-Extract) were used. Portions of around 20g of the drug material 
were extracted 3 times at 40°C with the respective solvent using ASE (Table 2). For the re-
extraction and re-fractionation of the most active fractions, 920g of rootlets were 
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pulverized and portions of 200g were extracted 4 times in the ultrasonic bath at 40°C for 
1 hour with 800ml CH2Cl2, each. 
 
 Leaves 
Metaxya 
rostrata 
5,8g 
Rootlets 
Metaxya 
rostrata 
7,6g 
Rhizomes 
Metaxya 
rostrata 
7,5g 
Roots 
Maranta 
arundinacea 
9g 
Roots 
Stachytarpheta 
jamaicensis 
5,4g 
CH2Cl2 148 99 39 53 124 
EA 33 33 19 8 20 
MeOH 1006 480 636 339 117 
Water 18 175 455 151 218 
 
Table 1: Yields (in mg) of the extracts for pretesting 
 
 Leaves 
Metaxya rostrata 
120g 
Rootlets 
Metaxya rostrata 
100g 
Rootlets 
Metaxya rostrata 
920g 
Rhizomes 
Metaxya rostrata 
300g 
CH2Cl2 - 1.01 5.37 - 
EA 0.82 1.22 - - 
MeOH - - - 30.63 
 
Table 2: Yields (in g) of selected extracts 
  
3.1.3 Chromatographic Methods 
3.1.3.1 Thin layer chromatography (TLC) 
Stationary phases 
1 Silica gel 60 F254-precoated plates, 20 x 20cm, Merck 
2 Polyamide plates, 20 x 20cm, Merck 
 
Table 3: Stationary phases in thin layer chromatography 
 
Mobile phases 
1 ethylacetate : formic acid : MeOH : H2O 70 : 8 : 8 : 11 
2 acetonitrile : formic acid : acetic acid : H2O   100 : 11 : 11 : 26 
3 ethylacetate : acetic acid : MeOH : H2O   100 : 11 : 11 : 26 
4 cyclohexane : dichlormethane : formic acid : ethylformiate 35 : 30 : 5 : 30 
5.1 dichlormethane : formic acid : ethylformiate 30 : 5 : 30 
5.2 dichlormethane : formic acid : ethylformiate 60 : 5 : 30 
6 n-pentane : ethylacetate 85 : 15 
7.1 chloroform : MeOH : H2O 70 : 22 : 3 
7.2 chloroform : MeOH : H2O 60 : 40 : 10 
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7.3 chloroform : MeOH : H2O 85 : 8 : 0,5 
8 ethylacetate : MeOH : H2O 81 : 11 : 8 
9 MeOH : H2O : trifluor-acetic acid  1 : 1 : 0.6 
10 toluene : ethylformiate : formic acid 10 : 4 : 1 
12 ethylacetate : formic acid : acetic acid : H2O 100 : 6 : 6 : 2 
13 2-propanol : acetone : 1M lactic acid 40 : 40 : 20 
 
Table 4: Mobile phases in thin layer chromatography 
After development, the plates were dried and sprayed with one of the following 
detection reagents: 
Detection  
1 Anisaldehyde-H2SO4 
reagent 
85ml MeOH + 10ml conc. acetic 
acid + 5ml  conc. sulphuric acid + 
0,5ml anisaldehyde 
 After spraying the plate 
was heated at 110° for 5-
10 min and analysed by 
daylight 
2 Naturstoff(NS)– 
Polyethylenglycol (PEG)– 
reagent  
1% methanolic solution of 
Naturstoffreagens A   
5% ethanolic solution of PEG  
 After spraying with NS, 
the plate was dried, then 
sprayed with PEG and 
analysed under UV366 
3 Anilin - diphenylamin – 
reagent        
0,5ml of aniline + 0,5g of 
diphenylamine + 20ml Aceton + 
4ml of 85% phosphoric acid 
 After spraying the plate 
was dried and analysed 
by daylight 
 
Table 5: Detection reagents in thin layer chromatography 
 
3.1.3.2 Column chromatography 
The columns were packed with the respective stationary phase. The application of the 
sample depended on the stationary phase. For Sephadex columns the sample was 
dissolved in a very small amount of the mobile phase and applied on the column. For 
silica gel columns the sample was adsorbed on double amount of the stationary phase 
and placed on top of the column. 
Stationary phases 
SP 1 Silica gel 60, particle size 0,063-0,200mm, Merck 
SP 2 Sephadex LH-20, Pharmacia Biotech AB 
 
Table 6: Stationary phases in column chromatography 
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Mobile phases for SP 1                                                            used for: 
MP 1/1 water-saturated EtOAc : MeOH (90+10)            CC-2, CC-5, CC-6  
MP 1/2 water-saturated EtOAc : MeOH (80+20)            CC-7  
MP 1/3 water-saturated EtOAc                                          CC-4  
 
Mobile phases for SP 2                    used for: 
MP 2/1 80% MeOH                                                               CC-1, CC-12  
MP 2/2 50% MeOH                                                               CC-3, CC-8  
MP 2/3 EtOAc                                                                        CC-9, CC-10, CC-11, CC-13 
 
Table 7: Mobile phases in column chromatography 
 
 
3.1.3.3 HPLC 
HPLC data were recorded on a Shimadzu instrument using LC solution software.  
HPLC-Instrumentation:  
Degasser  Shimadzu DGU 20A5 prominence Degasser 
Controller  Shimadzu CBM 20A prominence Communication Bus Module 
Autosampler  Shimadzu SIL 20AC HAT prominence Auto Sampler 
Pump   Shimadzu LC 20AD prominence Liquid Chromatograph 
Detector  1 Shimadzu SPD M20A prominence Diode Array Detector 
2 Shimadzu ELSD-LT (Low Temperature Evaporative Light 
Scattering Detector) 
Column Oven  Shimadzu CTO 20AC prominence Column Oven 
Software  LC Solution 
 
Method 1               Used for: 
Column LiChroCART, 250x4mm, RP-18e, 5µm                            SPE-3/4 
Eluent A 1% formic acid in water                                                    SPE-3/3 
Eluent B acetonitrile                                                                          SPE-7/3 
Flow Rate 1ml/min                                                                               SPE-8/4 
Temperature 25°C 
Gradient program 1 time, min % Eluent B 
 Start 60 % 
 0 - 25 min 60 % 
 26 - 65 min 100 % 
 66 - 70 min 100 % 
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Method 2                                  Used for: 
Column LiChroCART, 250x4mm, RP-18e, 5µm                            SPE-5/2 
Eluent A 1% formic acid in water                                                    SPE-6/2 
Eluent B acetonitrile 
Flow Rate 1ml/min 
Temperature 25°C 
Gradient program 2 time, min % Eluent B 
 Start 40 % 
 0 – 15 min 40 % 
 16 – 25 min 60 % 
 26 – 45 min 60 % 
 46 – 55 min 100 % 
 56 – 60 min 100 % 
 
Method 3                                   Used for: 
Column LiChroCART, 250x10mm, RP-18e, 5µm                           CC-9/5 
Eluent A 1% formic acid in water 
Eluent B acetonitrile 
Flow Rate 10ml/min 
Temperature 25°C 
Gradient program 3 time, min % Eluent B 
 Start 48 % 
 0 - 35 min 51 % 
 36 - 37 min 100 % 
 38 - 48 min 100 % 
 
Table 8: Methods for HPLC 
 
3.1.4 Removal of chlorophyll 
As chlorophyll is known to interfere unspecifically with different test systems, it was 
removed using liquid - liquid partition. 1g CH2Cl2-extract was dissolved in 150ml CH2Cl2 
and 150ml MeOH water (1:1) were added. After evaporation of CH2Cl2, the chlorophyll 
precipitated in the MeOH - water mixture and was removed by filtration. 
 
3.1.5 Solid phase extraction (SPE) 
RP-cartridges (C-18, 20ml, Bond Elut, Varian) were conditioned with 2 reservoir volumes 
MeOH and 2 reservoir volumes water. The fractions were dissolved in CH2Cl2, applied on 
the cartridges and dried by air purge. The fractions were eluted with 4 reservoir volumes 
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of 20%, 40%, 60%, 70%, 80%, 90% and 100% MeOH, each. The fractions of identical 
polarity were pooled and evaporated. 
 
3.1.6 Spectroscopic and spectrometric methods 
3.1.6.1 Mass-spectrometry (MS) 
ESI-MS data were recorded on a API 4000 triple quadrupole mass spectrometer (AB Sciex 
Instruments, Foster City, CA, USA) configurated for both negative and positive ionization 
mode. Mass spectra were acquired over the range m/z 100-1000, scan time was 1s. 
Product ions (MS/MS) were scanned from m/z 40-400 within 1s of scan time. FIA was 
carried out using MeOH/aqueous ammoniumacetate 5mmol (80:20).2 
 
3.1.6.2 Nuclear magnetic resonance (NMR) 
NMR spectra were recorded on a Bruker Advance DRX 600 NMR spectrometer using a 5 
mm switchable quadruple probe (QNP, 1H, 13C, 19F, 31P) with z axis gradients and 
automatic tuning and matching accessory. The resonance frequency for 1H NMR was 
600.13 MHz, for 13C NMR 150.92 MHz. All measurements were performed for a solution 
in fully deuterated methanol at 298 K. Standard 1D and gradient-enhanced (ge) 2D 
experiments, like double quantum filtered (DQF) COSY, TOCSY, NOESY, HSQC, and HMBC, 
were used as supplied by the manufacturer. Chemical shifts are referenced internally to 
the residual, non-deuterated solvent signal for 1H (d = 3.31 ppm) or to the carbon signal 
of the solvent for 13C (d = 49.00 ppm)  The analysis of the 1H–1H coupling constants (given 
in Hertz) were supported by the program Spin-Works (provided by Kirk Marat, University 
of Manitoba, Canada).3 
 
3.1.6.3 Infrared spectroscopy (IR) 
Infrared spectra were measured on a Perkin Elmer FT-IR 2000 instrument in attenuated 
total reflection mode using a Golden Gate ATR unit.  
                                                     
2  I am grateful to Dr. Martin Zehl and Mag. Oliver Donath (Department of Pharmacognosy, University of Vienna) for 
performing the MS experiments. 
 
3 I am grateful to Dr. Hanspeter Kählig (Institute of Organic Chemistry, University of Vienna) for performing the NMR 
experiments. 
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3.1.6.4 UV / VIS Spectroscopy 
UV-VIS spectra of KK1 were measured in a methanolic solution on a Beckman DU 640 
Spectrophotometer using MeOH as blank. 
 
3.1.7 Crystallography 
Compound KK1 was crystallized from a solvent mixture of methanol and diethylether. 
Single crystal X-ray structure analysis was performed on a Bruker X8 APEXII CCD 
diffractometer with graphite-monochromated MoK radiation,  = 0.71073 Å.4 
 
3.1.8 Histone deacetylase (HDAC) assay 
A fluorimetric in vitro enzyme assay was used to evaluate the influence of KK1 on HDACs. 
The principle of the assay is the deacetylation of ε-acetylated lysine-based substrate 
coupled with 4-methyl-coumarine-7-amide by HDAC. The endopeptidase recognizes the 
deacetylated substance as a substrate and releases 7-amino 4-methylcoumarin, which is 
highly fluorescent and can be measured.5 
 
3.1.9 Antibacterial assay 
A standard S. aureus strain (ATCC 25923) and a clinical isolate (XU212), which possesses 
the TetK efflux pump and is also a MRSA strain, were obtained from E. Udo. Strain 
RN4220, which has the MRSA macrolide efflux pump, was provided by J. Cove. EMRSA-15 
and EMRSA-16 were obtained from Paul Stapleton. Strain SA-1199B, which overexpresses 
the NorA MDR efflux pump, was the gift of Professor Glenn Kaatz. Norfloxacin was 
obtained from Sigma Chemical Co. Mueller-Hinton broth (MHB) was adjusted to contain 
20 mg/L Ca2+ and 10 mg/L Mg2+. 
Overnight cultures of each strain were made up in 0.9% saline to an inoculum density of 5 
× 105 cfu by comparison with a MacFarland standard. Tetracycline and oxacillin were 
dissolved directly in MHB, whereas norfloxacin and erythromycin were dissolved in DMSO 
and then diluted in MHB to give a starting concentration of 512μg/mL. Using Nunc 96-
                                                     
4 I am grateful to Dr. Vladimir Arion (Institute of Inorganic Chemistry, University of Vienna) for performing the X-ray 
diffraction crystallography. 
 
5 I am grateful to Dr. Stanimira Krasteva (Department of Pharmacognosy, University of Vienna) for performing the 
HDAC assay. 
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well microtiter plates, 125 μL of MHB was dispensed into wells 1-11. Then, 125 μL of the 
test compound or the appropriate antibiotic was dispensed into well 1 and serially diluted 
across the plate, leaving well 11 empty for the growth control. The final volume was 
dispensed into well 12, which being free of MHB or inoculum served as the sterile control. 
Finally, the bacterial inoculum (125 μL) was added to wells 1-11, and the plate was 
incubated at 37°C for 18 h. A DMSO control (3.125%) was also included. All MICs were 
determined in duplicate. The MIC was determined as the lowest concentration at which 
no growth was observed. A methanolic solution (5 mg/mL) of 3-[4,5-dimethylthiazol-2-yl]-
2,5-diphenyltetrazoliium bromide (MTT) was used to detect bacterial growth by a colour 
change from yellow to blue.6  
 
3.1.10 Antiviral assay 
Verocells were seeded in 96-well plates and grown for 24 h before treatment with 1, 10 
and 100µM of compound KK1 in serumfree MEM (SFM) with and without Herpes Simplex 
1 virus (HSV-1 17 syn+) for 48 h and one control with cells in SFM and one control with 
cells plus HSV-1.7 
 
3.1.11 Insecticidal assay 
The test organism for the insecticidal assay was Spodoptera littoralis, a Noctuidae, which 
is an important pest in tropical areas and feeds on over 50 different plant families. For the 
assay the compound was incorporated in different concentrations into the food and 20 
freshly slipt larvae were put directly on the food piece. After 4 and 7 days the larvae were 
weighed.8  
                                                     
6
 I am grateful to Dr. Simon Gibbons and his working group (School of Pharmacy, University of London) for performing 
the antibacterial tests. 
 
7
 I am grateful to Dr. Andreas Hensel and his working group (Institut für pharmazeutische Biologie und Phytochemie, 
Westfälische Wilhelms-Universität Münster) for performing the antiviral tests. 
 
8
 I am grateful to Mag. Johann Schinnerl (Department of Systematic and Evolutionary Botany, University of Vienna) for 
the support in performing the insecticidal assay. 
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                                                         Table 9: Food for Spodoptera littoralis 
 
3.1.12 Antifungal assay 
The test organism for the fungal assay was Cladosporium sphaerospermum. The fractions 
were separated on a TLC plate. After the complete removal of the mobile phase, the plate 
was sprayed with fungal spores and a growth medium. After 2 days the growth inhibition 
of active compounds were seen.9 
 
3.1.13 In Silico screening  
Pharmacophore profiling against more than 2200 models representing over 280 
pharmacological targets was performed using DiscoveryStudio 2.5 (www.accelyrs.com). A 
structural similarity search in the MDL Drug Data Report (MDDR) database was conducted 
with sea.docking.org.10 
 
3.1.14 Chemicals and Solvents  
All solvents used for extraction, chromatography and other phytochemical work were 
from highest purity grade available and purchased from VWR (Vienna, Austria).  
 
 
 
                                                     
9
 I am grateful to Mag. Johann Schinnerl (Department of Systematic and Evolutionary Botany, University of Vienna) for 
the support in performing the anti-fungal assay. 
 
10
  I am grateful to Dr. Daniela Schuster (Department of Pharmaceutical Chemistry, University of Innsbruck) for 
performing the in silico screening. 
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3.2 Cell Biology 
 
3.2.1 Cell lines 
All cell lines used (SW480, HT29, CaCo2, LT97 and F331) were obtained from ACCT. 
3.2.1.1 SW480 
SW480 is a human colorectal adenocarcinoma cell line, 
male, which was established by A. Leibovitz. SW480 
cells have epithelial form and the chromosome 
number is hypertriploid. This cell line expresses 
elevated levels of p53 and is positive for expression of 
myc, ras, myb, sis and fos oncogenes (www.atcc.org). 
SW480 cells grow attached with MEM with 10% FCS 
and 4% Penstrep and have a doubling time of 24 
hours. 
 
3.2.1.2 HT29 
HT29 is a human colorectal adenocarcinoma cell line, 
female, which was established by J. Fogh. HT29 cells 
have epithelial form and are hypertriploid. p53 is 
overproduced and the cells show positive expression 
of myc, ras, myb, sis and fos oncogenes 
(www.atcc.org). HT29 cells grow in monolayers and 
are cultivated in MEM with 10% FCS and 4% Penstrep 
and show a doubling time of 36 hours. 
 
3.2.1.3 Caco-2 
Caco-2 is a human colorectal adenocarcinoma cell line, 
male, which was established by J. Fogh 
(www.atcc.org). CaCo-2 are cultivated with MEM plus 
20% FCS and 4% Penstrep and show a doubling time of 
60-72 hours. 
 
 
Fig. 36: SW480 
 
Fig.4.: HT29 
 
 
 
Fi . 37: HT29 
 
Fig. 38: CaCo-2 
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3.2.1.4 LT97 
LT97 is a human colon adenoma cell line which was 
established in our laboratory by B. Marian and M. 
Richter. LT97 have lost both APC allele and show a Ki-
ras mutation. This cell line is cultivated in HAM-F12 
media plus 20% L-15 media, 2% FCS, 5.10-9 M 
natriumselenit, 2.10-10 M triiodotyronin, 10 μg/ml 
insulin, 2μg/ml transferrin,1 μg/ml hydrocortisone, 30 
ng/ml EGF. Under these conditions the cells show a 
doubling time 72-96 hours. 
 
3.2.1.5 F331 
F331 cells are embryonic human colon associated 
fibroblasts, which are cultivated in DMEM media plus 
4% Penstrep and 10% FCS. Under these conditions 
they show a doubling time 24 hours. 
 
3.2.2 Passaging of cells 
SW480, HT29, Caco2 and F331 cells are passaged when they reach a confluence of about 
90%. Medium is removed and the cells are washed with 5-10ml of PBS/EDTA and 
incubated with 0,5ml Trypsin/PBS for 5-10min at 37°C. The detached cells are taken up in 
10ml culture medium and passaged into new Petri dishes (PD).  
LT97 cells are split when they reach a confluence of about 90%. Culture medium is 
aspirated and the cells are washed with PBS/EDTA and incubated at 37°. The detached 
cells are taken up in medium, washed and passaged.  
 
 
SW480 HT29 Caco-2 LT97 F331 
1:10 1:10 1:3 1:3 1:3 
 
Table 10: Passaging of cells 
10cm PD 6cm PD 12-well plate 24-well plate 96-well plate 
1.3 x 106 5 x 105 5 x 104 2 x 104 3 x 103 
 
Table 11: Density of cells in different culture dishes 
Fig.7.: F331 
 
Fig.6.: LT97 
 
Fig. 39: LT97 
 
 
 
Fig. 40: F331 
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3.2.3 Materials used for cell culture 
 
Petridishes (10cm and 6cm)     Sarsted, Nümbrecht, Germany 
6-well plates, 24-well plates and 96-well plates   Sarsted, Nümbrecht, Germany 
Penicillin/Streptomycin (Penstrep)    PAA, Pasching, Austria 
Fetal calf serum (FCS)      PAA, Pasching, Austria 
Trypsin/PBS 10x (for use diluted 1:10 in PBS)   PAA, Pasching, Austria 
Eagles Minimal Essential Medium (MEM)   Sigma-Aldrich, St. Louis, MO, US 
Bovine Serum Albumin (BSA)     Sigma-Aldrich, St. Louis, MO, US 
Phosphate buffered saline (PBS)     Sigma-Aldrich, St. Louis, MO, US 
Tween        Sigma-Aldrich, St. Louis, MO, US 
Triton X-100      Sigma-Aldrich, St. Louis, MO, US 
DMSO       Sigma-Aldrich, St. Louis, MO, US 
PBS/EDTA (10mM EDTA in PBS)     Merck, Darmstadt, Germany  
Milk Powder      Fluka Biochemika, Buchs, Switzerland 
 
 
3.2.4 Measurement of cell viability 
3.2.4.1 MTT assay – EZ4U 
The MTT assay is a colorimetric assay which measures the activity of the mitochondrial 
dehydrogenase of living cells. The water soluble light yellow 3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide (MTT) is taken up by living cells and reduced to an 
intensely coloured formazan by a mitochondrial dehydrogenase. As the amount of 
product is proportional to the number of viable cells in the culture, this reaction is 
suitable to assess the number of viable cells.  
Cells were seeded at a density of 3x103 cells per well into 96-well plates and after 
treatment with active compounds, the supernatant was replaced by 100µl of freshly 
prepared EZ4U solution (EZ4U, Biomedica, Vienna, Austria). The cells were incubated at 
37°C for 2 hours and the absorbance was measured at 492 nm in a microplate reader 
Synergy H1 (Szabo Scandic, Vienna, Austria). 
 
3.2.4.2 Neutralred uptake 
This colorimetric assay is based on the ability of viable cells to incorporate and bind 
neutral red in their lysosomes, where due to the acidic pH-value it changes its colour into 
pink red. Dead cells cannot store Neutralred and are therefore not stained. 
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Cells were seeded at a density of 3x103 cells per well into 96-well plates and 5x104 cells 
per well into 24-well plates. 50 μg/ml Neutralred (Merck, Darmstadt, Germany) were 
dissolved in serumfree MEM at 37°C for 1 hour and filtered. After treatment with active 
compounds, the supernatant was removed and 200µl for each 96-well and 500µl of the 
neutral red solution for each 24-well were added. After incubation of the plates at 37°C 
for 2 hours, the neutral red solution was removed and the cells were washed with 1xPBS. 
Thereafter Neutralred was extracted with 100µl of 70% Ethanol + 1% acetic acid in 96-
wells and 250µl in 24-wells for 10 minutes at room temperature while shaking gently. The 
absorbance was measured at 562nm wavelength in a microplate reader Synergy H1 
(Szabo Scandic, Vienna, Austria). 
 
3.2.5 Fluorescence activated cell sorting (FACS) 
Fluorescence activated cell sorting is a specialized type of flow cytometry which is used to 
divide a heterogeneous mixture of cells with regard to size, complexicity and fluorescence 
emission.  
 
3.2.5.1 Cell cycle distribution 
Cells were seeded at a density of 5x105 cells per 6cm PD. The supernatant of treated cells 
was removed and the cells were washed with PBS/EDTA and Trypsin/EDTA was added. 
After incubation at 37°C for 5-10 minutes MEM with 10% FCS was added and the cells 
were transferred in a 15ml Falcon tube. After centrifugation at 1200 rpm for 5 minutes 
the cell pellet was resuspended in 1ml 1xPBS and transferred into a 1.5ml tube. 1ml of 
nuclear isolation buffer was added, mixed well and incubated for 5 minutes on ice. Nuclei 
were prepared and separated using a syringe. Then they were collected by centrifugation 
for 5 minutes at 4°C at 2000 rpm, resuspended in 0.5 ml propidium iodide staining 
solution and transferred into light protected FACS vials. Cell cycle was measured using a 
FACS Calibur (BD, Franklin Lakes, NJ, USA). 
 
Nuclear isolation buffer: RNAse stock solution: 
10.5g   citric acid 
0.5ml   Tween 20 
to 100ml            aqua bidest 
10mg   RNAse A 
10ml   1xPBS 
incubate 15 min 100°C 
Put on ice immediately; store at -20°C 
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Propidium Iodide stock solution: Staining solution: 
5mg   Propidium Iodide 
10ml   1xPBS 
0.05ml                RNAse stock solution 
0.05ml                PI stock solution 
5ml   1xPBS 
 
 
3.2.5.2 Quantification of apoptosis: JC-1-FACS 
Cells were seeded at a density of 5x105 cells per 6cm PD. The supernatant of treated cells 
was removed and the cells were washed twice with PBS/EDTA and Trypsin/EDTA was 
added. After incubation at 37°C for 5-10 minutes MEM with 10% FCS was added, the cells 
were transferred in a 15ml Falcon tube and centrifuged at 1200 rpm for 5 minutes. Under 
light protection, the cell pellet was suspended in 1 ml JC-1 solution (10µg JC-1 per 1 ml 
10% FCS MEM) and transferred into a 1.5 ml tube and incubated for 10 minutes at 37°C. 
After centrifugation at 4°C for 5 minutes at 1200 rpm the cell pellet was washed twice 
with cold 1xPBS, resuspended in 0.5 ml cold 1xPBS and transferred into FACS vials. 
Apoptosis was measured immediately on a FACS Calibur (BD, Franklin Lakes, NJ, USA). 
 
3.2.6 Detection of apoptosis: Hoechst-Staining 
Hoechst stain-33258 intercalates into DNA and is used to visualize the nuclei in the 
fluorescence microscope. This blue fluorescent dye is excited by ultraviolet light at 
365nm. The fixed cells after neutral red assay were used for Hoechst - Staining. The cells 
were washed with 1xPBS and thereafter 500µl of staining solution (5µg Hoechst in 1ml 
SFM) was added and incubated for 10 minutes under light protection. The cells were 
washed with 10mM citratebuffer (pH3) and covered with Geltol. Under the fluorescence 
microscope the apoptotic cells were counted. 
 
3.2.7 Lactatdehydrogenase (LDH)-assay  
The LDH-assay (Roche Diagnostics GmbH, Basel, Switzerland) is an enzymatic assay for the 
quantification of viable cells. Necrotic cell lysis is assessed by LDH release into the 
supernatant as a marker of dead cells.  
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In the first step the released LDH reduces the NAD+ to NADH+H+ and lactate is oxidized to 
pyruvate. In a second enzymatic reaction a tetrazolium salt is reduced to deep red 
formazan as shown in Fig. 41. 
 
 
Fig. 41: Principle of the LDH-assay 
(http://www.gbiosciences.com) 
 
After the treatment of the cells with the active compound, 100µl of the supernatant were 
mixed with 100µl of the reagent (Diaphorase/NAD+ Mixture, iodotetrazolium chloride, 
sodiumlactate) and incubated for 30 minutes at room temperature with light protection. 
The intensity was measured at 490nm. As a positive control cells treated with 1% Triton X 
100 were used. The cytotoxicity is stated in % of this maximum value and calculated 
according to: Cytotoxicity (%) = [(measured data – neg. control) / (pos. control – neg. control)] x 
100 
 
3.2.8 FoxM1-staining 
The forkhead transcription factor FoxM1 is an important regulator of gene expression 
during the G2 phase (Laoukili et al., 2008). Loss of the transcriptional factor FoxM1 affects 
genes necessary for chromosome segregation, generates mitotic spindle defects and 
delays in mitosis and leads to mitotic catastrophe (Vakifahmetoglu et al., 2008; Wonsey et 
al., 2005). Fixed cells were incubated with PBS containing 0.25% Triton X-100 for 10 
minutes. Thereafter the cells were washed 3 times with PBS and then incubated with 1% 
BSA in PBS-T for 30 minutes to block the unspecific binding. The cells were incubated then 
with the diluted antibody in 1% BSA in PBS-T for 1 hour. The solution was decanted and 
the cells were washed 3 times with PBS. Incubation with the secondary antibody (FICTS 
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anti-rabbit) in dark and again 3 washing steps with PBS in dark followed. After counter 
staining with Hoechst-stain and covering with Geltol the cells were analyzed with the 
fluorescence microscope. 
 
3.3 Protein chemistry 
 
3.3.1 Western blotting 
Western blotting is an analytical technique used to identify and locate proteins based on 
their ability to bind to specific antibodies which can give information on protein 
expression. 
Proteins are isolated and equal amounts of these protein lysates are applied to a 
polyacrylamid gel containing sodiumdodecylsulfate (SDS). SDS charges the proteins 
negativ so that the proteins can be separated via gel electrophoresis due to their size. 
Proteins are then transferred to a polyvinylidene fluoride membrane (PVDF), where they 
are detected using antibodies specific to the target protein. After incubation with an 
enzyme-coupled second antibody, detection is achieved by an enzymatic reaction 
producing chemoluminiscence and exposure to a photosensitive film. 
 
3.3.1.1 Protein isolation 
The treated cells were scraped from the PD surface, centrifuged, washed twice with cold 
1xPBS containing phosphatase inhibitors (1µl/ml Na3VO4 and 10µl/ml 1M NaF) and lysed 
with Hepes lysis buffer. The lysates were incubated for 30 minutes on ice and vortexed 3 
times. Thereafter they are exposed to ultrasound for 10 minutes to break up DNA and 
centrifuged at 15000rpm for 5 minutes. The supernatant, which contains the proteins is 
transferred into tubes and stored at -20°C. 
 
Hepes lysis buffer 
1M Hepes                                                            1ml 
1M NaCl                                                            10ml  
0,5M EDTA solution                                         40µl 
1M NaF solution                                            200µl 
1M NaVO4 solution                                       100µl  
Igepal (NP40)                                                 200µl 
1M MgCl2 solution                                          30µl  
Complete                                                2 tablettes 
aqua bidest                                                 8,03ml 
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3.3.1.2 Evaluation of protein concentration with Coomassie 
For the protein standard curve aqua bidest, Hepes lysis buffer and BSA solution (1µg/µl) 
are pipetted into a 96-well plate according to the following scheme: 
BSA concentration [µg/µl] 0 1 2 3 4 5 6 7 8 9 
Aqua bidest [µl] 9 8 7 6 5 4 3 2 1 0 
Hepes lysis buffer [µl] 1 1 1 1 1 1 1 1 1 1 
BSA [µl] 0 1 2 3 4 5 6 7 8 9 
Total volume [µl] 10 10 10 10 10 10 10 10 10 10 
 
Table 12: Pipette schemata for the evaluation of protein concentration 
For protein samples 1µl protein lysate and 9µl aqua bidest were mixed in a 96-well. 
Thereafter 150µl of a 1:5 diluted Coomassie Protein Assay Dye Reagent Concentrate 
(BioRad, Berkeley, US) solution was added to each well of the standard curve and protein 
samples. Standard curve and protein samples were determined in duplicates. The 
absorption was measured at 590nm and the protein concentration of the samples was 
calculated according to the standard curve. 
 
3.3.1.3 SDS-polyacrylamid gel electrophoresis (PAGE) 
An SDS separating gel was poured into a sandwich made of glass plates, overlayed with 
ethanol and left for 1 hour to polymerise. Then the ethanol was removed, the seperating 
gel was overlayed with an SDS collecting gel and a comb inserted during polymerisation to 
create slots. 30µg protein were mixed with 4x sample buffer, heated at 80°C for 5 
minutes and then loaded onto the gel. 5µl protein ladder (PageRulerTM Prestaind Protein 
Ladder, Fermentas, Burlington, Canada) were loaded into the reference slot. The 
chambers were filled with electrophoresis buffer and the run performed for 15 minutes 
with 60 Volt and then for 1 hour at 125 Volt. Gel electrophoresis apparatus was obtained 
from Bio-Rad. 
 
SDS separating gel 7% 12% 15% SDS collecting Gel  
40% Acrylamid 0.875ml 1.5 ml 1.875ml 40% Acrylamid 0.25ml 
1.5M Tris pH 8.8 1.25ml 1.75 ml 1.25ml 1.5M Tris pH 6.8 0.313ml 
Aqua bidest 2.8ml 2.15 ml 1.8ml Aqua bidest 1.9ml 
10% SDS 50μl 50μl 50μl 10% SDS 25μl 
10% APS 25μl 25μl 25μl 10% APS 12.5μl 
TEMED 2.5μl 2.5μl 2.5μl TEMED 2.5μl 
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Electrophoresis buffer 4x Sample buffer 
Glycin 72g SDS 0.2g 
Tris 15g Glycerol 1g 
SDS 5g 2-mercaptoethanol 0.5ml 
Aqua bidest                                   fill up to 500ml Tris/HCl pH 6.8 fill up to 2.5ml 
Bromphenolblue traces of 
 
3.3.1.4 Western blot 
Using a BioRad wet-blot system the proteins are blotted on a PVDF membrane (VWR). 
The blotting sandwich is prepared according to the following order: 
 
 
thick pad 
 
3 filter papers 
PVDF membrane (activated in methanol) 
Gel 
3 filter papers 
thin pad 
 
Table 13: Schemata for sandwich preparation 
 
This blot was running at 25 Volt over night at 4°C in 1x blotting buffer. The cathode was 
placed on the side of the gel, so that the negatively loaded proteins moved towards the 
positively charged anode and were bound on the membrane. After blotting the 
membrane was washed with aqua bidest, dried with methanol and either treated with 
the first antibody or stored at 4°C. 
 
 
10x Blotting buffer 1x Blotting buffer 
Glycin                                  72g 
Tris                     15g 
SDS                       1g 
Aqua bidest              to 500 ml 
10x blotting buffer           10% 
Methanol         20% 
Aqua bidest         70% 
 
 
 
3.3.1.5 Ponceau S staining 
The Ponceau S staining was used to visualize all protein bands on the membrane. The 
membrane was incubated in Ponceau S (Sigma-Aldrich, St. Louis, MO, US) solution for 10 
minutes, fotocopied for documentation and washed in aqua bidest. 
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3.3.1.6 Immunological detection of protein 
The membrane was incubated with the primary antibody in 1-5% non-fat dry milk in PBS-
T (1ml Tween in 1l 1xPBS) over night at 4°C. Thereafter the membrane was washed at 
least 3 times for 10 minutes with PBS-T before incubating with the secondary antibody 
(conjugated to horse radish peroxidase) in 1% non-fat dry milk in PBS-T for 1 hour at room 
temperature. For the phosphoproteins 1-5% BSA in TBS-T (1ml Tween in 1l 1xTBS) was 
used. After washing at least 3 times for 10 minutes each the membrane was covered with 
detection reagent (ECL Plus Western Blotting Detection System, AmershamTM, GE 
Healthcare) and visualized by exposing to an x-ray film. The protein bands were 
quantified after scanning in comparison to the expression of the housekeeping protein β-
Actin.  
Primary Antibody Dilution Source buffer MW Provider 
BCL-2 1:500 mouse 2% milk in PBS-T 26kDa BD biosciences 
BCL-XL (H5) 1:500 mouse 5% milk in PBS-T 30kDa Santa Cruz 
BAX (B-9) 1:500 rabbit 2% milk in PBS-T 23kDa Santa Cruz 
BAK (Ab-1) 1:1000 mouse 2% milk in PBS-T 30kDa Calbiochem 
Caspase 2 (mAB-415) 1:500 mouse 2% milk in PBS-T 47, 14kDa Enzo Life Science 
Caspase 3 (Asp-175) 1:2000 rabbit 2% milk in PBS-T 17, 19kDa Cell Signaling 
Cyclin A (H-432) 1:500 rabbit 2% milk in PBS-T 54kDa Santa Cruz 
Cyclin B 1:500 rabbit 2% milk in PBS-T 60kDa Cell Signaling 
Cyclin E (M-20) 1:500 rabbit 2% milk in PBS-T 53kDa Santa Cruz 
ATR (C-19) 1:500 goat 2% BSA in TBS-T 250kDa Santa Cruz 
ATM (Ab-1981) 1:500 rabbit 5% BSA in TBS-T 260kDa abm inc. 
CHK 1 1:500 rabbit 2% BSA in TBS-T 56kDa Cell Signaling 
Phospho CHK 1 (Ser317) 1:500 rabbit 2% BSA in TBS-T 56kDa Cell Signaling 
CDK 1 1:500 rabbit 2% BSA in TBS-T 34kDa Cell Signaling 
Phospho CDK 1 (Tyr15) 1:500 rabbit 2% BSA in TBS-T 34kDa Cell Signaling 
Survivin 1:1000 rabbit 3% BSA in TBS-T 16kDa Novus Biologicals 
PARP (C2-10) 1:1000 mouse 2% milk in PBS-T 116, 85kDa R&D systems 
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Cdc25C (5H9) 1:1000 rabbit 3% BSA in TBS-T 60kDa Cell signaling 
FoxM1 (D12D5) 1:1000 rabbit 5% BSA in TBS-T 110kDa Cell signaling 
Phospho-Histone H3 Ser10 1:1000 rabbit 5% BSA in TBS-T 17kDa Cell signaling 
β-Actin (AC-15) 1:500 mouse 1% milk in PBS-T 42kDa Sigma-Aldrich 
 
Table 14: Primary antibodies 
All antibodies were diluted in PBS-T or TBS-T and when recommended by the provider, 
BSA or milk powder was added. 
Secondary Antibody Dilution buffer Provider 
Goat Anti-mouse HRP- 
conjugated (#1858413) 
1:5000 
3% milk in PBS-T or 
3% BSA in TBS-T 
Pierce, Thermo Scientific, 
Rockford, US 
Goat Anti-rabbit IgG-h + I HRP 
(#A120-201P) 
1:20000 
3% milk in PBS-T or 
3% BSA in TBS-T 
Bethyl Laboratories Inc, 
Montgomery, US 
Polyclonal rabbit Anti-goat 
Immunoglobulin/ HRP 
1:2000 3% BSA in TBS-T Dako Cytomation 
Anti-rabbit IgG FITC, developed 
in goat (#114K6044) 
1:2000 3% BSA in TBS-T 
Sigma-Aldrich, 
St. Louis, MO, US 
 
 
Table 15: Secondary antibodies 
 
3.4 Statistics 
Statistical analysis was performed using GraphPad PRISMTM. Results were analyzed by 
student’s t-test or Kruskal-Wallis test depending on the results of normality testing. Data 
are expressed as means of at least three independent experiments including standard 
deviation and significance. Significances are indicated as *, **, and *** for significant 
increase at p ≤ 0.05, 0.01, and 0.001, respectively.  
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4 RESULTS 
 
4.1 Phytochemical investigations of Metaxya rostrata  
In a previous work 800g dried roots of Metaxya rostrata had been extracted by 
sonification with hot water according to the ethnomedicinal use. After lyophilization 80g 
water extract had been obtained and sequentially been extracted with ethylacetate and 
butanol. The residue of the water phase had additionally been extracted with methanol. 
The fractions had been subjected to vacuum liquid chromatography (VLC) on silica using 
EtOAc/MeOH/H2O mixtures of increasing polarity as mobile phases (Fig. 42) to yield 15 
fractions. Fraction 12 had shown reasonable cytotoxic activity (Virtbauer 2007). 
                     
 
        Fig. 42: Extraction and fractionation scheme of the rhizomes of Metaxya rostrata
  
      (according to: Virtbauer 2007) 
 
As a further fractionation of fraction 12 had not been performed yet, in this study 2,96g 
of fraction 12 were subjected to column chromatography on Sephadex LH-20 under 
elution with 80% MeOH to obtain 13 subfractions from a total of 288 fractions collected 
in CC-1 (Table 16). Every tenth fraction was analysed by TLC (stationary phase 1, mobile 
phase 1, see p. 41) and the fractions with similar compounds were combined Fig. 43).  
PLANT
H2O
WB+E
VLC1
WM
VLC2
MeOH
ME+B
VLC3
MW
VLC4
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Fig. 43: TLC of the combined fractions of CC-1 
Stationary phase 1, mobile phase 1, detection 1 
 
CC-1 parameters Mobile Phase Fraction No. Pooled fractions mg Further separation 
 
Stationary phase: 
Sephadex LH-20 
 
Column diameter: 
3cm 
 
Column height: 
65cm 
 
Fraction 
separation: 
2960mg 
of fraction 12 
 
Fraction size: 
8 ml/30 min 
80% MeOH 12/1 1-30 80 none 
“ 12/2 31-36 83 none 
“ 12/3 37-41 509 CC-2 (p.64) 
“ 12/4 42-52 691 CC-5 (p.70) 
“ 12/5 53-64 555 CC-6 (p.71) 
“ 12/6 65-78 60 none 
“ 12/7 79-98 75 none 
“ 12/8 99-118 172 none 
“ 12/9 119-148 178 none 
“ 12/10 149-155 101 CC-8 (p.73) 
“ 12/11 156-166 186 none 
“ 12/12 167-200 199 none 
“ 12/13 201-288 40 none 
 
Table 16: Conditions for CC-1 
 
Fractions 12/3, 12/4, 12/5 and 12/10 were chosen for further separation. Due to the 
smaller amounts of the other fractions no further experiments were performed. 
 
4.1.1 Isolation and structure elucidation of compound KK1 
Fr. 12/3 was chosen for further separation to isolate its main blue compound at Rf 0.56 
with detection 1. 509mg of fr.12/3 were subjected to column chromatography on Silica 
Gel 60 (particle size 0.063-0.200mm, Merck) under elution with water-saturated 
EtOAc:MeOH (90+10) (Table 17). Total 215 fractions were obtained from CC-2 and 
controlled by TLC (stationary phase 1, mobile phase 1, see p. 41) before pooling (Fig. 44). 
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Fig. 44: TLC of the combined fractions of CC-2 
Stationary phase 1, mobile phase 1, detection 1 
 
In fractions 24 to 28 compound KK1 cristallized (Fig. 45). After removal of the 
supernatant, TLC comparison of fractions 24 to 28 (Fig.46) proved that compound KK1 
was the main substance at Rf 0.56 of fr. 12/3 with the blue colour after detection 1. Thus, 
the fractions were combined and 58mg of pure compound KK1 was obtained. 
                                                                                                                         
 Fig. 45: Cristallization of compound KK1                    Fig. 46: TLC of compound KK1 in 5 fractions 
                          Stationary phase 1, mobile phase 1, detection 1  
 
 
 
 
 
 As KK1 was a polar compound, a TLC comparison with different sugars was performed. 
Glucose, fructose, lactose, saccharose, mannose and rhamnose were used as authentic 
compounds. KK1 was less polar as the tested sugars and could not be identified. The use 
of aniline-diphenylamin-reagent, a reagent for the detection of compounds containing 
sugars, showed that compound KK1 contains a sugar moiety (Fig. 47). 
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Fig. 47: TLC comparison of KK1 with different sugars 
    Stationary phase 1, mobile phase 13, detection 1             Stationary phase 1, mobile phase 1, detection 3 
                  
  
CC-2 parameters Mobile Phase Fraction No. Pooled fractions mg Further separation 
 
 
Stationary phase: 
Silica Gel 60 
 
Column 
diameter: 
2cm 
 
Column height: 
85cm 
 
Fraction 
separation: 
509mg 
of fraction 12/3 
 
Fraction size: 
5 ml/60 min 
Water sat. EtOAc:MeOH 12/3/1 1-19 156 none 
90 : 10 12/3/2 20-23 30 CC-4 (p.69) 
“ 12/3/3 24a-28a 58 KK1 crystalls 
“ 12/3/4 24b-28b 19 mother liquor 
“ 12/3/5 29-34 21 none 
“ 12/3/6 35-50 20 none 
“ 12/3/7 51-67 16 none 
“ 12/3/8 68-88 39 none 
“ 12/3/9 89-110 6 none 
“ 12/3/10 111-140 26 CC-3 (p.68) 
“ 12/3/11 141-160 33 none 
“ 12/3/12 161-180 7 none 
“ 12/3/13 181-215 29 none 
 
Table 17: Conditions for CC-2 
 
The characterization of compound KK1 was performed by mass spectrometry and 
detailed NMR-analysis. From the ESI-MS spectra, a molecular weight of 318 amu was 
deduced. Using Flow Injection Analysis the mass spectrum in the negative mode displayed 
a quasimolecular ion at m/z 317 [M – H]-, and accordingly in the positive mode m/z 341 
[m + Na]+ was measured. Product ions were recorded by MS/MS in both the positive and 
negative mode at various collision energies. Fragmentation showed quasimolecular ions 
in the positive mode at m/z 336 [M + NH4]
+, m/z 319 [M + H]+, m/z 157 [M-
dehydrohexose]+ and m/z 139 [aglycone – H2O]
-. Product ions of m/z 317 [M-H]- in the 
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negative mode were m/z 179 [hexose – H]-, m/z 161 [(hexose – H)-H2O]
-, m/z 119 [0,2A]- 
and m/z 89 [0,3A]- (Kainz et al., 2011). 
NMR experiments, using extensive one and two dimensional techniques, revealed the 
sugar part as a β-glucopyranose. The aglycon showed mainly signals for CH2 groups in the 
aliphatic region, one double bond CH signal and an additional CH signal at 4.2 ppm in the 
1H NMR. The key structure was identified as a methylenecyclopropane moiety, linked 
glycosidically with the glucose via an alcohol attached to the cyclopropane ring. This 
analysis was based on the characteristic 1H and 13C NMR chemical shifts of the 
cyclopropane signals together with rather large 1H-13C one bond coupling constants, 
namely 188.2 Hz for CH-9’ and 163.9 and 161.0 Hz for the CH2-8’, respectively (Xu et al., 
1992). The measured C=C stretching frequency of 1775 cm-1 in the infrared spectrum of 
KK1 correlates with published data of similar methylenecyclopropane structures (Stang et 
al., 1974; Kainz et al., 2011) (see supplementary information). 
Numerous HMBC correlations and NOESY crosspeaks established all connectivities, as 
well as the geometry of the double bond. Attached to the double bond is a 5 carbon 
aliphatic chain terminated by an alcohol function. Finally, a molecular weight of 318 
resulting from mass spectrometry established compound KK1 as (2E)-2-(6-
hydroxyhexyliden)cyclopropyl-β-glucopyranoside (Fig. 48) (Kainz et al., 2011). 
 
Fig. 48: Compound KK1 - (2E)-2-(6-hydroxyhexyliden)cyclopropyl-β-glucopyranoside 
 
Compound KK1 was crystallized from a solvent mixture of methanol and diethylether. 
Analysis of a derived single crystal by X-ray diffraction established the relative 
stereochemistry of the chiral centre in the methylenecyclopropylalcohol moiety relative 
to glucose (Fig. 49). The absolute configuration was deduced by comparing the optical 
rotatory power of compound KK1 with published data for β-alkylglucosides. The [α]D for 
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β-D-glucosides is about –30 to –90, only few examples for β-L-glucosides are available 
showing an [α]D of +30 to +60.6,7. The measured [α]D of –74.9 established compound 
KK1 as (1R,2E)-2-(6-hydroxyhexyliden)cyclopropyl-β-D-glucopyranoside (Kainz et al., 
2011). 
 
Fig. 49: ORTEP plot (ellipsoids 50% probability) of compound KK1 
 
This compound, with the very uncommon structural feature of a methylenecyclopropane 
alcohol, has never been described before, neither isolated from natural sources nor 
totally synthesized. 
 
4.1.2 Isolation and structure elucidation of compound KK5  
As Fraction 12/3/10 showed one major compound in TLC, it was chosen to isolate the 
blue compound at Rf 0.58 (Fig. 44). The fraction was subjected to column 
chromatography on Sephadex LH-20 under elution with 50% MeOH (     Table 18). 180 
fractions were obtained from CC-3 and every tenth fraction was controlled by TLC before 
pooling the fractions. In the combined fraction 12/3/10/1 4,9mg of compound KK5 were 
obtained. A TLC comparison with KK1 revealed a very similar polarity (Fig. 51). 
The characterization of compound KK5 was performed by NMR analysis and mass 
spectrometry. The MS showed the quasimolecular ion in the negative mode at m/z 331 
[M – H]-. In the positive mode m/z 333 [M + H]+, m/z 350 [M + NH4]
+ and m/z 355 [M + 
Na]+ were determined in FIA resulting in a molecular weight of 332 amu. MS/MS in the 
negative mode indicated an increased fragmentation of m/z 331 [M – H]- related to the 
enhancement of collision energy. Relevant product ions were m/z 169 [M – 
dehydrohexose]-, m/z 151 [aglycone – H2O]
-, m/z 119 [0,2A]- and m/z 89 [0,3A]-. Both 
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MS/MS measurements in the positive mode revealed corresponding results (Kainz et al., 
2011). 
In the NMR experiments, using extensive one and two dimensional techniques, the 
spectroscopic data for compound KK5 were very similar to compound KK1. Again the 
sugar part was a β-glucopyranose with the glycosidic bond to the unusual 
methylenecyclopropan alcohol. Differences were seen in the side chain. The signals for 
the terminal CH2-OH group were missing, one CH2 group was shifted to lower field, and a 
carbonyl signal at 182.90 ppm appeared in the 13C NMR spectrum.  
Therefore the terminal alcohol in the alkane side chain of KK1 had to be oxidized in KK5 
giving the corresponding carboxylic acid, (6E)-6[2-(β-glucopyranosyloxy)cyclo 
propylidene]hexanoic acid (Fig. 50) (Kainz et al., 2011). 
 
 
Fig. 50: Compound KK5 - (6E)-6[2-(β -glucopyranosyloxy)cyclopropylidene]hexanoic acid  
 
 (6E)-6[2-(β-glucopyranosyloxy)cyclopropylidene]hexanoic acid has also never been 
described before. The main structural feature of this new glycosidic compound is the 
extremly uncommon methylenecyclopropan alcohol in the aglycon as also seen in 
compound KK1.  
 
Fig. 51: TLC comparison of compound KK1 and KK5 
Stationary phase 1, mobile phase 1, detection 1 
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CC-3 parameters Mobile Phase Fraction No. Pooled fractions mg Further treatment 
 
Stationary phase: 
Sephadex LH-20 
 
Column diameter: 
1cm 
 
Column height: 
40cm 
 
Fraction 
separation: 
26mg 
of fraction 
12/3/10 
 
Fraction size: 
5 ml/60 min 
 
50% MeOH 12/3/10/1 1-10 5 KK5 
“ 12/3/10/2 11-20 1 none 
“ 12/3/10/3 21-30 3 none 
“ 12/3/10/4 31-40 1 none 
“ 12/3/10/5 41-50 1.5 none 
“ 12/3/10/6 51-60 2 none 
“ 12/3/10/7 61-70 1 none 
“ 12/3/10/8 71-90 4 none 
“ 12/3/10/9 91-110 5 none 
“ 12/3/10/10 111-130 1 none 
“ 12/3/10/11 131-150 3 none 
“ 12/3/10/12 151-180 2 none 
 
     Table 18: Conditions for CC-3  
 
4.1.3 Isolation and structure elucidation of compound KK7  
Fraction 12/3/2 was further purified by column chromatography on Silica Gel 60 using 
water-saturated EtOAc as a mobile phase (Table 19). Total 204 fractions were obtained 
from CC-4 and every tenth fraction was controlled with TLC before pooling (Fig. 52). In 
fraction 12/3/2/13 7mg of compound KK7 were obtained. 
 
      
Fig. 52: TLC of the combined fractions of CC-4 
Stationary phase 1, mobile phase 1, detection 1 
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CC-4 parameters Mobile Phase Fraction No. Pooled fractions mg Further treatment 
 
Stationary phase: 
Silica Gel 60 
 
Column diameter: 
0,5cm 
 
Column height: 
50cm 
 
Fraction 
separation: 
30mg 
of fraction 12/3/2 
 
Fraction size: 
5 ml/30 min 
Water sat. EtOAc 12/3/2/1 1-10 0.5 none 
100% 12/3/2/2 11-30 2 none 
“ 12/3/2/3 31-40 1 none 
“ 12/3/2/4 41-50 1 none 
“ 12/3/2/5 51-70 3 none 
“ 12/3/2/6 71-83 1 none 
“ 12/3/2/7 84-96 1.5 none 
“ 12/3/2/8 97-103 2 none 
“ 12/3/2/9 104-120 3 none 
“ 12/3/2/10 121-133 5 none 
“ 12/3/2/11 134-153 1 none 
“ 12/3/2/12 154-159 1 none 
“ 12/3/2/13 160-190 7 KK7 
“ 12/3/2/14 191-204 2 none 
 
Table 19: Conditions for CC-4 
 
In NMR experiments compound KK7 was identified as a methyl glycoside. Two CH2 groups 
and one quarternary carbon are indicative for a ketose. The detailed NMR analysis and 
the comparison of the 13C NMR data with the literature (Duker and Serianni, 1993) 
revealed compound KK7 as methyl-α-fructofuranoside (Fig. 53) (Kainz et al., 2011) 
 
 
 
 
     
Fig. 53: Compound KK7 - methyl-α-fructofuranosid 
 
 
4.1.4 Isolation and structure elucidation of compound KK6  
Fraction 12/4 was subjected to column chromatography on Silica gel under elution with 
water-saturated EtOAc:MeOH (90+10). 300 fractions were collected from CC-5 (Table 20) 
and TLC comparison combined to 13 collective fractions (Fig. 54). In fraction 12/4/9 5mg 
of compound KK6 were obtained. 
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Fig. 54: TLC of combined fractions of CC-5 
Stationary phase 1, mobile phase 1, detection 1 
In the NMR experiments β-glucopyranose was determined. Compound KK6 was a 
phenolic acid and showed only two duplet signals. KK6 could be identified as p-trans-
coumaric acid. HMBC cross peaks established the glycosidic linkage to the p-phenol group 
of the conjugated acid. Compound KK6 could be identified as 4-O-ß-D-glucopyranosyl-p-
trans-coumaric acid. The NMR spectroscopic data correspond to the published values                
Fig. 55) (Cui et al., 1990).  
 
 
                               Fig. 55: Compound KK6 – 4-O-ß-D-glucopyranosyl-p-trans-coumaric acid  
 
CC-5 parameters Mobile Phase Fraction No. Pooled fractions mg Further treatment 
 
Stationary phase: 
Silica Gel 60 
 
Column diameter: 
2cm 
 
Column height: 
70cm 
 
Fraction 
separation: 
691mg 
Water sat. EtOAc:MeOH 12/4/1 1-8 9 none 
90 : 10 12/4/2 9-14 292 none 
“ 12/4/3 15-20 137 none 
“ 12/4/4 21-40 72 none 
“ 12/4/5 41-60 54 none 
“ 12/4/6 61-80 24 none 
“ 12/4/7 81-90 2 none 
“ 12/4/8 91-106 6 none 
“ 12/4/9 107-113 5 KK6 
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of fraction 12/4 
 
Fraction size: 
7 ml/60 min 
“ 12/4/10 114-140 13 none 
“ 12/4/11 141-160 16 none 
“ 12/4/12 161-232 12 none 
“ 12/4/13 232-300 7 none 
 
Table 20: Conditions for CC-5  
 
4.1.5 Isolation and structure elucidation of compound KK3  
Fraction 12/5 was subjected to column chromatography on Silica Gel 60 under elution 
with water-saturated EtOAc:MeOH (90+10) (Table 21). After TLC comparision of every 
tenth fraction, the fractions were combined to obtain 9 pooled fractions (Fig. 56). 
CC-6 parameters Mobile Phase Fraction No. Pooled fractions mg Further separation 
 
 
Stationary phase: 
Silica Gel 60 
 
Column diameter: 
2cm 
 
Column height: 
80cm 
 
Fraction 
separation: 
555mg 
of fraction 12/5 
 
Fraction size: 
7 ml/60 min 
Water sat. EtOAc:MeOH 12/5/1 1-28 12 none 
90 :10 12/5/2 29-32 26 none 
“ 12/5/3 33-36 121 none 
“ 12/5/4 37-38 116 none 
“ 12/5/5 39-40 69 none 
“ 12/5/6 41-53 70 none 
“ 12/5/7 54-62 9 none 
“ 12/5/8 63-109 25 none 
“ 12/5/9 110-150 58 CC-7 (p.73) 
 
Table 21: Conditions for CC-6 
 
                                        
Fig. 56: TLC of the combined fractions of CC-6 
Stationary phase 1, mobile phase 1, detection 1 
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Subfraction 12/5/9 was further purified by column chromatography on Silica Gel 60 under 
elution with water-saturated EtOAc:MeOH (80+20) to isolate the greyish compound at Rf 
0.32 (Table 22). The CC resulted in 6 pooled fractions (Fig. 57). In the combined fractions 
12/5/9/2, 12/5/9/3 and 12/5/9/4 the compound cristallized (Fig. 58) yielding 7 mg of 
compound KK3. Due to the small amounts of other subfractions no further separation 
was performed.   
                                   
           Fig. 57: TLC of combined fractions of CC-7                                 Fig. 58: Cristallisation of KK3                               
      Stationary phase 1, mobile phase 1, detection 1 
 
The characterization of compound KK3 was performed with one and two dimensional 
NMR techniques. In compound KK3 β-glucopyranose was determined. The 1H NMR spin 
system for a trisubstituted benzene together with the trans double bond revealed 
compound KK3 as caffeic acid derivative. HMBC cross peaks established the glycosidic 
linkage to the p-phenol opposite group to identify 4-O-ß-D-glucopyranosyl-caffeic acid 
(Fig. 59). The NMR spectroscopic data corresponded to published values (Cui et al., 1990; 
Kainz et al., 2011).  
 
Fig. 59: Compound KK3 - 4-O-ß-D-glucopyranosyl-caffeic acid 
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CC-7 parameters Mobile Phase Fraction No. Pooled fractions mg Further treatment 
 
Stationary phase: 
Silica Gel 60 
 
Column diameter: 
1cm 
 
Column height: 
95cm 
 
Fraction separation: 
58mg of fraction 
12/5/9 
 
Fraction size: 
5 ml/60 min 
Water sat. EtOAc:MeOH 12/5/9/1 1-37 26 none 
 
80 : 20 12/5/9/2 38-60 20 KK3 
 
“ 12/5/9/5 61-65 2 none 
 
“ 12/5/9/6 66-95 7 none 
 
 
Table 22: Conditions for CC-7 
 
4.1.6 Isolation and identification of compound KK4  
Fraction 12/10 was subjected to column chromatography on Sephadex LH-20 and elution 
with 50% MeOH to obtain 6 pooled fractions (Fig. 60). In fraction 12/10/3 compound KK4 
could be identified by TLC comparison with two trimeric proanthocyanidines - 
cinnamtannin B-1 and aesculitannin B (JV-1) isolated before from Metaxya rostrata (Fig. 
61) (Virtbauer 2007). 
                                   
                    Fig. 60: TLC of the combined fractions of CC-7                Fig. 61: TLC comparision KK4 with JV-1  
                               Stationary phase 1, mobile phase 1, detection 1 
                                                              
CC-8 parameters Mobile Phase Fraction No. Pooled fractions mg Further treatment 
Stationary phase: 
Sephadex LH-20 
 
Column diameter: 
1cm 
 
Column height: 
Water sat. EtOAc:MeOH 12/10/1 1-19 11 none 
“ 12/10/2 20-23 4 none 
“ 12/10/3 24-26 22 KK4 
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40cm 
 
Fraction 
separation: 
101mg of fraction 
12/10 
 
Fraction size: 
8 ml/60 min 
“ 12/10/4 27-33 28 none
“ 12/10/5 34-40 6 none 
“ 12/10/6 41-70 7 none 
 
Table 23: Conditions for CC-8 
 
Fig. 62: Compound KK4 – mixture of cinnamtannin B-1 and aesculitannin B 
 
4.1.7 Overview over the isolation of the pure compounds from Metaxya rostrata 
The chromatographic separation of a fraction from a water extract from the rhizomes of 
Metaxya rostrata prepared in a previous study (Virtbauer 2007) was continued. In this 
thesis, fraction 12 was fractionated and several compounds were isolated (Fig. 81). Two 
new compounds (KK1 and KK5), with the very uncommon structural feature of a 
methylenecyclopropan alcohol in the aglycon, two phenolic acid glycosides (KK3 and KK6) 
and a methyl-α-fructofuranosid (KK7) were isolated for the first time from the tree fern 
Metaxya rostrata.  
 
Fig. 63: Isolation scheme of the compounds from Metaxya rostrata isolated in this study 
fr.12
fr.12/3
KK1 fr.12/3/2
KK7
fr.12/3/10
KK5
fr.12/4
KK6
fr.12/5 
fr.12/5/9
KK3
fr.12/10
KK4
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4.1.8 Biological Testing of compound KK1 
Compound KK1 - (2E)-2-(6-hydroxyhexyliden)cyclopropyl-β-glucopyranoside – a new 
unusual natural compound, was tested for several biological activities. 
As fraction 12, from which KK1 was isolated, showed moderate cytotoxic activity, the 
cytotoxicity of the compound was tested as well. 
 
4.1.8.1 Bioviability assay of compound KK1 and KK1 aglycon 
In order to determine the effect of compound KK1 on cancer cell viability, SW480 human 
colon carcinoma cells were exposed to increasing concentrations of KK1 for 48h. Using 
neutralred assay, no significant loss of cells could be seen up to a concentration of 
500µM. The KK1 aglycon (see chapter 4.1.8.8.) showed a stronger effect on cell viability 
compared to compound KK1 Fig. 64). 
 
Fig. 64: Viability of SW480 treated with KK1 
Viability of SW480 cells treated with KK1 and the aglycon of KK1 was assessed using neutralred assay. The cells 
were cultivated on 24-well plates and incubated for 48 hours with increasing concentrations (25, 125 and 
500µM). Data represent mean ± s.e.mean from three independent experiments performed in triplicate.  
 
4.1.8.2 HDAC assay of compound KK1 
Histone deacetylase inhibitors (HDACi) are in the focus of research as anti-cancer drugs. 
HDACi are reported to induce growth arrest and apoptosis of cancer cells. Therefore the 
HDAC inhibition of KK1 was measured using a fluorimetric assay. Even at a concentration 
of 250µM only a low inhibition of about 18% was measured (Fig. 65). 
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Fig. 65: HDAC inhibition by KK1 
HDAC inhibition of compound KK1 in different concentrations was assessed using a fluorimetric assay. Data 
represent mean ± s.e.mean from two independent experiments.  
 
4.1.8.3 In silico screening of compound KK1 
An in silico guided search for possible anti-viral activities of KK1 was realized because very 
few compounds with the extremely uncommon structural part of methylenecyclopropane 
had shown anti-viral activitiy against Epstein-Barr-, Human Herpes-, Hepatitis B-, Human 
Immunodeficiency- and Human Cytomegalo Virus in vitro (Rybak et al., 2000, Qiu et al., 
1998, Uchida et al., 1999). Pharmacophoric profiling against more than 2200 models 
representing over 280 pharmacological targets (Rollinger et al., 2009) suggested α-
glucosidase as potential target for KK1. A structural similarity search in the MDL Drug 
Data Report (MDDR) database (Keiser et al., 2007) was conducted and confirmed this 
result making α-glucosidase a promising target for biological evaluation of compound 
KK1. 
 
Fig. 66: Fitting of compound KK1 into the -glucosidase inhibitor pharmacophore model 
Chemical features are color-coded: hydrogen bond donor, hydrogen bond acceptor, hydrophobic, compound 
shape 
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4.1.8.4 Antiviral activity of compound KK1 
The antiviral activity against Herpes simplex Virus 1 was determined. KK1 did not have an 
effect on the cell viability and did not show antiviral activity (Fig. 67).  
As an in silico guided search suggested α-glucosidase as potential target for KK1, the anti-
HIV activity should be evaluated as well, but could not be performed within this study. 
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      Fig. 67: Cell viability and antiviral activity of compound KK1 
The grey bars show viability of vero cells treated with compound KK1. The cells were incubated with increasing 
concentrations (1, 10 and 100µM). The black bars show the activity (1, 10 and 100µM) on Herpes simplex virus 1. 
Data represent mean ± s.e.mean from two independent experiments.  
 
4.1.8.5 Insecticidal activity of compound KK1 
As KK1 was isolated in large amounts from the rootlets of Metaxya rostrata an insecticidal 
activity of KK1 was assumed and evaluated. For the assay KK1 was incorporated in 
different concentrations to the food of the test organism Spotoptera littoralis (see page). 
20 freshly slipt larvae were put directly on the food piece. After 4 and finally after 7 days 
the larvae were weighed (Fig. 68).  
 µg/piece solvent 
Larvae 
alive 
Larvae 
dead 
Rel. 
weight 
% 
dead 
Larvae 
alive 
Larvae 
dead 
Rel. 
weight 
% 
dead 
 After 4 days After 7 days 
KK1 1 MeOH 15 0 109,2% 0 15 0 99,8% 0 
KK1 2,4 MeOH 15 0 120,9% 0 15 0 110,3% 0 
Control 1 - MeOH 15 0 100% 0 15 0 100% 0 
Azadirachtin 1 1,8 MeOH 14 1 90,6% 6,7 14 1 94,3% 6,7 
Azadirachtin 2 9 MeOH 14 1 86,6% 6,7 14 1 88,6% 6,7 
Azadirachtin 3 45 MeOH 11 4 75,9% 26,7 5 10 68,3% 66,7 
 
Table 24: Conditions and results of the insecticidal assay of compound KK1 
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Fig. 68: Insecticidal activity of compound KK1 
Larvae on the food piece at day 0, day 4 and day 7. 
In the positive control (azadirachtin) group 6.7% of the larvae died at the lowest 
concentration of 1.8mg/piece. At the highest concentration of 45mg/piece 26.7% died 
after 4 days. After 7 days 66.7% of the larvae receiving the highest azadirachtin 
concentration were dead. 
KK1 showed the same results as the negative control. No larvae died after 4 and 7 days 
(Table 24). 
 
4.1.8.6 Antifungal Activity of compound KK1 
Compounds KK1, KK3, KK4, KK5, KK6 and KK7, as well as fractions 12/3/5, fraction 
12/10/4, fraction 12/4/4 and the MeOH-extract, the water extract and the MeOH-water 
phase were applied on a TLC plate. After complete removal of the solvents a suspension 
of the fungus Cladosporium sphaerospermum in growth medium was sprayed onto the 
plate (Fig. 70). After 3 days of incubation the inhibiton zones without fungus were 
evaluated (Fig. 69).   
Most pure compounds, fractions and extracts did not show any growth inhibition. Only 
compound KK5 seemed to inhibit the growth of the fungus. 
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Fig. 69: Antifungal Activity of different compounds    Fig. 70: Application of the fungus in growth medium        
 
Fraction 12, fraction 12/3/5, VLC-1 (Virtbauer 2007), the MeOH-extract and the water 
extract (Virtbauer 2007) were applied on a TLC plate, developed in mobile phase 1 and 
dried well in order to remove the solvent. Then the plate was sprayed with the fungus 
Cladosporium sphaerospermum in growth medium (Fig.72). 
The components of the extracts and fraction VLC-1 did not show any inhibition. In fraction 
12 an inhibiting compound at Rf 0.68 was detected. The compounds coloured red after 
detection with anisaldehyde sulfuric acid reagent at Rf 0.6 – 0.75 are trimeric 
proanthocyanidines. In fraction 12/3/5 at Rf 0.55 an inhibiting zone was visible. As KK1 
did not show any antifungal activity, the weak inhibition was probably caused by 
compound KK5 (Fig. 71).  
                   
Fig. 71: TLC of different fractions tested for anifungal activity       Fig. 72: Antifungal activity of different fractions  
   Stationary phase 1, mobile phase 1, detection 1          Stationary phase 1, mobile phase 1, detection fungus   
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4.1.8.7 Antibacterial activity of compound KK1 
As secondary metabolites often serve the plant as anti-microbial compounds, the 
antibacterial activity against six strains of Staphylococcus aureus was tested. KK1 did not 
show any activity up to a concentration of 128µM for any of the strains (Table 25). 
 SA1199B Xu212 ATCC RN 4220 EMRSA 15 EMRSA 16 
KK1 - - - - - - 
Norfloxacin 32 8 0,5 0,5 0,5 256 
 
Table 25: MICs of KK1 and norfloxacin against six strains of Staphylococcus aureus 
 
4.1.8.8 Hydrolysis of compound KK1 
The unsusual natural compound KK1 was evaluated for several biological activities, but 
did not exhibit an antibacterial, antiviral, antifungal or insecticidal activity and did not 
show effect on cell viability.  
As glycosides are storage forms, the aglycon of KK1 might be the active principle. KK1 was 
hydrolysed and the aglycon of KK1 (Fig. 73) was obtained (Bleier 2011).11 The effect of the 
aglycon of KK1 on cancer cell viability was evaluated (chapter) and exhibited a stronger 
effect on cell viability (Fig. 64). 
 
 
 
Fig. 73: Aglycon of KK1 - (2E)-2-(hydroxyhexyliden)cyclopropanol 
 
 
 
                                                     
11
 The hydrolysis of KK1 was performed by Johanna Bleier, a diploma student at the Department of Pharmacognosy, 
University of Vienna. 
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4.2 Bioactivity-guided fractionation and isolation of the active compounds from 
Metaxya rostrata  
 
4.2.1 Extraction of plant material with solvents of different polarity 
Metaxya rostrata C. Presl, Stachytarpheta jamaicensis L. Vahl and Maranta arundinacea 
Pulm. Ex. L. are used in traditional medicine in Costa Rica to treat intestinal diseases 
(Pekarek 2005) and were investigated in this work. To extract the secondary metabolites 
of these plants as exhaustive as possible within this study, the leaves, rootlets and 
rhizomes of Metaxya rostrata, as well as the roots of Stachytarpheta jamaicensis and 
Maranta arundinaceae, were ground and extracted with solvents of different polarity 
(CH2Cl2, EA and MeOH). The water extract, which is used in traditional medicine, had 
already been fractionated in a previous work (Virtbauer 2007).  
For the pretesting between 5 g and 9 g of the plant material were extracted with the 
respective solvent at 40° using Accelerated Solvent Extraction (ASE) (Table 26). The 
obtained extracts were investigated by TLC using different reagents for detection.  
 
 
             Fig. 74: TLC of the CH2Cl2-extracts 
(1) Stationary phase 1, mobile phase 10, detection 1  
(2) Stationary phase 1, mobile phase 4, detection 2 
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                Fig. 75: TLC of the EA-extracts  
(1) Stationary phase 1, mobile phase 8, detection 1  
(2) Stationary phase 1, mobile phase 1, detection 2  
 
                           Fig. 76: TLC of the MeOH-extracts  
(1) Stationary phase 1, mobile phase 8, detection 1  
(2) Stationary phase 1, mobile phase 1, detection 2  
In the TCL of the CH2Cl2-extract of the rootlets of Metaxya rostrata (2) a very complex 
pattern of phenolic compounds was detected and in the EA-extract and MeOH-extract of 
the rootlets of Metaxya rostrata a major blue fluorescent phenolcarboxylic acid at Rf 0.27 
was detected with detection 2. With detection 2 no phenolic compounds in the extracts 
of Maranta arundinacea (5) were seen, but one major pink compound and very polar 
compounds in the methanolic extract with detection 1. In the extracts of the rhizomes of 
Metaxya rostrata (3) and the roots of Stachytarpheta jamaicensis (4) phenolic 
components were detected. In the CH2Cl2-extract of the leaves of Metaxya rostrata (1) 
large amounts of chlorophyll were seen with detection 2. 
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 1 2 3 4 5 
 Leaves 
Metaxya 
rostrata 
Rootletts 
Metaxya 
rostrata 
Rhizomes  
Metaxya 
rostrata 
Roots 
Stachytarpheta 
jamaicensis 
Roots 
Maranta 
arundinaceae 
MeCl2 148 99 39 124 52 
EA 33 32 19 20 7 
MeOH 1005 480 636 117 339 
 
Table 26: Yield (mg) of extracts from ASE 
 
4.2.2 Pretesting of the extracts 
In order to determine the effect on cancer cell viability, SW480 colon carcinoma cells, 
were exposed to increasing concentrations (0.6, 6 and 60μg/ml) of extracts and the 
percentage of viable cells was determined by neutralred assay.  
The CH2Cl2-extract of the leaves (1) and the rhizomes of Metaxya rostrata (3) and the 
roots of Maranta arundinacea (5) led to a significant cell loss at a concentration of 
60µg/ml. The extract from the roots of Stachytarpheta jamaicensis (4) and the rootlets of 
Metaxya rostrata (2) showed a significant loss of cells compared to control already at a 
concentration of 6µg/ml (Fig. 77). 
 
             Fig. 77: Viability of SW480 cells treated with the CH2Cl2-extracts  
Viability of SW480 cells treated with the CH2Cl2-extracts of the different plant material (1, 2, 3, 4 and 5) was 
assessed using neutralred assay. The cells were cultivated on 24-well plates and incubated for 72 hours with 
increasing concentrations (0.6, 6 and 60µg/ml). Data represent mean ± s.e.mean from three independent 
experiments performed in triplicate (*P<0.05, **P<0.01, ***P<0.001 as compared to control cells).  
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After treatment of the cells with the EA-extracts from the rhizomes of Metaxya rostrata 
(3) and the roots of Stachytarpheta jamaicensis (4) significant cell loss at a concentration 
of 60µg/ml was observed. Incubation with the extracts from the leaves (1) and the 
rootletts of Metaxya rostrata (2) led to significant loss of cells as compared to the control 
at concentrations of 60µg/ml and 6µg/ml and the EA-extract from the roots of Maranta 
arundinacea (5) was active from 0.6µg/ml upwards (Fig. 78). 
 
            Fig. 78: Viability of SW480 cells treated with the EA-extracts  
Viability of SW480 cells treated with the EA-extracts of the different plant material (1, 2, 3, 4 and 5) was assessed 
with neutralred assay. The cells were cultivated on 24-well plates and incubated for 72 hours with increasing 
concentrations (0.6, 6 and 60µg/ml). Data represent mean ± s.e.mean from three independent experiments 
performed in triplicate (*P<0.05, **P<0.01, ***P<0.001 as compared to control cells).  
 
The MeOH-extracts of the roots of Stachytarpheta jamaicensis and the roots of Maranta 
arundinacea were inactive. The extracts from the leaves, the rootletts and the rhizomes 
of Metaxya rostrata showed a significant loss of cells compared to the control at a 
concentration of 60µg/ml (Fig. 79), with the extract from the rootlets being the most 
active. 
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Fig. 79: Viability of SW480 cells treated with the MeOH-extracts 
Viability of SW480 cells treated with the MeOH-extracts of the different plant material (1, 2, 3, 4 and 5) was 
assessed with neutralred assay. The cells were cultivated on 24-well plates and incubated for 72 hours with 
increasing concentrations (0.6, 6 and 60µg/ml). Data represent mean ± s.e.mean from three independent 
experiments performed in triplicate (*P<0.05, **P<0.01, ***P<0.001 as compared to control cells).  
 
 
4.2.2.1 Time-dependence of effects for selected fractions 
Due to the compounds pattern and the highest activity of the CH2Cl2-extract of the 
rootlets of Metaxya rostrata (2 CH2Cl2), the roots of Stachytarpheta jamaicensis (4 
CH2Cl2), the EA-extract of the leaves (1 EA), the rootlets of Metaxya rostrata (2 EA) and of 
the roots of Maranta arundinaceae (5 EA), as well as the MeOH-extracts of the rootletts 
(2 MeOH) and the rhizomes of Metaxya rostrata (3 MeOH) were selected for further 
investigation. 
The effect of cell viability was measured with Neutralred assay. To assess necrosis the 
LDH-assay was performed. The cells were cultivated on 24-well plates and were exposed 
to the extracts for 24, 48 and 72 hours. 
After 24 hours all studied extracts reduced the cell number significantly. 2 CH2Cl2 reduced 
cell viability to 20% and in the LDH assay proved that the cell loss was not due to necrosis. 
The cell loss after treatment with 4 CH2Cl2 and 2 MeOH was due to necrosis (see Fig. 80). 
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Fig. 80: Viability of SW480 cells (1) and LDH assay (2) after 24h 
(1)Viability of SW480 cells treated with the most interesting extracts (2 and 4 CH2Cl2, 1, 2 and 5 EA and 2 and 3 
MeOH) was assessed with neutralred assay. (2) Cytotoxicity of the most interesting extracts on SW480 cells was 
evaluated with  the  LDH  assay.  The  cells were  cultivated on 24‐well plates  and  incubated  for 24 hours with  a 
concentration of 30µg/ml. Data represent mean ± s.e.mean from three  independent experiments performed  in 
triplicate (*P<0.05, ***P<0.001 as compared to control cells). 
 
After 48 hours the 5 EA, 2 MeOH and 3 MeOH showed low or no significant cell loss. The 
cell loss of 2 MeOH and of 4 CH2Cl2 was due to necrosis. 2 CH2Cl2 reduced cell viability to 
30% and in the LDH assay it was shown that the cell loss was not due to necrosis. 1 EA and 
2 EA showed significant cell loss which was not due to necrosis (Fig. 81). 
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Fig. 81 Viability of SW480 cells (1) and LDH assay (2) after 48h 
(1)Viability of SW480 cells treated with the most interesting extracts (2 and 4 CH2Cl2, 1, 2 and 5 EA and 2 and 3 
MeOH) was assessed with neutralred assay. (2) Cytotoxicity of the most interesting extracts on SW480 cells was 
evaluated with  the  LDH  assay.  The  cells were  cultivated on 24‐well plates  and  incubated  for 48 hours with  a 
concentration of 30µg/ml. Data represent mean ± s.e.mean from three  independent experiments performed  in 
triplicate (*P<0.05, **P<0.01, ***P<0.001 as compared to control cells). 
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After  72  hours  all  extracts  reduced  the  cell  viability  significantly. But  the  cell  loss  in  2 
MeOH and 4 CH2Cl2 was due to necrosis. 1 EA and 2 EA showed significant cell loss which 
is not due to necrosis. 2 CH2Cl2 reduced cell viability to 20% with a little higher LDH level 
as after 48h.  
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Fig. 82: Viability of SW480 cells (1) and LDH assay (2) after 72h 
(1)Viability of SW480 cells treated with the most interesting extracts (2 and 4 CH2Cl2, 1, 2 and 5 EA and 2 and 3 
MeOH) was assessed with neutralred assay. (2) Cytotoxicity of the most interesting extracts on SW480 cells was 
evaluated with  the  LDH  assay.  The  cells were  cultivated on 24‐well plates  and  incubated  for 72 hours with  a 
concentration of 30µg/ml. Data represent mean ± s.e.mean from three  independent experiments performed  in 
triplicate (*P<0.05, **P<0.01, ***P<0.001 as compared to control cells). 
 
The  results  of  the  neutralred‐  and  the  LDH‐assays  in  these  experiments  showed  the 
highest activity for the CH2Cl2‐extract of the rootletts of Metaxya rostrata (2 CH2Cl2), the 
EA‐extract of the leaves (1 EA), the EA‐extract of the rootletts of Metaxya rostrata (2 EA) 
and the MeOH‐extracts of the rhizomes of Metaxya rostrata (3 MeOH). Cell loss was not 
caused  by  necrosis.  Thus,  these  extracts  were  chosen  for  the  isolation  of  the  active 
principles. 
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4.2.3 Extraction, fractionation and testing of the CH2Cl2-extract from the rootlets of 
Metaxya rostrata  
From 97g plant material after extraction with dichloromethane at 40° using Accelerated 
Solvent Extraction (ASE) 1g CH2Cl2-extract was obtained. This extract was subjected to 
column chromatography on Sephadex LH-20 under elution with EtOAc (Table 27) to 
obtain 9 pooled subfractions CC-9/1 to CC-9/9 (Fig. 83).  
    
Fig. 83: TLC of the combined fractions of CC-9 
Stationary phase 1, mobile phase 1, detection 1 and 2 
The TLC of the pooled fractions of CC-9 showed terpenoid compounds in fractions CC-9/1 
to fraction CC-9/3 and very polar compounds in fractions CC-9/5 to CC-9/9 with detection 
1. With detection 2 a complex pattern of phenolic compounds was detected. 
CC-9 parameters Mobile Phase Fraction No. Pooled fractions mg Further treatment 
 
Stationary phase: 
Sephadex LH-20 
 
Column diameter: 
2cm 
 
Column height: 
85cm 
 
Fraction separation: 
1g 
of CH2Cl2 Extract 
 
Fraction size: 
12 ml/60 min 
EtOAc CC-9/1 1-7 308 testing 
“ CC-9/2 8-11 304 testing 
“ CC-9/3 12-18 99 testing 
“ CC-9/4 19-33 61 testing 
“ CC-9/5 34-62 43 testing 
“ CC-9/6 63-90 18 testing 
“ CC-9/7 91-120 9 testing 
“ CC-9/8 121-145 18 testing 
“ CC-9/9 146-200 35 testing 
 
Table 27: Conditions for CC-9 
All fractions were tested for their cytotoxic potential. The neutralred assay revealed a 
dose-dependent reduction of cell viability. At a concentration of 6µg/ml, fractions CC-9/3, 
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CC-9/4, CC-9/5 reduced cell viability significantly to 10% and fraction CC-9/6 and CC-9/8 
down to 20% of the control (Fig. 84). 
 
Fig. 84: Viability of SW480 cells treated with the fractions of CC-9  
Viability of SW480 cells treated with the fractions of CC-9 (fraction CC-9/1 to fraction 9) was assessed with 
neutralred assay. The cells were cultivated on 24-well plates and incubated for 48 hours with increasing 
concentrations (0.6, 6 and 60µg/ml). Data represent mean ± s.e.mean from three independent experiments 
performed in triplicate (*P<0.05, **P<0.01, ***P<0.001 as compared to control cells). 
 
4.2.4 Extraction, fractionation and testing of the EA extract from the rootlets of 
Metaxya rostrata 
After extraction with dichloromethane the plant material (see p.88) was extracted with 
ethylacetate at 40° using Accelerated Solvent Extraction (ASE) to yield 1.2g of EA-extract 
fractionated by column chromatography CC-10 on Sephadex LH-20 under elution with 
EtOAc and EtOAC-MeOH (Table 28) to obtain 20 pooled subfractions (Fig. 85 and 86). 
(1)                                                                                    (2) 
   
Fig. 85: TLC -1 of the combined fractions of CC-10 
(1) Stationary phase 1, mobile phase 5.1, detection 1.   (2) Stationary phase 1, mobile phase 1, detection 1. 
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(1)                                                                                      (2) 
 
        Fig. 86: TLC-2 of the combined fractions of CC-10 
(1) Stationary phase 1, mobile phase 5.1, detection 2.   (2) Stationary phase 1, mobile phase 1, detection 2. 
The TLC of the pooled fractions of CC-10 showed a complex pattern of phenolic 
compounds in fractions CC-10/2 to 9. In fractions CC-10/14 and CC-10/15 a major blue 
fluorescent compound at Rf 0.24 can be detected with detection 2. Proanthocyandinines 
coloured red with detection 1 were seen in fraction CC-10/12 at Rf 0.57 and 0.66 and the 
blue compound at Rf 0.39 in the same fraction was identified as KK1. 
CC-10 parameters Mobile Phase Fraction No. Pooled fractions mg Further treatment 
 
 
 
Stationary phase: 
Sephadex LH-20 
 
 
Column diameter: 
2cm 
 
 
Column height: 
90cm 
 
 
Fraction 
separation: 
1200mg 
of EA Extract 
 
 
Fraction size: 
12 ml/60 min 
EtOAc CC-10/1 1-6 27 testing 
“ CC-10/2 7-11 96 testing 
“ CC-10/3 12-20 67 testing 
“ CC-10/4 21-30 31 testing 
“ CC-10/5 31-40 21 testing 
“ CC-10/6 41-50 14 testing 
“ CC-10/7 51-70 21 testing 
“ CC-10/8 71-90 19 testing 
“ CC-10/9 91-120 16 testing 
EA:MeOH(70:30) CC-10/10 121-170 327 testing 
“ CC-10/11 171-221 45 testing 
“ CC-10/12 222-250 32 testing 
“ CC-10/13 251-280 16 testing 
“ CC-10/14 281-300 21 testing 
“ CC-10/15 301-324 10 testing 
“ CC-10/16 325-333 14 testing 
“ CC-10/17 334-360 57 testing 
“ CC-10/18 361-400 61 testing 
“ CC-10/19 401-430 33 testing 
“ CC-10/20 431-470 38 testing 
 
Table 28: Conditions for CC-10 
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The cytotoxic activity of fractions CC-10/1 to CC-10/17 was determined in the neutralred 
assay which revealed a significant dose-dependent reduction of cell viability in fraction 
CC-10/2, CC-10/3, CC-10/4, CC-10/5 and CC-10/6. These fractions showed significant cell 
loss down to a concentration of 6µg/ml or 0.6µg/ml. The other fractions exhibited lower 
or no activity (Fig. 87 and Fig. 88). 
 
                    Fig. 87: Viability of SW480 cells treated with the fractions of CC-10  
Viability of SW480 cells treated with the fractions of CC-10 (fraction CC-10/1 to fraction 9) was assessed with 
neutralred assay. The cells were cultivated on 24-well plates and incubated for 48 hours with increasing 
concentrations (0.6, 6 and 60µg/ml). Data represent mean ± s.e.mean from three independent experiments 
performed in triplicate (*P<0.05, **P<0.01, ***P<0.001 as compared to control cells). 
 
                              Fig. 88: Viability of SW480 cells treated with the fractions of CC-10  
Viability of SW480 cells treated with the fractions of CC-10 (fraction CC-10/10 to fraction 17) was assessed with 
neutralred assay. The cells were cultivated on 24-well plates and incubated for 48 hours with increasing 
concentrations (0.6, 6 and 60µg/ml). Data represent mean ± s.e.mean from three independent experiments 
performed in triplicate (*P<0.05, **P<0.01, ***P<0.001 as compared to control cells). 
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To additionally confirm the previous results, the experiment was repeated with the most 
active fractions. Fractions CC-10/3, CC-10/4, CC-10/5, CC-10/6 reduced cell viability 
significantly at a concentration of 60µg/ml to about 20%. At a concentration of 6µg/ml 
the cell viability in these fractions is reduced to 40% in CC-10/5 or about 65% in CC-10/3, 
CC-10/4 and CC-10/6 (see Fig. 89). 
 
                  Fig. 89: Viability of SW480 cells treated with the selected fractions of CC-10  
Viability of SW480 cells treated with the most active fractions of CC-10 (fractions CC-10/2, 3, 4, 5 and 6) was 
assessed with neutralred assay. The cells were cultivated on 24-well plates and incubated for 48 hours with 
increasing concentrations (0.6, 6 and 60µg/ml). Data represent mean ± s.e.mean from three independent 
experiments performed in triplicate (*P<0.05, **P<0.01, ***P<0.001 as compared to control cells). 
 
 
4.2.5 Extraction, fractionation and testing of the EA extract from the leaves of 
Metaxya rostrata 
120g leaves, after extraction with dichloromethane and drying, were extracted by ASE 
with ethylacetate at 40° to obtain 820mg of EA-extract. Before fractionation by column 
chromatography, chlorophyll was removed using liquid/liquid partition (see p.44). TLC 
analysis was used to confirm the removal of a large amount of chlorophyll. The intensive 
red colored zones with an Rf values of 0.9 and above and the enriched polar compounds 
showed that the procedure had been effective (Fig. 90). 
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Fig. 90: TLC of the fractions after removal of chlorophyll 
Stationary phase 1, mobile phase 14, detection 2 
 
The purified EA-extract was further subjected to column chromatography on Sephadex 
under elution with EtOAc. Column chromatography CC-11 yielded 10 pooled fractions 
Table 29) which were tested for their activity on cell proliferation. The blue fluorescent 
compound in CC-11/9 at Rf 0.76 was identified as caffeic acid by TLC comparison with the 
authentic reference (Fig. 91). 
 
(1)                                                                                      (2) 
  
Fig. 91: TLC of the combined fractions of CC-11 
(1) Stationary phase 1, mobile phase 5.2, detection 1  
(2) Stationary phase 1, mobile phase 5.1, detection 2 
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CC-11 parameters Mobile Phase Fraction No. Pooled fractions mg Further treatment 
Stationary phase: 
Sephadex LH-20 
 
Column diameter: 
2cm 
 
Column height: 
85cm 
 
Fraction separation: 
240mg 
of purified EA Extract  
 
Fraction size: 
6 ml/60 min 
EtOAc CC-11/1 1-6 3 testing 
“ CC-11/2 7 13 testing 
“ CC-11/3 8-14 33 testing 
“ CC-11/4 15-28 7 testing 
“ CC-11/5 29-40 7 testing 
“ CC-11/6 41-60 10 testing 
“ CC-11/7 61-80 10 testing 
“ CC-11/8 81-92 7 testing 
“ CC-11/9 93-115 12 testing 
“ CC-11/10 116-200 79 testing 
 
Table 29: Conditions for CC-11 
 
In order to evaluate the effect of the fractions of the EA-extract on cancer cell viability, 
the SW480 cells were exposed to increasing concentrations (0.6, 6 and 60μg/ml) of these 
fractions. 
The neutralred assay revealed a significant dose-dependent reduction of cell viability in 
fraction CC-11/3, CC-11/7, CC-11/8 and CC-11/9. These fractions showed significant cell 
loss at a concentration of 6µg/ml. For other fractions lower or no activity was revealed 
(Fig. 92). 
 
Fig. 92: Viability of SW480 cells treated with the selected fractions of CC-11 
Viability of SW480 cells treated with the fractions of CC-11 (fractions CC-11/2 to 10) was assessed with neutralred 
assay. The cells were cultivated on 24-well plates and incubated for 48 hours with increasing concentrations (0.6, 
6 and 60µg/ml). Data represent mean ± s.e.mean from three independent experiments performed in triplicate 
(*P<0.05, **P<0.01, ***P<0.001 as compared to control cells). 
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4.2.6 Extraction, fractionation and testing of the MeOH extract from the rhizomes of 
Metaxya rostrata 
300g of the plant material were extracted with methanol at 40° using Accelerated Solvent 
Extraction (ASE) to obtain 30,6g of MeOH-extract. Due to the content of tannins in this 
extract and to avoid interferences of these compounds with the assay, a detannification 
step was performed following the scheme depicted in Fig. 93.  
 
Fig. 93: Scheme of detannification of the MeOH-extract of the rhizomes of Metaxya rostrata 
The methanol extract was dissolved in water by sonification for 15min. After 
centrifugation the supernatant was collected (H2O-Phase I). The tannins remained in the 
residue, which was again sonicated with water (H2O-Phase II). The two water phases were 
combined and partitioned with butanol (BuOH-Phase) (Fig. 94) which was then subjected 
to column chromatography on Sephadex LH-20.                                                     
 
                                                                    
Fig. 94: TLCs of detannification of the MeOH-extract of the rhizomes from Metaxya rostrata 
Stationary phase 1, mobile phase 1, detection 1 and 2 
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After detection with anisaldehyde-sufuricacid-reagent a red compound in the BuOH-
phase with Rf 0.81 was identified as a mixture of cinnamintannin B and aesculitannin B1 
by TLC-comparison with the reference compound. A blue compound at Rf 0.54 was 
identified as compound KK5 and another blue compound at Rf 0.48 as compound KK1. 
The purified MeOH-extract was further subjected to column chromatography on 
Sephadex LH-20 under elution with 80% MeOH (Table 30). Column chromatography CC-
12 yielded 13 fractions (Fig. 95 and Fig. 96), which were tested for their activity on cell 
proliferation. 
    
Fig. 95: TLC of the combined fractions of CC-12 
Stationary phase 1, mobile phase 1, detection 1 
 
  
Fig. 96: TLC of the combined fractions of CC-12 
Stationary phase 1, mobile phase 1, detection 2 
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CC-12 parameters Mobile Phase Fraction No. Pooled fractions mg Further treatment 
 
 
Stationary phase: 
Sephadex LH-20 
 
Column diameter: 
2cm 
 
Column height: 
85cm 
 
Fraction separation: 
7500mg 
of MeOH Extract  
 
Fraction size: 
10 ml/60 min 
80% MeOH CC-12/1 1-4 16 testing 
“ CC-12/2 5-7 934 testing 
“ CC-12/3 8-13 1366 testing 
“ CC-12/4 14-21 677 testing 
“ CC-12/5 22-29 334 testing 
“ CC-12/6 30-42 629 testing 
“ CC-12/7 43-55 130 testing 
“ CC-12/8 56-70 103 testing 
“ CC-12/9 71-81 62 testing 
“ CC-12/10 82-93 63 testing 
“ CC-12/11 94-102 31 testing 
“ CC-12/12 103-120 45 testing 
“ CC-12/13 121-140 34 testing 
 
Table 30: Conditions for CC-12 
 
 
In the bioassay, fractions CC-12/3 to CC-12/10 reduced cell viability significantly only at a 
concentration of 60µg/ml. At concentrations of 6µg/ml or lower the fractions had no 
effect on the cell viability (Fig. 97).  
 
Fig. 97: Viability of SW480 cells treated with the fractions of CC-12 
Viability of SW480 cells treated with the fractions of CC-12 (fractions CC-12/2 to 11) was assessed with neutralred 
assay. The cells were cultivated on 24-well plates and incubated for 48 hours with increasing concentrations (0.6, 
6 and 60µg/ml). Data represent mean ± s.e.mean from three independent experiments performed in triplicate 
(*P<0.05, **P<0.01, ***P<0.001 as compared to control cells). 
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4.2.7 Bioassay of the most active CH2Cl2-fractions of CC-9 
In order to confirm the earlier results on cancer cell viability, SW480 cells were again 
exposed to increasing concentrations (1.875, 3.75, 7.5, 15, 30 and 60μg/ml) of the most 
active fractions obtained from the CH2Cl2-extract of the rootlets of Metaxya rostrata. 
After neutralred assay and LDH assay, the pooled fractions CC-9/3, CC-9/4, CC-9/5, CC-9/6 
and CC-9/8, which caused no or little necrosis, were selected. Fraction CC-9/3 reduced 
cell viability significantly to about 20% down to a concentration of 3.75µg/ml and more. 
Fraction CC-9/5 was almost as effective as CC-9/3. Fraction CC-9/4 and CC-9/6 showed 
similar activity reducing the cell viability significantly at concentrations from 7.5µg/ml 
upwards. Only Fraction CC-9/3 was able to reduce the cell viability in a significant manner 
at a concentration of 1.875µg/ml (Fig. 98).  
 
Fig. 98: Bioviability assay of the selected fractions of the CH2Cl2-extract of the rootlets of Metaxya rostrata 
Viability of SW480 cells treated with the most active fractions of CC-12 (fractions CC-12/3, 4, 5, 6 and 8) was 
assessed with neutralred assay. The cells were cultivated on 24-well plates and incubated for 48 hours with 
increasing concentrations (1.875, 3.75, 7.5, 15, 30 and 60μg/ml). Data represent mean ± s.e.mean from three 
independent experiments performed in triplicate (*P<0.05, **P<0.01, ***P<0.001 as compared to control cells). 
 
 
4.2.8 Isolation and structure elucidation of the active compounds of the most active 
CH2Cl2-fractions of the rootlets of Metaxya rostrata 
Due to their high activity, fractions CC-9/3, CC-9/4, CC-9/5 and CC-9/6 of the CH2Cl2-
extract of the rootlets (Fig. 99) were selected for further fractionation and isolation of the 
active compounds. The small amout of the fractions made re-extraction and re-
fractionation necessary for the isolation of the active principles. 
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(1)                                                                 (2)                                                                 
                                
     Fig. 99: TLC of the most active fractions of the CH2Cl2 –extract of the rootlets from Metaxya rostrata 
(1) Stationary phase 1, mobile phase 1, detection 1  
(2) Stationary phase 1, mobile phase 1, detection 2  
 
The TLC of the most active fractions showed a complex pattern of phenolic compounds 
with detection 2. In fraction CC-9/3 a major compound coloured purple at Rf 0.72 with 
detection 1 and a major green fluorescent compound with detection 2 were detected. 
With detection 2 a major blue fluorescent compound in CC-9/6 can be seen. 
 
4.2.8.1 Reextraction and refractionation of the CH2Cl2-extract of the rootlets from 
Metaxya rostrata 
The active fractions, which were further fractionated, were CC-9/3 (90mg), CC-9/4 
(60mg), CC-9/5 (40mg) and CC-9/6 (15mg). Due to the small amout of these fractions, 
new plant material was extracted and fractionated in the same way to obtain more of the 
active fractions. 920g dried rootletts of Metaxya rostrata were pulverized and extracted 
by sonification with CH2Cl2 yielding 5,3g CH2Cl2-extract. This CH2Cl2-extract was compared 
by TLC to the first CH2Cl2-extract. Detection with different spraying reagents revealed the 
qualitative composition and showed good correlations (Fig. 100).        
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                                 Fig. 100: TLC comparision of the two CH2Cl2-extracts of the rootlets  
                                   (1) Stationary phase 1, mobile phase 10, detection 1.  
(2) Stationary phase 1, mobile phase 10, detection 2. 
 
Thus, the “new” extract was fractionated in the same manner as the first CH2Cl2-extract 
and subjected to column chromatography on Sephadex LH-20 under elution with EtOAc 
Table 31) to obtain a total of 290 fractions which were combined after TLC comparison to 
16 subfractions CC-13/1 to CC-13/16 (Fig. 101 and Fig. 102).  
(1)                                                                                        (2) 
 
Fig. 101: TLC of the combined fractions 1-7 of CC-13 
              (1) Stationary phase 1, mobile phase 1, detection 1  
       (2) Stationary phase 1, mobile phase 1, detection 2  
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 (1)                                                                                        (2) 
  
Fig. 102: TLC of the combined fractions 8 to 16 of CC-13 
           (1) Stationary phase 1, mobile phase 1, detection 1 
      (2) Stationary phase 1, mobile phase 1, detection 2 
 
CC-13 parameters Mobile Phase Fraction No. Pooled fractions mg Further treatment 
 
 
Stationary phase: 
Sephadex LH-20 
 
 
Column diameter: 
4cm 
 
 
Column height: 
75cm 
 
 
Fraction 
separation: 
5370mg 
of new CH2Cl2 
Extract 
 
 
Fraction size: 
8 ml/60 min 
EtOAc CC-13/1 1-42 540 testing 
“ CC-13/2 43-54 1620 testing 
“ CC-13/3 55-65 1390 testing 
“ CC-13/4 66-71 518 testing 
“ CC-13/5 72-77 171 testing 
“ CC-13/6 78-82 52 testing 
“ CC-13/7 83-101 192 testing 
“ CC-13/8 102-116 77 testing 
“ CC-13/9 117-127 51 testing 
“ CC-13/10 128-136 45 testing 
“ CC-13/11 137-140 25 testing 
“ CC-13/12 141-150 30 testing 
“ CC-13/13 151-180 25 testing 
“ CC-13/14 181-202 30 testing 
“ CC-13/15 203-224 30 testing 
“ CC-13/16 225-290 15 testing 
 
Table 31: Conditions for CC-13 
 
4.2.8.2 Bioassay of the fractions from CC-13  
In order to evaluate the effect of the fractions of CC-13 on SW480 viability, the cells were 
exposed to increasing concentrations (0.6, 6 and 60μg/ml).  
Fractions CC-13/2, CC-13/3, CC-13/4, CC-13/11 and CC-13/16 reduced cell viability 
significantly only at a concentration of 60µg/ml. At a concentration of 6µg/ml or lower 
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these fractions had no effect on the cell viability. Fractions CC-13/5, CC-13/6, CC-13/7, CC-
13/8, CC-13/14 and CC-13/15 showed higher activity, reducing the cell viability in a 
significant manner at concentrations of 6µg/ml (see Fig. 103 and Fig. 104).      
 
Fig. 103: Viability of SW480 cells after treatment with fractions 1-7 of CC-13 
Viability of SW480 cells treated with the fractions of CC-13 (fractions CC-13/1 to 7) was assessed with neutralred 
assay. The cells were cultivated on 24-well plates and incubated for 48 hours with increasing concentrations (0.6, 
6 and 60μg/ml). Data represent mean ± s.e.mean from three independent experiments performed in triplicate 
(*P<0.05, **P<0.01, ***P<0.001 as compared to control cells). 
 
 
Fig. 104: Viability of SW480 cells after treatment with fractions 8-16 of CC-13 
Viability of SW480 cells treated with the fractions of CC-13 (fractions CC-13/8 to 16) was assessed with neutralred 
assay. The cells were cultivated on 24-well plates and incubated for 48 hours with increasing concentrations (0.6, 
6 and 60μg/ml). Data represent mean ± s.e.mean from three independent experiments performed in triplicate 
(*P<0.05, **P<0.01, ***P<0.001 as compared to control cells). 
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4.2.8.3 Bioassay of selected fractions of CC-13 
Based on the results of the first screening, the pattern and the amount of the fractions, 
fractions CC-13/5, CC-13/6, CC-13/7, CC-13/8, CC-13/14 and CC-13/15 were seleceted for 
the isolation of the active compounds of the rootlets of Metaxya rostrata. 
In order to confirm the earlier results on cancer cell viability a second set of experiments 
was performed. Results from the earlier experiments were confirmed making these 
fractions the most interesting ones for the isolation of the active principles (Fig. 105). 
 
Fig. 105: Viability of SW480 cells after treatment with the selected fractions of CC-13 
Viability of SW480 cells treated with the most active fractions of CC-13 (fractions CC-13/5, 6, 7, 8, 14 and 15) was 
assessed with neutralred assay. The cells were cultivated on 24-well plates and incubated for 48 hours with 
increasing concentrations (0.6, 6 and 60μg/ml). Data represent mean ± s.e.mean from three independent 
experiments performed in triplicate (*P<0.05, **P<0.01, ***P<0.001 as compared to control cells). 
A TLC comparison of the active fractions from the CC-9 and those from CC-13 showed 
similar composition (Fig. 106). Nevertheless, due to some differing compounds the 
fractions were not combined and further fractionated separately. 
 
   
Fig. 106: TLC comparison of CC-9 and CC-13 
Stationary phase 1, mobile phase 1, detection 1 and 2 
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Comparative TLC analysis of the active fractions with different methylated flavonoids 12 
was performed based on the fluorescence and polarity of the compounds. But none of 
the major compounds in the fractions was identical to a standard and could be identified. 
                             
Fig. 107: TLC comparison of the active fractions of CC-13 with methylated flavonoids 
Stationary phase 1, mobile phase 10, detection 2  (A=Quercetin-3-3-4‘-trimethylether, B=Kaempferol-3-4‘-
dimethylether, C=Kaempferol-3-7‘-dimethylether, D=Quercetin-3-7‘-dimethylether, E=Quercetin-3-7-3‘-
trimethylether, F=Quercetin-3-7-4‘-trimethylether, G=Kaempferol-3-7-4‘-trimethylether)  
 
4.2.9 Fractionation of the most active fractions from CC-9 and CC-13 by solid phase 
extraction (SPE) 
Selected based on their activity, the fractions CC-13/5, CC-13/6, CC-13/7, CC-13/8, CC-
13/14, CC-13/15 and the fractions CC-9/3 and CC-9/4 were further fractionated using 
solid phase extraction.  
Fraction CC-13/5 CC-13/6 CC-13/7 CC-13/8 CC-13/14 CC-13/15 CC-9/3 CC-9/4 
Yield (mg) 170 50 190 75 30 30 90 60 
 
Table 32: Yield (mg) of the most active fractions of CC-9 and CC-13 
 
4.2.9.1 Fractionation of fraction CC-13/5 by solid phase extraction (SPE-1) 
The active fraction CC-13/5 of the CH2Cl2-extract of the rootlets of Metaxya rostrata was 
submitted to fractionation by SPE-1. The fraction was applied on the cartridges (C-18, 
                                                     
12
 The authentic substances were kindly provided by Prof. E. Wollenweber (Institut für Botanik, TU Darmstadt, 
Deutschland). 
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20ml, Bond Elut, Varian) and elution was performed sequentially with 4 reservoir volumes 
each of 60%, 70%, 80%, 90% and 100% MeOH. The fractions of identical polarity were 
pooled (Fig. 108). 
 
Fig. 108: TLC of the fractions of SPE-1 
Stationary phase 1, mobile phase 10, detection 2 
Fraction SPE-1/1 SPE-1/2 SPE-1/3 SPE-1/4 SPE-1/5 
Eluent 60% 70% 80% 90% 100% 
Yield (mg) 5,3 7,4 22,3 49,9 35,3 
 
        Table 33: Yield (mg) of the fractions of SPE-1  
 
In order to evaluate the effect of the SPE-1 fractions of fraction CC-13/5 on cancer cell 
viability, the cells were exposed to increasing concentrations (0.6, 6 and 60μg/ml) for 48h.  
The SPE-1/1 and SPE-1/2 fractions had no effect on cell viability below a concentration of 
60µg/ml. Fractions SPE-1/3 and SPE-1/5 reduced cell number in a significant manner at a 
concentration of 6µg/ml. Fraction SPE-1/4 was the most active, reducing cell viability 
significantly already at a concentration of 0.6µg/ml (Fig. 109).  
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Fig. 109: Viability of SW480 cells treated with the fractions of SPE-1 
Viability of SW480 cells treated with the SPE-1 fractions (SPE-1/1 to 5) of fraction CC-13/5 was assessed with 
neutralred assay. The cells were cultivated on 24-well plates and incubated for 48 hours with increasing 
concentrations (60, 6 and 0.6µg/ml). Data represent mean ± s.e.mean from three independent experiments 
performed in triplicate (*P<0.05, **P<0.01, ***P<0.001 as compared to control cells). 
 
4.2.9.2 Fractionation of fraction CC-13/6 by solid phase extraction (SPE-2) 
The active fraction CC-13/6 of the new CH2Cl2-extract of the rootlets of Metaxya rostrata 
was further fractionated by SPE-2. The fraction was applied on the cartridges and eluted 
with 4 reservoir volumes each of 40%, 60%, 80% and 100% MeOH. The fractions of 
identical polarity were pooled and evaporated (Fig. 110).                       
 
Fig. 110: TLC of the fractions of SPE-2 
Stationary phase 1, mobile phase 10, detection 2 
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Fraction SPE-2/1 SPE-2/2 SPE-2/3 SPE-2/4 
Eluent 40% 60% 80% 100% 
Yield (mg) 0.8 1.5 10.1 16.8 
 
 
    Table 34: Yield (mg) of the fractions of SPE-2 
 
The fractions SPE-2/1 and SPE-2/2 eluted with 40% and 60% MeOH contained very low 
amounts, were not tested for their effect on cancer cell viability. Both, the SPE-2/3 and 
SPE-2/4 fractions reduced the SW480 cell viability significantly from a concentration of 
0.6µg/ml upwards (Fig. 111). 
 
                                         Fig. 111: Viability of SW480 cells treated with the fractions of SPE-2 
Viability of SW480 cells treated with the SPE-2 fractions (SPE-2/3 and 4) of fraction CC-13/6 was assessed with 
neutralred assay. The cells were cultivated on 24-well plates and incubated for 48 hours with increasing 
concentrations (60, 6 and 0.6µg/ml). Data represent mean ± s.e.mean from three independent experiments 
performed in triplicate (*P<0.05, **P<0.01, ***P<0.001 as compared to control cells). 
 
4.2.9.3 Fractionation of fraction CC-13/7 by solid phase extraction (SPE-3) 
Fraction CC-13/7 of the new CH2Cl2-extract of the rootlets of Metaxya rostrata was 
applied on the cartridges and eluted with 4 reservoir volumes each of 60%, 70%, 80%, 
90% and 100% MeOH. The fractions of identical polarity were pooled and evaporated 
(Fig. 112). 
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Fig. 112: TLC of the fractions of SPE-3 
Stationary phase 1, mobile phase 10, detection 2 
 
Fraction SPE-3/1 SPE-3/2 SPE-3/3 SPE-3/4 SPE-3/5 
Eluent 60% 70% 80% 90% 100% 
Yield (mg) 18.4 21.4 35,5 57 28,3 
 
Table 35: Yield (mg) of the fractions of SPE-3 
In the biological assay, fraction fraction SPE-3/1 only reduced cell viability significantly at 
a concentration of 60µg/ml. Fractions SPE-3/2 and SPE-3/5 decreased the cell number in 
a significant manner down from a concentration of 6µg/ml upwards. Fractions SPE-3/3 
and SPE-3/4 were able to reduce the cell viability significantly already at a concentration 
of 0.6µg/ml (Fig. 113). Thus, the latter were chosen for further investigation. 
 
Fig. 113: Viability of SW480 cells treated with the fractions of SPE-3 
Viability of SW480 cells treated with the SPE-3 fractions (SPE-3/1 to 5) of fraction CC-13/7 was assessed with 
neutralred assay. The cells were cultivated on 24-well plates and incubated for 48 hours with increasing 
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concentrations (60, 6 and 0.6µg/ml). Data represent mean ± s.e.mean from three independent experiments 
performed in triplicate (*P<0.05, **P<0.01, ***P<0.001 as compared to control cells). 
 
4.2.9.4 Fractionation of fraction CC-13/8 by solid phase extraction (SPE-4) 
Fraction CC-13/8, an active fraction of the new CH2Cl2-extract of the rootlets of Metaxya 
rostrata, was further fractionated by SPE in the same manner as described before and 
eluted with 4 reservoir volumes each of 60%, 70%, 80%, 90% and 100% MeOH. The 
fractions of identical polarity were pooled and evaporated (Fig. 114). 
 
Fig. 114: TLC of the fractions of SPE-4 
Stationary phase 1, mobile phase 10, detection 2 
 
 
Fraction SPE-4/1 SPE-4/2 SPE-4/3 SPE-4/4 SPE-4/5 
Eluent 60% 70% 80% 90% 100% 
Yield (mg) 5.5 4.8 14.8 13.4 7.9 
 
Table 36: Yield (mg) of the fractions of SPE-4 
 
After treatment of SW480 cells with fraction SPE-4/3 no effect on the cell viability was 
observed. A low activity with significant reduction of cell viability only at the highest 
concentration was determined for fractions SPE-4/2 and SPE-4/5. Fraction SPE-4/3 was 
able to decrease the cell number significantly at a concentration of 6µg/ml and fraction 
SPE-4/4, the most active one reduced the cell viability significantly from a concentration 
of 0.6µg/ml upwards (Fig. 115).  
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Fig. 115: Viability of SW480 cells treated with the fractions of SPE-4 
Viability of SW480 cells treated with the SPE-4 fractions (SPE-4/1 to 5) of fraction CC-13/8 was assessed with 
neutralred assay. The cells were cultivated on 24-well plates and incubated for 48 hours with increasing 
concentrations (60, 6 and 0.6µg/ml). Data represent mean ± s.e.mean from three independent experiments 
performed in triplicate (*P<0.05, **P<0.01, ***P<0.001 as compared to control cells). 
 
4.2.9.5 Fractionation of fraction CC-13/14 by solid phase extraction (SPE-5) 
For SPE-5, fraction CC-13/14 of the new CH2Cl2-extract of the rootlets of Metaxya rostrata 
was applied on the cartridges and eluted and pooled under the same conditions as 
described before (Fig.116). 
 
                    Fig. 116: TLC of the fractions of SPE-5 
   Stationary phase 1, mobile phase 10, detection 2 
 
Fraction SPE-5/1 SPE-5/2 SPE-5/3 SPE-5/4 SPE-5/5 
Eluent 60% 70% 80% 90% 100% 
Yield (mg) 4 8.2 5.5 3.8 6.4 
 
Table 37: Yield (mg) of the fractions of SPE-5 
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In the cell assay, fraction SPE-5/1 showed little activity only. Treatment with fractions 
SPE-5/4 and SPE-5/5 resulted in a significant reduction of cell viability at a concentration 
of 6µg/ml. Fractions SPE-5/2 and SPE-5/3 were the most active ones decreasing cell 
viability significantly from a concentration of 0.6µg/ml upwards (Fig. 117) and SPE-5/2 
was further investigated because of only 3 main compound in TLC after detection 2. 
 
Fig. 117: Viability of SW480 cells treated with the fractions of SPE-5 
Viability of SW480 cells treated with the SPE-5 fractions (SPE-5/1 to 5) of fraction CC-13/14 was assessed with 
neutralred assay. The cells were cultivated on 24-well plates and incubated for 48 hours with increasing 
concentrations (60, 6 and 0.6µg/ml). Data represent mean ± s.e.mean from three independent experiments 
performed in triplicate (*P<0.05, **P<0.01, ***P<0.001 as compared to control cells). 
 
4.2.9.6 Fractionation of fraction CC-13/15 by solid phase extraction (SPE-6) 
The active fraction CC-13/15, an active fraction of the new CH2Cl2-extract of the rootlets 
of Metaxya rostrata, was further fractionated by SPE-6. The fraction was applied on the 
cartridges eluted with 4 reservoir volumes each of 60%, 70%, 80%, 90% and 100% MeOH. 
The fractions of identical polarity were pooled and evaporated (Fig.118). 
 
Fig. 118: TLC of the fractions of SPE-6 
Stationary phase 1, mobile phase 10, detection 2 
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Fraction SPE-6/1 SPE-6/2 SPE-6/3 SPE-6/4 SPE-6/5 
Eluent 60% 70% 80% 90% 100% 
Yield (mg) 3 5.9 4.1 3.9 4.6 
 
Table 38: Yield (mg) of the fractions of SPE-6 
 
In the bioviability assay, fraction SPE-6/5 reduced the cell number significantly only at a 
concentration of 60µg/ml. Fraction SPE-6/1 reduces cell viability at a concentration of 
6µg/ml in a significant manner. Fractions SPE-6/2, SPE-6/3 and SPE-6/4 exhibited the 
highest activities reducing cell viability significantly already at a concentration of 0.6µg/ml 
(Fig. 119). Fractions SPE-6/2 was selected for further investigation due to its high activity 
and its major orange compound at Rf 0.45. 
 
Fig. 119:  Viability of SW480 cells treated with the fractions of SPE-6 
Viability of SW480 cells treated with the SPE-6 fractions (SPE-6/1 to 5) of fraction CC-13/15 was assessed with 
neutralred assay. The cells were cultivated on 24-well plates and incubated for 48 hours with increasing 
concentrations (60, 6 and 0.6µg/ml). Data represent mean ± s.e.mean from three independent experiments 
performed in triplicate (*P<0.05, **P<0.01, ***P<0.001 as compared to control cells). 
 
4.2.9.7 Fractionation of fraction CC-9/3 by solid phase extraction (SPE-7) 
The active fraction CC-9/3 of the old CH2Cl2-extract of the rootlets of Metaxya rostrata 
was fractionated with SPE-7. The fraction was applied on the cartridges, eluted and 
pooled under the same conditions as described before (Fig. 120). 
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Fig. 120: TLC of the fractions of SPE-7 
Stationary phase 1, mobile phase 10, detection 2 
Fraction SPE-7/1 SPE-7/2 SPE-7/3 SPE-7/4 SPE-7/5 
Eluent 60% 70% 80% 90% 100% 
Yield (mg) 15.3 7.5 26.7 13.8 14.7 
 
 
Table 39: Yield (mg) of the fractions of SPE-7 
 
After treatment of SW480 cells with fractions SPE-7/1, SPE-7/2, SPE-7-3 and SPE-7/5 the 
cell number was reduced significantly down to a concentration of 6g/ml. Fraction SPE-7/4 
was the most active one reducing the cell viability in a significant manner at a 
concentration of 0.6µg/ml (Fig. 121). Due to a similar compound pattern of SPE-7/4 and 
SPE-7/3 and higher amounts of the latter, it was selected for further investigation.   
 
Fig. 121: Viability of SW480 cells treated with fractions of SPE-7 
Viability of SW480 cells treated with the SPE-7 fractions (SPE-7/1 to 5) of fraction CC-9/3 was assessed with 
neutralred assay. The cells were cultivated on 24-well plates and incubated for 48 hours with increasing 
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concentrations (60, 6 and 0.6µg/ml). Data represent mean ± s.e.mean from three independent experiments 
performed in triplicate (*P<0.05, **P<0.01, ***P<0.001 as compared to control cells). 
 
4.2.9.8 Fractionation of fraction CC-9/4 by solid phase extraction (SPE-8) 
Fraction CC-9/4, a fraction of the first CH2Cl2-extract of the rootlets of Metaxya rostrata, 
was further fractionated by SPE-8 under elution with 4 reservoir volumes of 40%, 60%, 
80% and 100% MeOH. The fractions of identical polarity were pooled (Fig. 122). 
 
Fig. 122: TLC of the fractions of SPE-8 
Stationary phase 1, mobile phase 10, detection 2 
 
Fraction SPE-8/1 SPE-8/2 SPE-8/3 SPE-8/4 
Eluent 40% 60% 80% 100% 
Yield (mg) 1.2 2.7 6.7 23.2 
 
Table 40: Yield (mg) of the fractions of SPE-8 
 
 
As fractions SPE-8/1 and SPE-8/2 eluted with 40% and 60% MeOH contained very little 
amounts, they were not tested for their effect on cancer cell viability. Fraction SPE-8/4 
reduced cell viability significantly at a concentration of 6µg/ml. Fraction SPE-8/3 showed 
even higher activity reducing the cell number in a significant manner from a 
concentration of 0.6µg/ml upwards. Because of the bigger amounts and also high activity, 
of fraction SPE-8/4 was selected and further investigated. 
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Fig. 123: Viability of SW480 cells treated with the fractions of SPE-8 
Viability of SW480 cells treated with the SPE-8 fractions (SPE-8/3 and 4) of fraction CC-9/4 was assessed with 
neutralred assay. The cells were cultivated on 24-well plates and incubated for 48 hours with increasing 
concentrations (60, 6 and 0.6µg/ml). Data represent mean ± s.e.mean from three independent experiments 
performed in triplicate (*P<0.05, **P<0.01, ***P<0.001 as compared to control cells). 
 
4.2.9.9 TLC comparison of the active SPE fractions with methylated flavonoids 
The detection with Naturstoffreagent A after TLC-separation of the selected fractions 
with high activity showed numerous phenolic compounds with yellow, orange and green 
fluorescence and low polarity. Thus, the occurrence of methylated flavonoids in the 
fractions was assumed and a TLC comparison of these fractions with different authentic 
compounds was performed. Although some compounds showed similar fluorescence and 
polarity, none of the major compounds could be identified (Fig. 124). 
    
                            Fig. 124: TLC comparison of the active SPE fractions with methylated flavonoids 
Stationary phase 2, mobile phase 10, detection 2 (B=Kämpferol-3-4‘-dimethylether, C=Kämpferol-3-7‘-
dimethylether, D=Quercetin-3-7‘-dimethylether, E=Quercetin-3-7-3‘-trimethylether, G=Kämpferol-3-7-4‘-
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trimethylether, H= Quercetin-3-3‘-dimethylether, I=Quercetagetin-3-6-4‘-trimethylether, J=Quercetagetin-3-6-
dimethylether, K=6-OH-Kämpferol-3-6-7-trimethylether).  
 
4.2.10 Investigation of the selected SPE-fractions by high performance liquid 
chromatography (HPLC)  
In order to identify and to isolate the active compounds in the most active SPE-fractions 
HPLC was performed. 
 
4.2.10.1  Investigation of SPE-3/4 by HPLC  
Due to its high activity, the fraction SPE-3/4 was studied in detail and subjected to a HPLC 
(Method 1, Gradient Programm 1, see p. 43). Besides UV detection at 290nm, Evaporative 
Light Scattering Detection (ELSD) was used to detect compounds without chromophors. 
Under UV detection fraction SPE-3/4 showed several minor compounds with 
uncharacteristic UV spectra, although in TLC (Fig.112) one prominent substance had been 
detected. 
 
Fig. 125: HPLC analysis (1) of fraction SPE-3/4 
Method 1, gradient programm 1, detection at 290nm 
 
Thus, fraction SPE-3/4 was also analysed by ELSD-detection and showed one main peak at 
Rt 43,5min with a purity of 98% (Fig. 126).  
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Fig. 126: HPLC analysis (2) of fraction SPE-3/4 
Method 1, gradient programm 1, detection with ELSD 
Additional experiments by LC-MS pointed to ursolic or betulinic acid. Final identification 
by TLC and rechromatography in HPLC with the reference compound, confirmed the 
major peak as betulinic acid (Fig. 127). 
 
                            Fig. 127: TLC comparison of SPE-3/4 with ursolic and betulinic acid                     
 
As Betulinic acid is known for cytotoxic effects (Zuco et al., 2001; Ciurlea et al., 2010; 
Fulda et al., 1997) and was the major compound in fraction SPE-3/4, betulinic acid was 
unambiguously identified as the active principle in this fraction. 
 
Fig. 128: Betulinic acid 
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4.2.10.2  Investigation of SPE-3/3 by HPLC  
In fraction SPE-3/3 two major phenolic compounds were detected at Rf 0.58 and 0.47 by 
TLC (Fig. 112). Therefore and due to the high activity fraction SPE-3/3 was further 
investigation by RP-HPLC (Method 1, Gradient Programm 1, see p. 43) should reveal 
further informations on the structure. Both Evaporative Light Scattering Detection (ELSD) 
and UV detection at 290nm were used for this purpose. 
The chromatogram with UV-detection showed four major compounds at Rt 11.5min, 
18min, 19min and 26.5min (Fig. 129). 
 
Fig. 129: HPLC analysis (1) of fraction SPE-3/3 
Method 1, gradient programm 1, detection at 290nm 
 
Under use of ELSD detection besides these peaks a further compound at Rt 43.5min 
without chromophor was detected. The retention time of the latter correlated to the one 
of betulinic acid (Fig. 130).  
 
Fig. 130: HPLC analysis (2) of fraction SPE-3/3 
Method 1, gradient programm 1, detection with ELSD 
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The identity of betulinic acid was confirmed by rechromatography with the authentic 
reference. The peak at Rt 11.5min was studied by MS analysis and identified as 
tetrahydroxy-C-prenylxanthone (MW 238). As in the bioassay fraction SPE-3/3 showed 
similar activity to fraction SPE-3/4, the activity was assigned to betulinic acid. However, 
xanthones are also known to effect cell viability, so that a synergistic effect of both main 
compounds is possible. 
 
4.2.10.3 Investigation of SPE-7/3 by HPLC  
Fraction SPE-7/3 has shown several orange and green fluorescent phenolic substances in 
TCL (Fig. 120). HPLC analysis with UV-detection resulted in a major compound at Rt 31min 
and several minor compounds at Rf 24min, 25min, 27min, 37.5min (Method 1, Gradient 
Programm 1, see page 43).  
 
Fig. 131: HPLC analysis (1) of fraction SPE-7/3 
Method 1, gradient programm 1, detection at 290nm 
 
In the chromatogram with ELSD-detection again one major peak at Rt 43.5min was 
observed and identified by comparison with the authentic reference as betulinic acid with 
a purity of 98%. Thus, betulinic acid comprised as the active principle in this fraction as 
well. 
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Fig. 132: HPLC analysis (2) of fraction SPE-7/3 
Method 1, gradient programm 1, detection with ELSD 
 
4.2.10.4  Investigation of SPE-8/4 by HPLC  
Fraction SPE-8/4 revealed a complex phenolic pattern in TLC after detection 2 (Fig. 122). 
By UV-detection after RP-HPLC separation (Method 1, Gradient Programm 1, see page) 5 
major components at Rt 25min, 27min, 31min, 38min and 40.5min were observed (Fig. 
133).  
 
Fig. 133:  HPLC analysis (1) of fraction SPE-8/4 
Method 1, gradient programm 1, detection at 290nm 
 
The chromatogram after ELSD-detection showed the major compounds at Rt 27min and 
at 43.5min (Fig. 134). 
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Fig. 134: HPLC analysis (2) of fraction SPE-8/4 
Method 1, gradient programm 1, detection with ELSD 
The main peak at Rt 43,5min was identified with the authentic reference as betulinic acid. 
The structure of the second main peak at Rt 27min was studied by MS analysis and 
identified as tetrahydroxy-di-C-prenylxanthone (MW 396). The substitution pattern could 
not be elucidated. Isolation of the substance was not possible due to the composition and 
the small amount of the fraction. The activity of SPE-8/4 could be a synergistic effect 
between betulinic acid and the xanthon. 
 
4.2.10.5 Investigation of SPE-5/2 by HPLC  
Fraction SPE-5/2 showed one major orange fluorescent compound with Rf 0.45 with small 
amounts of two further fluorescent substances at Rf 0.23 and 0.38 in TLC (Fig. 116). In RP-
HPLC (Method 1, Gradient Programm 1, see page 43) the main compound was detected 
at Rt 24.5min in both detection modes (Fig. 135). 
 
Fig. 135: HPLC analysis (1) of fraction SPE-5/2 
Method 1, gradient programm 1, detection at 290nm 
5.0 10.0 15.0 20.0 25.0 30.0 35.0 40.0 45.0 50.0 55.0 60.0 65.0 min
0
25
50
75
100
125
mV
0.0
5.0
10.0
15.0
20.0
25.0
30.0
35.0
MPa
A.Conc.(Method)
AD2 
5.0 10.0 15.0 20.0 25.0 30.0 35.0 40.0 45.0 50.0 55.0 min
-25
0
25
50
75
100
125
150
175
200
225
250
275
300
mAU
0.0
5.0
10.0
15.0
20.0
25.0
30.0
35.0
40.0
45.0
50.0
55.0
60.0
65.0
70.0
75.0
80.0
85.0
90.0
95.0
%
A.Conc.(Method)290nm,4nm (1.00)
Results 
122 
 
 
Fig. 136: HPLC analysis (2) of fraction SPE-5/2 
Method 1, gradient programm 1, detection with ELSD 
Due to only traces of accompanying substances in this fraction, structure elucidation by 
MS and NMR experiments was possible without further purification (Fig. 136). The 
compound at Rt 24.5min was identified as 2-deprenyl-rheediaxanthone B (MW 328). As 2-
deprenyl-rheediaxanthone B is the major compound with a purity of 99% in fraction SPE-
5/2, it is certain that the high activity in the bioassay is due to that rare natural compound 
(Fig. 137) (see supplementary information). Thus, for the biological tests 8mg of 2-
deprenyl-rheediaxanthone B were available. 
 
 
Fig. 137: 2-deprenyl-rheediaxanthone B 
 
 
4.2.10.6   Investigation of SPE-6/2 by HPLC  
The same orange fluorescent compound with detection 2 at Rf 0.45, seen in fraction SPE-
5/2, was detected in fraction SPE-6/2 in TLC (Fig. 118). In RP-HPLC (Method 1, Gradient 
Programm 1, see p. 43) with UV-detection the compound at Rt 24.5 appeared to be pure 
(Fig. 138), but in ELSD-detection a second component was observed at Rt 16min (Fig. 
139). 
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Fig. 138: HPLC analysis (1) of fraction SPE-6/2 
Method 1, gradient programm 1, detection at 290nm 
 
Fig. 139: HPLC analysis (2) of fraction SPE-6/2 
Method 1, gradient programm 1, detection with ELSD 
 
MS analysis revealed the peak at Rt 16min as tetrahydroxy-C-prenylxanthone and the 
peak at Rt 24.5min was confirmed as 2-deprenyl-rheediaxanthone B.  
 
Both compounds had been already identified in other active fractions. In fraction SPE-5/2 
2-deprenyl-rheediaxanthone B was identified as the active principle. Tetrahydroxy-C-
prenylxanthone was also detected in fraction SPE-3/3 together with betulinic acid. The 
activity of fraction SPE-6/2 is assumed to be a synergystic effect of 2-deprenyl-
rheediaxanthone B and the second xanthone. 
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4.2.11 Isolation of 2-deprenyl-rheediaxanthone B by semipreparative HPLC 
Betulinic acid and 2-deprenyl-rheediaxanthone B were identified as the active principles 
in the most active fractions of the CH2Cl2-extract of the rootlets of Metaxya rostrata. In 
order to isolate a higher amount of this compound for the biological assays, fraction CC-
9/5, which also contained 2-deprenyl-rheediaxanthone B (Fig. 140) served for the 
isolation of this compound with semipreparative HPLC.  
 
Fig. 140: TLC comparison of fraction CC-9/5 and CC-13/14 
Stationary phase 1, mobile phase 10, detection 2 
 
A HPLC method had to be developed for a separation of the peaks suitable for 
semipreperative HPLC. In several experiments the gradient was optimized for baseline 
sparation resutling in method 3 (Method 3, Gradient Programm 3, see p. 44).  
After optimization of the separation in the analytical scale, 43mg of fraction CC-9/5 were 
seperated by semipreparative HPLC. 5 fractions were collected. Fraction 4 contained 2-
deprenyl-rheediaxanthone B (Fig. 141).  
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Fig. 141: Semipreparative HPLC of fraction CC-9/5 
Method 3, gradient programm 3, detection at 290nm 
After combining all fractions 4 (3mg), this combined fraction was evaporated and again 
analysed with HPLC to check the purity.  
Only one major compound at 40min could be detected with UV detection (Fig. 142). 
 
 
Fig. 142: HPLC analysis of fraction 4 
Method 3, gradient programm 3, detection at 290nm 
 
With the ELSD a purity of more than 99% was determined for this compound at Rt 40min 
(Fig. 143). 
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Fig. 143: HPLC analysis of fraction 4 
Method 3, gradient programm 3, detection with ELSD 
 
By MS analysis this compound was verified as 2-deprenyl-rheediaxanthone B. Thus, by 
semipreparative HPLC 3mg of 2-deprenyl-rheediaxanthone B were isolated additionally. 
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4.2.12 Biological effects of 2-deprenyl-rheediaxanthone B  
Betulinic acid and 2-deprenyl-rheediaxanthone B were identified as the active compounds 
in the most active fractions of the CH2Cl2 extract of the rootlets of Metaxya rostrata. As 
the cytotoxic activity of betulinic acid is very well investigated, this compound was not 
studied further. For 2-deprenyl-rheediaxanthone B there have been no studies on 
cytotoxicity performed yet. Consequently, this compound was evaluated for its biological 
effects. 
 
4.2.12.1    Effect of 2-deprenyl-rheediaxanthone B on cell viability 
In order to evaluate the effect of 2-deprenyl-rheediaxanthone B (XB) on cell viability, 
SW480 cells were exposed to increasing concentrations (3, 6 and 9µM) for 24, 48 and 72 
h. The percentage of viable cells was determined by the Neutralred assay. To determine 
the impact on necrosis, a LDH-assay was performed. 
          (1)                                                                                (2) 
 
Fig. 144: Viability of SW480 (1) and LDH assay (2) of 2-deprenyl-rheediaxanthone B after 24, 48 and 72h 
Viability of SW480 cells treated with 2-deprenyl-rheediaxanthone B (XB) was assessed with neutralred assay (1). 
Cytotoxicity of XB on SW480 cells was evaluated with the LDH assay (2). The cells were cultivated on 24-well 
plates and incubated for 24, 48 and 72 hours with increasing concentrations (3, 6 and 9µM). Data represent mean 
± s.e.mean from three independent experiments performed in triplicate (*P<0.05, **P<0.01 as compared to 
control cells). 
 
After 24 hours no effect on cell viability at 3 and 6µM could be seen, but 9µM XB reduced 
cell viability significantly to about 60%. No cytotoxicity due to necrosis was detected 
under these conditions (Fig. 144). After 48 hours no effect on the cell number was seen at 
a concentration of 3µM, but XB reduced cell viability in a significant manner at a 
concentration of 6µM. In the LDH assay only very low cytotoxicity after 48h was seen. The 
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cell loss seemed not to be due to necrosis. After 72 hours 2-Deprenyl-rheediaxanthone B 
reduced cell viability significantly at a concentration of 6µM. At a concentration of 3µM 
no effect was observed. In the LDH assay slight cytotoxicity at a concentration of 9µM was 
determined. Thus, 48 hours incubation was chosen for further investigations. 
 
4.2.12.2    Effect of 2-deprenyl-rheediaxanthone B on the cell viability of different cell 
types 
To determine the activity of 2-deprenyl-rheediaxanthone B (XB) in another colon cancer 
cell line, experiments were performed with MTT assay using CaCo-2 cells, the non-
malignant LT97 adenoma cell line and the normal colonic fibroblasts F331. SW480 was 
included to confirm the previous results in another viability assay and as a standard for 
assessment of cell line dependent relative activity.  
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Fig. 145: Viability of SW480, CaCo-2, LT97 and F331 after treatment with 2-deprenyl-rheediaxanthone B 
Viability of SW480, CaCo-2, LT97 and F331 cells treated with 2-deprenyl-rheediaxanthone B (XB) was evaluated 
with MTT assay. The cells were cultivated on 24-well plates and incubated for 48 hours with increasing 
concentrations (10, 15 and 20µM). Data represent mean ± s.e.mean from three independent experiments 
performed in triplicate (*P<0.05, **P<0.01, *** P<0.001 as compared to control cells). 
In CaCo-2 cells XB reduced cell viability at concentrations of 10, 15 and 20µM in a 
significant manner (Fig. 145). XB also reduced cell viability of LT97 at the same 
concentrations. At a concentration of 10 and 15µM the cell viability was reduced to about 
85% and at a concentration of 20µM to about 60%.  
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The effect of the compound on human colon associated fibroblasts, F331, was evaluated 
as well. XB did not have an effect at 10µM, but reduced the cell number significantly to 
75% at a concentration of 20µM. Compared to the effect of 2-deprenyl-rheediaxanthone 
B on the colon carcinoma cell lines, SW480 and CaCo-2, the effect on the the adenoma 
cell line LT 97 and the fibroblasts is much weaker (Fig. 145). 
 
4.2.12.3    Effect of 2-deprenyl-rheediaxanthone B on the cell cycle 
In order to investigate the mechanism of the cytotoxicity induced by 2-deprenyl-
rheediaxanthone B (XB) in SW480 cells, the first step was to assess the effect on cell cycle 
distribution. Flow cytometric analysis of PI-stained nuclei was employed after incubation 
with increasing concentrations (10, 15 and 20µM) for 48 and 72 h.  
The results showed a concentration-dependent decrease of the proportion of cells in the 
G0-G1 phase. The percentage of cells in S phase increased slightly and the proportion of 
cells in G2-M phase increased dose-dependently and significantly after incubation with 2-
deprenyl-rheediaxanthone B for 48h and 72h (Fig. 146).  
The data suggest that 2-deprenyl-rheediaxanthone B induced a G2-M phase cell cycle 
arrest in SW480 cells. 
        (1)                                                                              (2)       
 
Fig. 146: Effect of XB on cell cycle distribution of SW480 after 48h (1) and 72h (2) 
Cell cycle distribution of SW480 cells treated with 2-deprenyl-rheediaxanthone B (XB) after 48h (1) and 72h (2). 
Cells were cultivated on 6 Pd plates and incubated with increasing concentrations (10, 15 and 20µM) of XB. Cells 
were harvested, stained with PI and the percentage of cells in G0-G1, S and G2-M phase was quantified by flow 
cytometry. Data represent mean ± s.e.mean from three independent experiments.  
Results 
130 
 
4.2.12.4    Expression of specific cell cycle signaling proteins 
In order to confirm the cell cycle blockade shown by FACS analysis, specific cell cycle 
regulatory proteins were determined by western blot from cell lysates obtained after 
exposure to 2-deprenyl-rheediaxanthone B (XB). 
The results showed a large increase in the level of cyclin A and a slight increase in the 
level of the cyclin B1 protein. The protein level of cyclin E was decreased compared to the 
control (Fig. 147). These changes confirmed the G2-M phase cell cycle arrest seen with 
FACS analysis. 
 
Fig. 147: Influence of XB on cell cycle signaling proteins 
Cells were cultured for 24 h before incubation with 20µM 2-deprenyl-rheediaxanthone B for 20h. Cell lysates 
were then subjected to Western blot analysis for the indicated proteins. One representative blot is shown.  
 
4.2.12.5    Microscopic analysis of 2-deprenyl- rheediaxanthone B treated SW480 cells  
The SW480 cells were analysed by light microscopy for possible morphological changes 
associated with the 2-deprenyl-rheediaxanthone B treatment.  
    (1)                                                                               (2) 
    
Fig. 148: Light microscopy analysis of control (1) and XB treated cells (2) 
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SW480 cells were seeded in 24-well plates and grown for 24 h before treatment with 20µM 2-deprenyl-
rheediaxanthone B, incubation for 48 h and examination by light microscopy. 
Incubation of the cells with 20µM of XB (2) for 48h revealed morphological modifications 
such as cell shape alterations and cell detachment compared to the control (1). 
Nuclear morphology was visualized by fluorescence microscopy after staining with 
Hoechst-33258, which intercalates into the DNA. 
Treatment with 2-deprenyl-rheediaxanthone B (XB) for 48h caused morphological 
modifications such as pycnotic and fragmented nuclei (2). The most prominent change 
was an increase in the size of the nulcei compared to the control (1). In the control 
cultures most nuclei had almost the same size. Also one apoptotic body could be seen (1). 
After treatment with 20µM of XB a high number of giant polyploid nuclei as well as 
apoptotic bodies could be detected (2).  
   (1)                                                                                (2) 
    
Fig. 149: Fluorescence microscopy analysis of control (1) and XB treated cells (2) 
SW480 cells were seeded in 24-well plates and grown for 24 h before treatment with 20µM 2-deprenyl-
rheediaxanthone B. After incubation for 48 h, the cells were stained with Hoechst-33258 and examined by 
fluorescence microscopy. The picture is color-coded: Normal Nucleus G1, Normal Nucleus G2, Apoptotic body, 
Giant nucleus. 
 
4.2.12.6    Effect of 2-deprenyl-rheediaxanthone B on apoptosis 
In order to investigate the effect on apoptosis, a JC-1 FACS analysis was conducted after 
incubation of SW480 cells with increasing concentratiOns (10, 15 and 20µM) of 2-
deprenyl-rheediaxanthone B (XB) for 48 and 72 h. JC-1 is a mitochondrial tracer 
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concentrated in intact mitochondria. A loss of mitochondrial membran polarisation during 
apoptosis causes a shift in fluorescence and can be measured by FACS analysis.  
 
The results showed a dose- and time-dependent increase in dying cells compared to the 
control (Fig. 150). After 48h about 18% dead cells were detected in the samples incubated 
with 10µM of the compound. At a concentration of 15 and 20µM about 50% of cells with 
depolarized mitochondria were seen. At 72h 10 and 15µM were sufficient to achieve this 
effect, and almost all cells were dead at a concentration of 20µM. 
             (1)                                                                                  (2) 
 
Fig. 150: JC-1 FACS analysis after treatment with XB after 48h (1) and 72h (2) 
Results of JC-1 FACS analysis of SW480 cells treated with 2-deprenyl-rheediaxanthone B (XB) after 48h (1) and 
72h (2). The cells were cultivated on 6 Pd plates and incubated with increasing concentrations (10, 15 and 20µM) 
of XB. Cells were harvested, stained with JC-1 and the percentage of dead cells was quantified by flow cytometry. 
Data represent mean ± s.e.mean from two independent experiments.  
 
4.2.12.7    Effect of 2-deprenyl-rheediaxanthone B on apoptosis related proteins 
Treatment with 2-deprenyl-rheediaxanthone B led to concentration- and time-dependent 
loss of SW480 cells as detected with JC-1 FACS analysis, suggesting cell death due to 
apoptosis. In order to confirm this result, BAX, BAK and survivin were measured as 
specific pro- and anti-apoptotic effector molecules. 
Cell lysated were obtained after incubation of SW480 cells with 20µM 2-deprenyl-
rheediaxanthone B for 20h and analsed by western blotting. The results showed a slight 
increase in the levels of the pro-apoptotic proteins BAX and BAK as well as a slight 
decrease of survivin as compared to the control (Fig. 151). These changes in the levels of 
the apoptosis markers indicated the mitochondrial way of apoptosis. 
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Fig. 151: Influence of XB on apoptosis signaling proteins I 
Cells were cultured for 24 h before incubation with 20µM 2-deprenyl-rheediaxanthone B for 20h. Cell lysates 
were then subjected to Western blot analysis for the indicated proteins. One representative blot is shown.  
Detection of the anti-apoptotic proteins BXL-XL and BCL 2, as well as the pro-apoptotic 
protein caspase 3 demostrated an upregulation of BCL-XL and BCl 2, while caspase 3 
almost not affected compared to the control (Fig. 152). 
     
Fig. 152: Influence of XB on apoptosis signaling proteins II 
Cells were cultured for 24 h before incubation with 20µM 2-deprenyl-rheediaxanthone B for 20h. Cell lysates 
were then subjected to Western blot analysis for the indicated proteins. One representative blot is shown.  
 
2-deprenyl-rheediaxanthone B did not induce cleavage of poly(ADP-ribose) polymerase 
(PARP), which is catalyzed by caspase-3. PARP protein at 116 kDa was detected, but no 
cleavage with the cleavage product at 85 kDa (Fig. 153). 
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Fig. 153: Influence of XB on PARP 
Cells were cultured for 24 h before incubation with 20µM 2-deprenyl-rheediaxanthone B for 20h. Cell lysates 
were then subjected to Western blot analysis for the indicated protein. One representative blot is shown. PARP 
protein at 116 kDa. No cleavage product at 85 kDa. 
 
By contrast, an increase was observed in the levels of both caspase 2 and activated 
caspase 2 (Fig. 154). 
      
Fig. 154: Influence of XB on Caspase 2 
Cells were cultured for 24 h before incubation with 20µM 2-deprenyl-rheediaxanthone B for 20h. Cell lysates 
were analysed by Western blot analysis for the indicated protein. One representative blot is shown.  
 
The effect of 2-deprenyl-rheediaxanthone B on apoptotic cell death, investigated by the 
influence on pro- and anti-apoptotic markers, was evaluated. The results indicated that 
the cell loss, which was proven by JC-1 FACS analysis, MTT- and Neutralred-assays, is 
probably not due to apoptosis. 
In order to analyse the induction of damage response after treatment with 2-deprenyl-
rheediaxanthone B, the levels of the DNA damage marker Chk1 (total) and 
phosphorylated Chk1 (phospho-Chk1) were analysed by Western Blot analysis. The results 
showed an increase in total Chk1 as well as activation by phosphorylation of Chk1 and a 
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slight increase in total Cdc 2 and phosphorylated Cdc 2. The levels of Cdc25C were 
decreased clearly compared to the control (Fig. 155).  
 
 
Fig. 155: Influence of XB on DNA-damage markers 
SW480 cells were cultured for 24 h before incubation with 20µM 2-deprenyl-rheediaxanthone B for 20h. Cell 
lysates were analysed by Western blot for the indicated proteins. One representative blot is shown.  
 
As the forkhead transcription factor FoxM1 is an important regulator of gene expression 
during the G2 phase and essential for correct mitotic progression, it was also evaluated. 
After incubation of SW480 cells with 20µM XB for 20h, FoxM1 was blocked completely 
compared to the control (Fig.156). 
           
                                                   Fig. 156: Influence of XB on FoxM1 
SW480 cells were cultured for 24 h before incubation with 20µM 2-deprenyl-rheediaxanthone B for 20h. Cell 
lysates were analysed by Western blot for the indicated protein. One representative blot is shown.  
 
With FoxM1-staining the same effect as with Westernblot analysis could be seen. The 
staining of the giant nuclei after treatment with 2-deprenyl-rheediaxanthone B was weak 
or even absent. 
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  (1)                                                                                          (2) 
  
  (3)                                                                                 (4) 
 
  
   Fig. 157: Fluorescence microscopy analysis of control (1) and XB treated cells (3) with Höchst staining and 
analysis of control (2) and XB treated cells (4) with FoxM1 staining 
SW480 cells were seeded in 24-well plates and grown for 24 h before treatment with 20µM 2-deprenyl-
rheediaxanthone B. After incubation for 24 h, the cells were stained with Hoechst-33258 and FoxM1 and 
examined by fluorescence microscopy. The picture is color-coded: Giant nucleus. 
 
As Chk1 is activated in response to different genomic lesions by ATR, the influence of 2-
Deprenyl-rheediaxanthone B (XB) on this protein was also evaluated. After incubation of 
SW480 cells with 20µM XB for 20h, the results showed a slight increase of ATR protein. 
ATM seems not to be influenced (Fig.158). 
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                                             Fig. 158: Influence of XB on ATR and ATM 
SW480 cells were cultured for 24 h before incubation with 20µM 2-deprenyl-rheediaxanthone B for 20h. Cell 
lysates were analysed by Western blot for the indicated proteins. One representative blot is shown.  
 
Phosphorylation at Ser10 of Histone H3 is tightly correlated with chromosome 
condensation during mitosis. After treatment of the cells with 2-deprenyl-
rheediaxanthone B for 20h, phospho Histone H3 (Ser10) was blocked completely. 
                        
      Fig. 159: Influence of XB on phospho Histone H3 (Ser
10
) 
SW480 cells were cultured for 24 h before incubation with 20µM 2-deprenyl-rheediaxanthone B for 20h. Cell 
lysates were analysed by Western blot for the indicated proteins. One representative blot is shown. 
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5 DISCUSSION 
 
Cancer therapy is one of the most addressed issues in drug discovery and natural 
products are an important source of anticancer agents, providing over 50% of the drugs in 
present clinical use (Newman and Cragg 2007). Tropical plants used in ethnic medicine 
are a rich source for such new cytotoxic compounds (Kim and Park 2002). 
The present study describes the phytochemical investigation of the tree fern Metaxya 
rostrata used as traditional remedy as well as the bioactivity-guided fractionation and 
isolation of the active principles of this plant. 
 
5.1 Phytochemical investigations of Metaxya rostrata 
Metaxya rostrata, a tree fern belonging to the family of the Metaxyaceae, is used in 
traditional medicine in Costa Rica against intestinal diseases such as ulcers and tumors 
(Pekarek 2005). Until now only two proanthocyanidines (cinnamtannin B-1 and 
aesculitannin B), sugars and common sterols had been isolated from the plant (Virtbauer 
2007). Therefore a profound chemical investigation, isolation and structure elucidation of 
the constituents of Metaxya rostrata was an important objective of this study. 
In a previous study dried powdered roots of Metaxya rostrata had been extracted with 
water according to the ethnomedicinal use. Cinnamtannin B and aesculitannin B1 had 
been identified as cytotoxic principles (Virtbauer 2007). Another fraction of this water 
extract - fraction 12 - had shown reasonable cytotoxic activity as well (Virtbauer 2007) 
and thus was further fractionated by column chromatography by the use of different 
stationary and mobile phases. Several substances were isolated from this fraction:  
The main compound of fraction 12 at Rf 0.56, coloured blue after detection 1, crystallized 
from several fractions and 58mg of compound KK1 were obtained (see chapter 4.1.1.). 
After MS- and extensive one and two dimensional NMR-analysis the structure of KK1 was 
established as (2E)-2-(6-hydroxyhexyliden)cyclopropyl-β-glucopyranoside. This compound 
has never been described before, neither isolated from natural sources nor totally 
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synthesized. The main structural feature of this new glycosidic compound is the extremely 
uncommon methylenecyclopropane alcohol in the aglycon (Kainz et al., 2011).  
In addition, 4,9mg of the novel compound KK5 were obtained by further CC separation of 
the combined fraction 12/3/10. Mass spectrometry and NMR experiments identified KK5 
as a close relative to KK1. KK5 was unambiguously elucidated as (6E)-6[2-(β-glucopyrano-
syloxy)cyclopropylidene] hexanoic acid (Kainz et al., 2011). Also this compound has never 
been isolated before.  
 
The fraction also contained several known compounds that were identified by NMR and 
TLC experiments. Compound KK6 was identified as 4-O-ß-D-glucopyranosyl-p-trans-
coumaric-acid. This compound has been isolated before from the ferns Drynaria fortunei 
J. Sm. (Shang et al., 2010), Matteuccia struthiopteris L. Todaro (Yang et al., 2004) and 
Davallia mariesii Moore (Cui et al., 1990). Furthermore, 4-O-ß-D-glucopyranosyl-p-trans-
coumaric-acid was proven in Meconopsis quintuplinervia Regel (Shang et al., 2006), 
Carthamus tinctorius L. (Zhou et al., 2008), Ranunculus ternatus Thunb. (Tian et al., 2006), 
Pinus sibirica Du Tour (Khamidullina et al., 2004), Crataegus oxyacantha L. (Sakai et al., 
2007), Onobrychis viciifolia Scop. (Lu et al., 2000), Clitoria ternatea L. (Terahara et al., 
1990), Scutellaria baicalensis Georgi (Liu et al., 2009) and in Camptosorus sibiricus Rupr. 
(Li et al., 2006). 4-O-ß-D-glucopyranosyl-p-trans-coumaric-acid was also found in flaxseed 
(Johnsson et al., 2002), in bee-collected rape pollen (Guo et al., 2009) and in white clover 
flowers (Foo et al., 2000). 4-O-ß-D-glucopyranosyl-p-trans-coumaric-acid and derivatives 
are reported to possess selective herbicidal activity against Sesbania exaltata Cory and 
other similar plant species (Ueda et al., 2003).  
The NMR characterization of compound KK3 identified it as 4-O-ß-D-glucopyranosyl-
caffeic-acid (Kainz et al., 2011) that has been isolated before from ferns such as Davillia 
mariesii Moore. (Cui et al., 1990), Matteuccia struthiopteris L. Todaro (Yang et al., 2004), 
Drynaria propinqua (Wall) J. Smith (Li et al., 2009; Liu et al., 1992), Cyathea phalerata 
Mart. (Pizzolatti et al., 2007) and dregei Kunze (Bringmann et al., 1999). Additionally 4-O-
ß-D-glucopyranosyl-caffeic-acid has been proven in Ilex rotunda Thunb. (Hui et al., 2009), 
Olinia usambarensis Gilg. (Nyandat et al., 1993), Camptosorus sibiricus Rupr. (Li et al., 
2006), Clematis trichotoma Nakai (Ham et al., 1999), in the Colchicaceae family in Gloriosa 
rothschildiana Carsonii (Mimaki et al., 1991) and in Kiwi fruits (Fiorentino et al., 2009). 
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Compound KK7 was identified as methyl-α-fructofuranoside (Kainz et al., 2011). This 
substance has been isolated before from different plant species such as Morinda citrifolia 
L. (Su et al., 2005), Aralia cordata Thunb. (Hyun et al., 2010), Turnera diffusa Willd ex 
Schult. (Zhao et al., 2007), Castanea mollissima Blume (Long et al., 2009), Saussurea lappa 
C.B Clarke (Yin et al., 2006), Porana spectabilis Kurz (Zhu et al., 2001) and Eurya tigang K. 
Schum. & Lauterb. (Khan et al., 1992) and others. 
Besides two new unusual compounds, some know compounds were isolated and 
identified. The phenolic acid glycosides, 4-O-ß-D-glucopyranosyl-caffeic-acid and 4-O-ß-D-
glucopyranosyl-p-trans-coumaric-acid, were proven in several plant families before, but 
seem to be enriched in ferns. Methyl-α-fructofuranoside was isolated before as well, but 
this simple sugar seems not to be very widespread in plant kingdom. 
Biological activities were studied for the novel compound (2E)-2-(6-hydroxyhexyliden)-
cyclopropyl-β-glucopyranoside (KK1). As this compound was isolated from fraction 12, 
which showed moderate cytotoxic activity (Virtbauer 2007), KK1 was tested for its 
cytotoxicity on colon carcinoma cells, but it did not show any effect on cancer cell viability 
up to a concentration of 500µM.  
As secondary metabolites often serve the plant as anti-microbial substances, the anti-
fungal activity against Cladosporium sphaerospermum (see chapter 4.1.8.6.), the anti-
bacterial effect against six strains of Staphylococcus aureus (see chapter 4.1.8.7.) and the 
insecticidal activity against Spodoptera littoralis (see chapter 4.1.8.5.) of KK1 was 
evaluated. KK1 did not show any effect in these assays.  
An in silico guided search for possible anti-viral activities of compound KK1 was 
undertaken because compounds with the extremely uncommon structural part of 
methylenecyclopropane have shown anti-viral activity against Epstein-Barr-, Human 
Herpes-, Hepatitis B-, Human Immunodeficiency- and Human Cytomegalo Virus in vitro 
(Rybak et al., 2000, Qiu et al., 1998, Uchida et al., 1999). Pharmacophoric profiling 
(Rollinger et al., 2009) and a structural similarity search in the MDL Drug Data Report 
(MDDR) database (Keiser et al., 2007) suggested α-glucosidase as potential target for KK1. 
The antiviral activity against Herpes simplex Virus 1 was determined (see chapter 
4.1.8.4.), but KK1 remained without any effect. 
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As compound KK1 did not show any activity in the evaluated assays, its aglycon was 
tested for biological activities. KK1 was hydrolysed and the effect on cancer cell viability 
of the KK1-aglycon was evaluated showing stronger activity than compound KK1 (see 
chapter 4.1.8.1.). The other experiments on anti-fungal, anti-viral and insecticidal activity 
need to be repeated with the aglycon of KK1 as well. 
 
To sum up the phytochemical investigation of a fraction from the water extract of 
Metaxya rostrata, two unsusual new compounds - (2E)-2-(6-hydroxyhexyliden)-
cyclopropyl-β-glucopyranoside (KK1) and (6E)-6[2-(β-glucopyranosyloxy)cyclopropylidene] 
hexanoic acid (KK5) -, with the very uncommon structural feature of a 
methylenecyclopropane alcohol in the aglycon, two phenolic acid glycosides - 4-O-ß-D-
glucopyranosyl-caffeic-acid (KK3) and 4-O-ß-D-glucopyranosyl-p-trans-coumaric-acid 
(KK6) - and a methyl-α-fructofuranosid (KK7) were isolated for the first time from the tree 
fern Metaxya rostrata.  
 
5.2 Bioactivity-guided fractionation and isolation of the active compounds of 
Metaxya rostrata  
The second objective of this study was a bioactivity-guided fractionation and isolation of 
the active principles of Metaxya rostrata. The water extract, which is used in traditional 
medicine, had already been analysed in a previous work (Virtbauer 2007). To extract the 
secondary metabolites of this plant as exhaustive as possible within this study, the dried 
and powered leaves, rootlets and rhizomes of Metaxya rostrata were extracted with 
solvents of different polarity (CH2Cl2, EA and MeOH).  
After every step of fractionation the obtained fractions were evaluated for their effect on 
cancer cell viability on SW480, a colon cancer cell line. The most active extracts and 
fractions were chosen for further separation. The CH2Cl2-extract and the EA-extract of the 
rootlets, the EA-extract of the leaves and the MeOH-extracts of the rhizomes of Metaxya 
rostrata reduced the cell viability significantly and cell loss was not due to necrosis (see 
chapter 4.2.2.1.). 
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Thus, these four extracts were fractionated by column chromatography on Sephadex LH-
20. As chlorophyll and tannins are known to interact unspecifically with different proteins 
(Chernomorsky et al., 1999; Lee et al., 1990; Silvia et al., 1998) and in order to exclude 
false positive results, chlorophyll was removed from the EA-extract of the leaves using 
liquid-liquid partition before further fractionation. From the methanol extract of the 
rhizomes tannins were removed before column chromatography (Wall et al., 1996). 
 The obtained fractions after with column chromatography on Sephadex LH-20 were 
evaluated for their effect on cancer cell viability. Fractions of the CH2Cl2-extract CC-9/3, 
CC-9/4, CC-9/5, CC-9/6 and CC-9/8 showed a significant dose-dependent reduction of cell 
viability at a concentration of 0,6µg/ml (see chapter 4.2.3.). The fractions of the EA-
extract of the rootlets CC-10/2, CC-10/3, CC-10/4 and CC-10/5 reduced the cell number in 
a significant manner at the same concentration (see chapter 4.2.4.). The fractions of the 
EA-extract of the leaves CC-11/3, CC-11/7, CC-11/8 and CC-11/9 revealed a reduction of 
cell viability at a concentration of 6µg/ml (see chapter4.2.5.). Fractions CC-12/3 to CC-
12/10 of the MeOH-extract of the rhizomes reduced cell viability significantly only at a 
concentration of 60µg/ml (see chapter 4.2.6.). All the other fractions showed lower or no 
effect on cell viability. 
Due to the high activity and the pattern of compounds, the pooled fractions CC-9/3 and 
CC-9/4 of the CH2Cl2-extract of the rootlets of Metaxya rostrata were selected for further 
fractionation and isolation of the active compounds. Due to the small amount of these 
fractions, new plant material was extracted and fractionated in the same way to obtain a 
bigger amount of the active fractions (see chapter 4.2.8.1.). 
Fractions CC-13/5, CC-13/6, CC-13/7, CC-13/8, CC-13/14 and CC-13/15 reduced the cell 
viability in a significant manner at a concentration of 6µg/ml (see chapter4.2.8.1.). A TLC 
comparison of the active fractions from the first CH2Cl2–extract and the active fractions 
from the new CH2Cl2–extract showed some similarity, but due to some compounds 
occurring in one of the extracts only, the fractions were further fractionated separately 
using solid phase extraction (SPE).  
The obtained fractions after SPE separation were again evaluated for their activity on cell 
viability. SPE-fractions SPE-3/3, SPE-3/4, SPE-5/2, SPE-6/2 of the new CH2Cl2–extract and 
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the SPE-fractions SPE-7/3 and SPE-8/4 of the first CH2Cl2–extract showed the highest 
activity and were chosen for the identification of the active principles by HPLC and 
spectroscopic methods. 
In fractions SPE-3/4 of the new CH2Cl2–extract and SPE-7/3 of the first CH2Cl2–extract, the 
main compound eluting at Rt 42,5min was identified as betulinic acid by comparison the 
authentic reference. Betulinic acid was the major compound in these fractions with a 
purity of more than 98% and thus identified as the active principle. Betulinic acid, a 
pentacyclic triterpenoid widely distributed in plant kingdom, is a very well studied natural 
compound with a wide range of biological effects. Betula alba L., which contains high 
amounts of betulinic acid was already used by native americans to treat stomach and 
intestinal problems (Fulda 2008). Betulinic acid is known to be cytotoxic against 
melanoma, neuroectodermal and malignant brain tumor cell lines (Zuco et al., 2001; 
Ciurlea et al., 2010; Fulda et al., 1997). Its cytotoxic effect on other types of cancer 
including glioblastoma, leukemia, colon, breast or cervix carcinoma was reported 
(Ehrhardt et al., 2004; Ren et al., 2010; Jung et al., 2007; Fulda 2008). The anti-cancer 
activity of betulinic acid is associated to its ability to induce apoptosis by triggering the 
mitochondrial pathway of apoptosis (Fulda 2008; Mullauer et al., 2009). 
In fractions SPE-3/3 of the new CH2Cl2–extract and SPE-8/4 of the first CH2Cl2–extract 
betulinic acid was identified as one of the major compounds as well. In fraction SPE-3/3 of 
the new CH2Cl2–extract a second main compound with a retention time at 11,5min was 
identified by MS as a tetrahydroxy-C-prenylxanthone. In fraction SPE-8/4 the second 
major compound at Rt 27min elucidated by MS analysis as a tetrahydroxy-di-C-
prenylxanthone. Due to the small amount of these fractions the two xanthone derivatives 
could not be isolated. Some prenylated xanthones exhibited inhibitory effects against 
Mycobacterium tuberculosis (Suksamrarn et al., 2003), had potent immunomodulatory 
activities (Ngoupayo et al., 2009), antiplasmodial activity (Mahabussarakam et al., 2006; 
Molinar-Toribio et al., 2006; Azebaze et al., 2006) and antioxidant scavenging activity 
against DPPH radicals (Chen et al., 2010). Furthermore, prenylated xanthones possess 
activity against MCF-7, NCI-H460 cell lines (Castanheiro et al., 2009), HeLa and MDA-MB-
231 cancer cell lines (Lim et al., 2011). α-Mangostin, the best studied prenylated 
xanthone from Garcinia mangostana, induced cell-cycle arrest in G1 and apoptosis 
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through the activation of intrinsic pathway in human colon cancer DLD-1 cells 
(Matsumoto et al., 2005; Akao et al., 2008).  
The activity of the fractions – SPE-3/3 of the new CH2Cl2–extract and SPE-8/4 of the first 
CH2Cl2–extract - could therefore be due to betulinic acid or to a synergistic effect of 
betulinic acid with the prenylated xanthones.  
In fraction SPE-5/2 of the new CH2Cl2–extract the major compound at Rt 24,5min was 
isolated and identified as 2-deprenyl-rheediaxanthone B using MS and NMR analysis. As 
2-deprenyl-rheediaxanthone B was the major compound with a purity of more than 98% 
in this fraction, it is certain that the high activity in the bioassay is due to that compound. 
2-Deprenyl-rheediaxanthone B is a very rare natural compound and has been isolated 
before only from two species of the family of the Guttiferae, from the roots of Rheedia 
benthamiana Pl. Triana (Monache et al., 1981) and the roots of Hypericum roeperanum 
Schimp. ex A. Rich. (Rath et al., 1996). Hostettmann and his group showed an anti-fungal 
activity against Candida albicans for this compound (Hostettmann et al., 1996), but no 
further biological activity of 2-deprenyl-rheediaxanthone B had been studied before 
making it an interesting compound for further investigations. 
The two main compounds at Rt 15,5min and 24,5min in fraction SPE-6/2 of the new 
CH2Cl2–extract were identified by MS analysis as tetrahydroxy-C-prenylxanthone and as 2-
deprenyl-rheediaxanthone B. Both compounds were already identified in other active 
fractions. In fraction SPE-5/2 2-deprenyl-rheediaxanthone B was identified as the active 
principle. Tetrahydroxy-C-prenylxanthone was identified in fraction SPE-3/3 together with 
betulinic acid. The activity of fraction SPE-6/2 is probably due to 2-deprenyl-
rheediaxanthone B or to a synergistic effect with the other xanthone derivative. 
The bioactivity-guided approach led to the isolation of betulinic acid and 2-deprenyl-
rheediaxanthone B. These compounds were elucidated as active principles in the 
cytotoxic fractions of the CH2Cl2-extract of the rootlets of Metaxya rostrata. As there is no 
data about the cytotoxicity of 2-deprenyl-rheediaxanthone B, this compound was chosen 
for detailed investigations to evaluate its biological effects and the underlying 
mechanisms. 
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5.3 Effect of 2-deprenyl-rheediaxanthone B on cell growth 
2-deprenyl-rheediaxanthone B showed a significant dose and time-dependent reduction 
of cell viability of SW480 cells at a concentration of 6µM. In the LDH assay no cytotoxicity 
due to necrosis was detected after 24 and 48 hours. After 72 hours some probably 
secondary necrotic effects were seen.  
2-deprenyl-rheediaxanthone B reduced the cell viability strongly in SW480 cell line. The 
effect on other cell lines was also studied. The compound significantly decreased the cell 
viability of CaCo-2, another colon carcinoma cell line, at a concentration of 10µM to about 
70% and also reduced the cell viability of LT97, a human colon adenoma cell line, to about 
85%at a concentration of 10µM and of human colon associated fibroblasts F331 to 75% at 
a concentration of 20µM. Compared to the effect of 2-deprenyl-rheediaxanthone B on 
cell viability of the colon carcinoma cell lines, SW480 and CaCo-2, the effect on the 
adenoma cell line LT97 and the fibroblasts was much weaker (see chapter 4.2.12.2.), 
making this compound very promising.  
 
5.4 Effect of 2-deprenyl-rheediaxanthone B on cell cycle 
Analysis of the cell cycle distribution after treatment with 2-deprenyl-rheediaxanthone B 
showed a concentration-dependent decrease of the proportion of cells in the G0-G1 
phase and a concentration dependent accumulation of SW480 cells in the G2-M phase 
after 48 and 72h, suggesting a G2-M phase arrest (see chapter 4.2.12.3.). Analysis of the 
protein levels of specific cell cycle regulatory proteins like cyclin A, cyclin E and cyclin B1 
by Western Blot analysis after exposure to 2-deprenyl-rheediaxanthone B confirmed that 
a cell cycle block had been induced. The cyclins are key regulators of the cell cycle as they 
activate members of the cyclin-dependent kinase (Cdk) family and effect cell cycle 
progression (Coverley et al., 2002). Cyclin A functions in S phase and mitosis, starts to 
accumulate during S phase, is abruptly destroyed before metaphase and reaches high 
levels in G2-phase (Pagano et al., 1992; Yam et al., 2002). Cyclin E is needed for G1/S 
transition, cylcin B1 is the regulatory subunit of M-phase promoting factor and its correct 
regulation is essential for the initiation of mitosis (Pagano et al., 1992; Sanchez & 
Dynlacht, 2005; Yuan et al., 2004).  
Discussion 
 
147 
 
The 20 hours time point was chosen for Western Blot analysis because high cell loss was 
observed after 48 hours. Thus, 20 hours seemed a good time point for the observation of 
the responsible proteins. Due to the little amount of 2-deprenyl-rheediaxanthone B 
isolated, no other time points could be evaluated. 
After incubation of SW480 cells with 2-deprenyl-rheediaxanthone B for 20h, the results 
showed a large increase in the level of cyclin A and a slight increase in the level of cyclin 
B1 protein. The protein level of cyclin E was decreased compared to the control. These 
changes in the regulatory protein expression confirmed the G2-M phase cell cycle arrest 
also seen in FACS analysis. 
 
5.5 Effect of 2-deprenyl-rheediaxanthone B on apoptosis 
JC-1 FACS analysis was conducted to investigate the effect of 2-deprenyl-rheediaxanthone 
B on apoptosis. The loss of mitochondrial membrane potential is a hallmark for apoptosis 
and mitochondrial permeability transition is an important step in the induction of 
apoptosis. When the electrochemical gradient across the mitochondrial membrane 
collapses it causes a shift in fluorescence. In non-apoptotic healthy cells, JC-1 accumulates 
as aggregates in the mitochondria which stain red. Whereas in apoptotic cells, JC-1 exists 
in monomeric form and the cytosol is stained green (Smiley et al., 1991; Cossarizza et al., 
1993). 
Treatment with 2-deprenyl-rheediaxanthone B led to a concentration- and time- 
dependent loss of SW480 cells detected by JC-1 FACS analysis.  
Specific apoptosis markers were analyzed with Western Blot analysis after exposure to 2-
deprenyl-rheediaxanthone B. BAX and BAK are pro-apoptotic proteins and operate at 
both the mitochondria and endoplasmic reticulum to regulate the intrinsic apoptotic 
pathway (Ruiz-Vela et al., 2005; Oltvai et al., 1993). After incubation of SW480 cells with 
2-deprenyl-rheediaxanthone B for 20h, the results showed a slight increase in the levels 
of these pro-apoptotic proteins.  
Survivin is an apoptosis inhibitor and a cell cycle regulator. It is required for suppression 
of apoptosis and for normal cell division in the G2/M phase of the cell cylce (Zaffaroni et 
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al., 2005; Shin et al., 2001). Survivin protein level was decreased by XB compared to the 
control.  
BCL-XL and BCL 2 are anti-apoptotic proteins of the BCL 2 family which play an important 
role in inhibiting mitochondria dependent cell death pathways (Kim 2005) and have anti-
proliferative effects (Janumyan et al., 2003). After treatment with 2-deprenyl-
rheediaxanthone B for 20h, the protein levels of both BCL-XL and BCL 2 were upregulated. 
Caspase 3, is proteolytically activated in cells during apoptosis (Peng et al., 2004), but 
after treatment with 2-deprenyl-rheediaxanthone B for 20h, no increase of the active 
caspase 3 cleavage products was seen compared to the control. After activation of 
caspases from their proenzyme forms, they cleave different protein substrates during 
apoptosis such as PARP (Shin et al., 2000; Nicholson et al., 1995; Kaufmann et al., 1993). 
After incubation of the SW480 cells with 2-deprenyl-rheediaxanthone B for 20h, the PARP 
protein at 116 kDa could be detected, but no cleavage product at 85 kDa could be seen. In 
summary, these observations indicate that the mode of XB-induced cell death in SW480 
cells distinctly differs from classical apoptosis. The same conclusion is also supported by 
the morphological appearance of both cells and nuclei.  
After treatment with 2-deprenyl-rheediaxanthone B, morphological modifications of the 
cells such as cell shape alterations and cell detachment compared to the control were 
detected by light microscopy. After Hoechst staining and analysis with fluorescence 
microscopy morphological modifications such as changes in the size of the nuclei was 
observed. A large fraction of giant polyploid nuclei as well as apoptotic bodies could be 
detected (see chapter 4.2.12.5.).  
Upregulation of the anti-apoptotic proteins BCL-XL and BCL 2 further support the 
conclusion that the main mechanism of cell loss is not apoptosis. In contrast to caspase 3 
another caspase, caspase 2, was highly activated after treatment with 2-deprenyl-
rheediaxanthone B.  
It has been difficult to formally characterize caspase 2 as an initiator or an executor 
caspase because it has features of both groups (Zhivotovsky and Orrenius, 2005). Unlike 
other initiator caspases, caspase 2 does not activate executor caspases directly (Bouchier-
Hayes 2010). Its role in apoptosis seems to be stimulus- and/or cell type specific 
Discussion 
 
149 
 
(Bergeron et al., 1998), but there is evidence for potential roles of caspase-2 in other 
processes like DNA repair and cell cycle regulation (Vakifahmetoglu-Norberg and 
Zhivotovsky 2010). After incubation of SW480 cells with 2-deprenyl-rheediaxanthone B 
for 20h, the results showed an increase in the levels of the caspase 2 and activated 
caspase 2 compared to the control. 
There is evidence that in some cases, caspase 2 may be responsible for direct 
permeabilization of the mitochondria, which would explain our JC-1 FACS results. In other 
cases it may act in conjunction with BAX/BAK to amplify cytochrom C release (Zhivotovsky 
and Orrenius 2005). Different stimuli like DNA-damage inducers such as doxorubicin or 
cytoskeletal disruptors like paclitaxel, ER stress inducers like tunicamycin or others like 
resveratrol have been reported to activate caspase 2 (Bouchier-Hayes 2010). Exposure of 
doxorubicin, one of the most effective anti-tumor drugs, to human breast carcinoma cells 
induced polyploidy and cell death by mitotic catastrophe and activation of caspase 2 
(Mansilla et al., 2006). HCT116 colon carcinoma cells treated with doxorubicin undergo 
mitotic catastrophe as well (Chan et al., 1999; Castedo et al., 2004). Polyploidy and 
caspase 2 activation was also seen after treatment of SW480 cells with 2-deprenyl-
rheediaxanthone B in this study suggesting that mitotic catastrophe could be the reason 
of cell loss. 
It has been discussed that mitotic catastrophe is totally different from apoptosis 
(Roninson et al., 2001) because some manipulations preventing apoptosis, such as 
overexpression of BCL 2 in etoposide-treated HeLa cells (Lock and Stribinskiene 1996; 
Ruth and Roninson 2000), reduce apoptosis, while they enhance the frequency of 
catastrophic mitoses (Castedo et al., 2004). BCL 2 is reported to have the ability to 
enhance cell death in the interaction of BCL-XL with other factors. Kim discussed that BCL 
2 and BCL-XL may switch their anti-apoptotic function to a pro cell death function in some 
situations (Kim 2005). In case of metaphase associated death, caspase 2 activation can be 
detected even when apoptosis is suppressed and it can not be inhibited by BCL 2 (Castedo 
et al., 2004; Peart et al, 2003). Both, the protein levels of BCL-XL and BCL 2 were 
increased after treatment with 2-deprenyl-rheediaxanthone B which leads to the 
conclusion that SW480 cells treated with this compound die due to mitotic catastrophe.  
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There is also evidence that depletion of survivin led to a defect in mitosis, without any 
direct induction of apoptosis. Inhibition of survivin was reported in glioma cells to be 
followed by spontaneous apoptosis, mitotic catastrophe and cell cycle arrest and the 
downregulation of survivin led to mitotic catastrophe in esophageal cancer cells as well 
(Zhen et al., 2007; Ngan et al., 2008; Vakifahmetoglu et al., 2008). That indicates that the 
role of survivin as a protection from apoptosis is rather secondary to its role during 
mitosis (Castedo et al., 2004; Carvalho et al., 2003; Lens et al., 2003). In this study, 
downregulation of survivin after the treatment with 2-deprenyl-rheediaxanthone B was 
also seen. Castedo discussed that survivin may play an important role in the coupling of 
abnormal mitotic progression to the onset of mitotic catastrophe (Castedo et al., 2004). 
 
5.6 Effect of 2-deprenyl-rheediaxanthone B on checkpoint kinases  
After treatment of SW480 cells with 2-deprenyl-rheediaxanthone B, the levels of the DNA 
damage marker Chk1 and phosphorylated Chk1 were analyzed by Western Blot analysis. 
Chk1 is an essential component in the G2 damage checkpoint as it is activated in response 
to a variety of lesions and ensuring that Cdc2 remains in an inactive state until DNA repair 
is completed (Tapia-Alveal et al., 2009; Stracker et al., 2009). Cdc2, a subunit of the M-
phase promoting factor, induces entry into mitosis and is a key player in cell cycle 
regulation (Draetta et al, 1988). In late G2 phase Chk1 phosphorylates the protein 
phosphatase Cdc25C, which controls cell cycle transitions by dephosphorylating cyclin-
dependent kinases. In response to DNA damage, Chk1 phosphorylates and inhibits 
Cdc25C, thus preventing activation of the Cdc2/Cyclin B complex and mitotic entry 
(Sanchez et al., 1997; Graves et al., 2000; Abraham 2001). It is believed that mitotic 
catastrophe occurred when the G2 damage checkpoint is inhibited (Niida et al., 2005). 
However, there is now evidence that supports the multiplicity in the role of Chk1 in 
mitotic catastrophe. Huang and group reported that the mitotic exit damage checkpoint is 
Chk1 dependent and DNA damage not just delays mitotic exit but blocks it leading to 
mitotic catastrophe. Yamane and group showed that DNA damage induced mitotic 
catastrophe was mediated by Chk1 dependent mitotic exit. Thus, it seemed that 
checkpoint activation would result in an early event that was the mitotic exit followed by 
mitotic catastrophe (Huang et al., 2005; Yamane et al., 2007). Zhang and group reported 
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that exposure of human lung cancer cell line to 8-chloro-adenosine induced cell arrest in 
the G2/M phase accompanied by accumulation of polyployid cells and loss of 
phosphorylated Cdc25C that allows progression into mitosis. These results indicate a G2 
checkpoint failure (Zhang et al., 2004). G2 checkpoint failure promotes mitotic 
catastrophe (Roninson et al., 2001).  
After incubation of SW480 cells with 2-deprenyl-rheediaxanthone B for 20h, the results 
showed a large increase in the activation of phosphorylated Chk1 and total Chk1 
indicating a cell cycle arrest which was also proven by FACS analysis. It is reported that 
overexpression of Chk1 alone caused a G2 cell cycle arrest (Walworth et al., 1993). A 
slight increase in total Cdc 2 and phosphorylated Cdc2 could be detected and in 
correlation with the upregulation of Chk1, Cdc25C is blocked after treatment with 2-
deprenyl-rheediaxanthone B.  
As Chk1 is activated in response to different genomic lesions by ATR (Tapia-Alveal et al., 
2009; Bartek and Lukas, 2003), this protein was also evaluated in our study. After 
incubation of SW480 cells with 2-deprenyl-rheediaxanthone B for 20h, the results showed 
a slight increase in the activation of ATR. ATM seems not to be influenced in accordance 
with literature linking Chk1 with ATR. The reason for seeing just a slight increase of ATR 
could be that at the time point when the upregulation of Chk1 was detected, ATR protein 
levels are already declining again. As ATR is a classical mediator of damage response, the 
results could indicate DNA damage after treatment with 2-deprenyl-rheediaxanthone B, 
which needs to be further investigated. 
The forkhead transcription factor FoxM1 is an important regulator of gene expression 
during the G2 phase (Laoukili et al., 2008) and is essential for correct mitotic progression 
(Laoukili et al., 2005). Loss of the transcriptional factor FoxM1 affects genes that are 
essential for chromosome segregation, generates mitotic spindle defects, delays in 
mitosis and leads to mitotic catastrophe (Vakifahmetoglu et al., 2008; Wonsey et al., 
2005). A more precise marker of mitotic cells is phosphorylation at Ser10 of Histone H3 
which is tightly correlated with chromosome condensation in mitosis (Wei et al., 1999; 
Portugal et al., 2010). The incubation of SW480 cells with 2-deprenyl-rheediaxanthone B 
for 20h resulted in an almost complete loss of the FoxM1 protein compared to the control 
demonstrating the mechanistic basis for the delay of cells in late G2/M phase. 
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Phosphorylation at Ser10 of Histone H3 was also almost completely absent from giant 
nuclei, which indicates a defect in chromosome condensation and places the exact point 
of cell cycle arrest in late G2. Together these observations support the conclusion that 
SW480 cells treated with 2-deprenyl-rheediaxanthone B die due to mitotic catastrophe.  
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6 CONCLUSION 
In the phytochemical investigation of the presented study, two unusual novel compounds 
- (2E)-2-(6-hydroxyhexyliden)cyclopropyl-β-glucopyranoside (KK1) and (6E)-6[2-(β-
glucopyranosyloxy)cyclopropylidene] hexanoic acid (KK5) - with the very uncommon 
structural feature of a methylenecyclopropane alcohol in the aglycon, two phenolic acid 
glycosides - 4-O-ß-D-glucopyranosyl-caffeic-acid (KK3) and 4-O-ß-D-glucopyranosyl-p-
trans-coumaric-acid (KK6) - and a methyl-α-fructofuranosid (KK7) were isolated for the 
first time from the tree fern Metaxya rostrata.  
The present work also demonstrates for the first time the cytotoxicity of the rare natural 
compound 2-deprenyl-rheediaxanthone B, isolated from the rootlets of the traditional 
herbal remedy Metaxya rostrata and gives insight into the underlying mechanism of 
action. The present study shows that 2-deprenyl-rheediaxanthone B significantly reduces 
cell viability in the SW480 cell line, but does not affect normal fibroblasts as much, thus 
making this compound very promising. 
After treatment with 2-deprenyl-rheediaxanthone B a G2-M phase arrest and a large 
number of giant polyploid nuclei as well as apoptotic bodies were detected. 2-deprenyl-
rheediaxanthone B treatment did not affect caspase 3 and did not lead to PARP cleavage. 
An upregulation of the protein levels of caspase 2, BCL 2, BCL-XL, BAX, BAK, ATR, Chk1 
was observed. Survivin was downregulated and FoxM1, phospho Histone H3 and Cdc25C 
were blocked completely compared to the control.  
The results indicate that the cell loss after treatment of SW480 cells with 2-deprenyl-
rheediaxanthone B is due to mitotic catastrophe. 
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7 SUMMARY 
Natural products deriving from plants used in traditional medicine are an important 
source for anti-cancer agents or new lead-compounds. The structural relatives of natural 
compounds provide over 50% of drugs in current clinical use. Therefore the aim of this 
study was to identify the active principles in the tree fern Metaxya rostrata, which is used 
as a herbal remedy against intestinal diseases in Costa Rica.  
Metaxya rostrata was investigated phytochemically and fractionated in a bioactivity-
guided approach. The phytochemical investigation of a fraction from a water extract led 
to the isolation of two unusual new compounds - (2E)-2-(6-hydroxyhexyliden)cyclopropyl-
β-glucopyranoside and (6E)-6[2-(β-glucopyranosyloxy)cyclopropylidene] hexanoic acid - 
with the very uncommon structural feature of a methylenecyclopropane alcohol in the 
aglycon. In addition, two phenolic acid glycosides - 4-O-ß-D-glucopyranosyl-caffeic-acid 
and 4-O-ß-D-glucopyranosyl-p-trans-coumaric-acid - and a methyl-α-fructofuranosid were 
isolated for the first time from Metaxya rostrata.  
The bioactivity-guided approach led to the isolation of the cytotoxic principles betulinic 
acid and 2-deprenyl-rheediaxanthone B (XB), which is a very rare natural compound. The 
present study shows cytotoxic activity of XB for the first time and provides insight into the 
underlying mechanism. XB reduced the cell viability in the SW480 colon carcinoma cell 
line, but affected adenoma cells and normal fibroblasts much less, suggesting a very 
promising compound. Treated cells were arrested in G2-M phase causing appearance of 
giant polyploid nuclei as well as apoptotic bodies. Treatment with 2-deprenyl-
rheediaxanthone B did not affect caspase 3 and did not lead to PARP cleavage indicating 
that cell loss is not due to apoptosis even though BAX and BAK were up-regulated and 
survivin was decreased. An upregulation of the protein levels of caspase 2, BCL 2, BCL-XL, 
ATR, Chk1 compared to the control was detected and FoxM1, phospho Histone H3 and 
Cdc25C were blocked completely.  
These results indicate that 2-deprenyl-rheediaxanthone B induced reduction of cell 
viability due to mitotic catastrophe. The present work anticipates future studies to further 
elucidate the potential of 2-deprenyl-rheediaxanthone B and other xanthones for the 
development of novel anti-cancer drugs. 
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8 ZUSAMMENFASSUNG 
Naturstoffe aus ethnomedizinisch verwendeten Arzneipflanzen sind eine wichtige Quelle 
für neue Medikamente in der Krebstherapie, sodass pflanzliche Leitsubstanzen und von 
ihnen abgeleitete chemische Verbindungen über 50% aller klinisch verwendeten 
Chemotherapeutika ausmachen. Aus diesem Grund wurde der Baumfarn Metaxya 
rostrata, der in der traditionellen Medizin in Costa Rica bei Erkrankungen des Magen-
Darm-Trakts Anwendung findet, untersucht. 
 
Metaxya rostrata wurde phytochemisch untersucht und in einem zweiten Ansatz auch 
bioactivity-geleitet fraktioniert. Die phytochemische Untersuchung führte zur Isolierung 
zweier außergewöhnlicher neuer Substanzen - (2E)-2-(6-hydroxyhexyliden)cyclopropyl-β-
gluco pyranosid and (6E)-6[2-(β-glucopyranosyloxy)cyclopropyliden] hexan säure – mit 
dem ungewöhnlichen Strukturmerkmal eines Methylencyclopropanalkohols im Aglycon. 
Außerdem wurden zwei Phenolcarbonsäureglycoside - 4-O-ß-D-glucopyranosyl-
Kaffeesäure and 4-O-ß-D-glucopyranosyl-p-trans-Cumarsäure - sowie Methyl-α-
fructofuranosid zum ersten Mal aus Metaxya rostrata isoliert.  
 
Die bioactivity-geleitete Fraktionierung führte zur Isolierung der zwei zytotoxischen 
Verbindungen Betulinsäure und 2-Deprenyl-rheediaxanthone B (XB), eines sehr seltenen 
Naturstoffes. Die Arbeit weist zum ersten Mal Zytotoxizität von 2-Deprenyl-
rheediaxanthone B nach und gibt Einblick in den zellulären Wirkmechanismus dieser 
Substanz. Die Überlebensfähigkeit von SW480 Kolonkarzinomzellen wurde durch 
Behandlung mit XB signifikant reduziert, während Adenomzellen und normale 
Fibroblasten deutlich weniger betroffen waren. Diese selektive Wirkung macht XB zu 
einer vielversprechenden Verbindung. Behandelte Zellen sind in der G2/M Phase 
arretiert, wodurch sich große polyploide Zellkerne sowie apoptotische Kerne anhäufen. 
Obwohl die pro-apoptotischen Protein BAX und BAK hochreguliert werden und Survivin 
reduziert wird, spricht eine fehlende Aktivierung von Caspase 3 und die Abwesenheit von 
PARP Spaltprodukten gegen das Vorliegen von Apoptose in mit XB behandelten Kulturen. 
Hochregulation von Caspase 2, BCL 2, BCL-XL, ATR, Chk1 im Vergleich zu Kontrollzellen, 
sowie ein kompletter Verlust von FoxM1 und Cdc25C wurden beobachtet. Diese 
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Ergebnisse beweisen, dass mitotische Katastrophe für die Induktion des Zelltodes nach 
Behandlung mit 2-Deprenyl-rheediaxanthone B verantwortlich ist. Weitere Studien an 
dieser wirksamen Verbindung und an der Substanzklasse der Xanthone könnten das 
Potential dieser Verbindungen für die Entwicklung neuer Krebstherapeutika evaluieren.  
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S2 
Experimental Procedures 
All NMR spectra were recorded on a Bruker Avance DRX 600 NMR spectrometer using a 5 
mm switchable quadruple probe (QNP, 1H, 13C, 19F, 31P) with z axis gradients and 
automatic tuning and matching accessory. The resonance frequency for 1H NMR was 
600.13 MHz, for 13C NMR 150.92 MHz. All measurements were performed for a solution 
in fully deuterated methanol at 298 K. Standard 1D and gradient-enhanced (ge) 2D 
experiments, like double quantum filtered (DQF) COSY, TOCSY, NOESY, HSQC, and HMBC, 
were used as supplied by the manufacturer. Chemical shifts are referenced internally to 
the residual, non-deuterated solvent signal for 1H (d = 3.31 ppm) or to the carbon signal 
of the solvent for 13C (d = 49.00 ppm)  The analysis of the 1H–1H coupling constants (given 
in Hertz) were supported by the program Spin-Works (provided by Kirk Marat, University 
of Manitoba, Canada).  
Single crystal X-ray structure analysis was performed on a Bruker X8 APEXII CCD 
diffractometer with graphite-monochromated MoK radiation,  = 0.71073 Å. 
 
Compound KK1: (1R,2E)-2-(6-hydroxyhexyliden)cyclopropyl-β-D-glucopyranoside 
X-ray: C15H26O7, Mr = 318.36, monoclinic, space group P21 (no.4), a = 9.5033(10),  
b = 8.4361(13), c = 20.625(3) Å, V = 1631.5(4) Å3, Z = 4, calc = 1.296 g/cm
3,  = 0.102 mm-1 
 
    Figure S1: ORTEP plot of compound KK1 (50% probability ellipsoids) 
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Table S1: Atomic coordinates for non-hydrogen atoms of compound KK1 
Atom x y z  Atom x y z 
O1A 0.58862 0.65502 0.82777  O1B 1.07454 0.60611 0.82215 
O2A 0.56711 0.48067 0.74237  O2B 1.05703 0.44365 0.73272 
O3A 0.75310 0.88307 0.90807  O3B 1.23613 0.82009 0.90726 
O4A 0.52487 0.22582 0.82940  O4B 1.01612 0.17673 0.81073 
O5A 0.63917 0.28790 0.96403  O5B 1.13081 0.22115 0.94854 
O6A 0.59558 0.60311 1.00604  O6B 1.06551 0.53600 0.99626 
O7A 0.24219 0.54544 0.20564  O7B 0.76214 0.49866 0.19955 
C1A 0.53009 0.50609 0.80457  C1B 1.01767 0.45898 0.79491 
C2A 0.59325 0.37170 0.84982  C2B 1.08204 0.32017 0.83707 
C3A 0.56980 0.40628 0.92038  C3B 1.05615 0.34309 0.90798 
C4A 0.62744 0.56906 0.94172  C4B 1.10581 0.50730 0.93363 
C5A 0.55695 0.69308 0.89196  C5B 1.03768 0.63527 0.88592 
C6A 0.60371 0.86117 0.90854  C6B 1.08558 0.80187 0.90626 
C7A 0.47106 0.55643 0.69196  C7B 0.98088 0.54991 0.68635 
C8A 0.44815 0.48762 0.62586  C8B 0.93853 0.49324 0.61913 
C9A 0.33337 0.46897 0.66537  C9B 0.82481 0.51268 0.65918 
C10A 0.49120 0.47147 0.56871  C10B 0.97676 0.44693 0.56309 
C11A 0.40738 0.39557 0.50841  C11B 0.87602 0.38886 0.50431 
C12A 0.38125 0.50916 0.44971  C12B 0.88949 0.47948 0.44148 
C13A 0.31746 0.42537 0.38579  C13B 0.79374 0.41242 0.38028 
C14A 0.29584 0.53501 0.32601  C14B 0.82110 0.48914 0.31656 
C15A 0.25054 0.44436 0.26260  C15B 0.72917 0.42027 0.25611 
 
Table S2: Bond lengths for compound KK1 (Å) 
Bond Length  Bond Length 
O1A-C1A 1.4249  O1B-C1B 1.4316 
O1A-C5A 1.4409  O1B-C5B 1.4363 
O2A-C1A 1.4008  O2B-C7B 1.4201 
O2A-C7A 1.4191  O2B-C1B 1.3993 
O3A-C6A 1.4333  O3B-C6B 1.4358 
O4A-C2A 1.4231  O4B-C2B 1.4287 
O5A-C3A 1.4316  O5B-C3B 1.4382 
O6A-C4A 1.4369  O6B-C4B 1.4265 
O7A-C15A 1.4433  O7B-C15B 1.4196 
O3A-H3A 0.8400  O3B-H3B 0.8400 
O4A-H4A 0.8400  O4B-H4B 0.8400 
O5A-H5A 0.8400  O5B-H5B 0.8400 
O6A-H6A 0.8400  O6B-H6B 0.8400 
O7A-H7A 0.8400  O7B-H7B 0.8400 
C1A-C2A 1.5279  C1B-C2B 1.5260 
C2A-C3A 1.5356  C2B-C3B 1.5343 
C3A-C4A 1.5169  C3B-C4B 1.5298 
C4A-C5A 1.5405  C4B-C5B 1.5316 
C5A-C6A 1.5086  C5B-C6B 1.5154 
C7A-C9A 1.5244  C7B-C9B 1.5304 
C7A-C8A 1.4651  C7B-C8B 1.4598 
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C8A-C10A 1.3161  C8B-C10B 1.3256 
C8A-C9A 1.4724  C8B-C9B 1.4723 
C10A-C11A 1.5063  C10B-C11B 1.4996 
C11A-C12A 1.5323  C11B-C12B 1.5278 
C12A-C13A 1.5314  C12B-C13B 1.5387 
C13A-C14A 1.5282  C13B-C14B 1.5247 
C14A-C15A 1.5157  C14B-C15B 1.5169 
C1A-H1A 1.0000  C1B-H1B 1.0000 
C2A-H2A 1.0000  C2B-H2B 1.0000 
C3A-H3A 1.0000  C3B-H3B 1.0000 
C4A-H4A 1.0000  C4B-H4B 1.0000 
C5A-H5A 1.0000  C5B-H5B 1.0000 
C6A-H6A1 0.9900  C6B-H6B1 0.9900 
C6A-H6A2 0.9900  C6B-H6B2 0.9900 
C7A-H7A 1.0000  C7B-H7B 1.0000 
C9A-H9A1 0.9900  C9B-H9B1 0.9900 
C9A-H9A2 0.9900  C9B-H9B2 0.9900 
C10A-H10A 0.9500  C10B-H10B 0.9500 
C11A-H11A1 0.9900  C11B-H11B1 0.9900 
C11A-H11A2 0.9900  C11B-H11B2 0.9900 
C12A-H12A1 0.9900  C12B-H12B1 0.9900 
C12A-H12A2 0.9900  C12B-H12B2 0.9900 
C13A-H13A1 0.9900  C13B-H13B1 0.9900 
C13A-H13A2 0.9900  C13B-H13B2 0.9900 
C14A-H14A1 0.9900  C14B-H14B1 0.9900 
C14A-H14A2 0.9900  C14B-H14B2 0.9900 
C15A-H15A1 0.9900  C15B-H15B1 0.9900 
C15A-H15A2 0.9900  C15B-H15B2 0.9900 
 
Table S3: Bond angles for compound KK1 (°) 
Atoms Angle  Atoms Angle 
C1A-O1A-C5A 112.12  C1B-O1B-C5B 112.03 
C1A-O2A-C7A 112.00  C1B-O2B-C7B 112.09 
C6A-O3A-H3A 109.00  C6B-O3B-H3B 109.00 
C2A-O4A-H4A 109.00  C2B-O4B-H4B 109.00 
C3A-O5A-H5A 109.00  C3B-O5B-H5B 109.00 
C4A-O6A-H6A 109.00  C4B-O6B-H6B 109.00 
C15A-O7A-H7A 109.00  C15B-O7B-H7B 109.00 
O2A-C1A-C2A 108.27  O2B-C1B-C2B 108.02 
O1A-C1A-O2A 107.46  O1B-C1B-O2B 107.44 
O1A-C1A-C2A 110.86  O1B-C1B-C2B 110.55 
C1A-C2A-C3A 109.56  C1B-C2B-C3B 109.57 
O4A-C2A-C1A 110.23  O4B-C2B-C1B 108.84 
O4A-C2A-C3A 108.37  O4B-C2B-C3B 109.93 
C2A-C3A-C4A 110.23  C2B-C3B-C4B 110.82 
O5A-C3A-C2A 109.91  O5B-C3B-C2B 108.90 
O5A-C3A-C4A 109.96  O5B-C3B-C4B 110.57 
C3A-C4A-C5A 108.91  C3B-C4B-C5B 109.98 
O6A-C4A-C3A 109.18  O6B-C4B-C3B 110.71 
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O6A-C4A-C5A 110.19  O6B-C4B-C5B 108.33 
C4A-C5A-C6A 114.03  C4B-C5B-C6B 113.54 
O1A-C5A-C4A 109.12  O1B-C5B-C4B 109.09 
O1A-C5A-C6A 108.66  O1B-C5B-C6B 107.78 
O3A-C6A-C5A 112.04  O3B-C6B-C5B 110.92 
C8A-C7A-C9A 58.97  C8B-C7B-C9B 58.94 
O2A-C7A-C9A 117.24  O2B-C7B-C9B 118.32 
O2A-C7A-C8A 118.94  O2B-C7B-C8B 117.67 
C7A-C8A-C10A 148.61  C7B-C8B-C10B 148.46 
C7A-C8A-C9A 62.53  C7B-C8B-C9B 62.92 
C9A-C8A-C10A 148.30  C9B-C8B-C10B 148.47 
C7A-C9A-C8A 58.50  C7B-C9B-C8B 58.14 
C8A-C10A-C11A 125.72  C8B-C10B-C11B 124.87 
C10A-C11A-C12A 112.49  C10B-C11B-C12B 113.06 
C11A-C12A-C13A 112.46  C11B-C12B-C13B 113.07 
C12A-C13A-C14A 113.43  C12B-C13B-C14B 112.95 
C13A-C14A-C15A 111.89  C13B-C14B-C15B 112.94 
O7A-C15A-C14A 111.99  O7B-C15B-C14B 108.81 
O1A-C1A-H1A 110.00  O1B-C1B-H1B 110.00 
C2A-C1A-H1A 110.00  O2B-C1B-H1B 110.00 
O2A-C1A-H1A 110.00  C2B-C1B-H1B 110.00 
O4A-C2A-H2A 110.00  O4B-C2B-H2B 110.00 
C3A-C2A-H2A 110.00  C1B-C2B-H2B 109.00 
C1A-C2A-H2A 110.00  C3B-C2B-H2B 109.00 
C2A-C3A-H3A 109.00  C2B-C3B-H3B 109.00 
O5A-C3A-H3A 109.00  O5B-C3B-H3B 109.00 
C4A-C3A-H3A 109.00  C4B-C3B-H3B 109.00 
O6A-C4A-H4A 110.00  O6B-C4B-H4B 109.00 
C3A-C4A-H4A 110.00  C3B-C4B-H4B 109.00 
C5A-C4A-H4A 110.00  C5B-C4B-H4B 109.00 
O1A-C5A-H5A 108.00  O1B-C5B-H5B 109.00 
C6A-C5A-H5A 108.00  C6B-C5B-H5B 109.00 
Atoms Angle  Atoms Angle 
C4A-C5A-H5A 108.00  C4B-C5B-H5B 109.00 
O3A-C6A-H6A1 109.00  O3B-C6B-H6B1 109.00 
C5A-C6A-H6A1 109.00  C5B-C6B-H6B1 109.00 
C5A-C6A-H6A2 109.00  C5B-C6B-H6B2 109.00 
O3A-C6A-H6A2 109.00  O3B-C6B-H6B2 109.00 
H6A1-C6A-H6A2 108.00  H6B1-C6B-H6B2 108.00 
C9A-C7A-H7A 116.00  C9B-C7B-H7B 117.00 
O2A-C7A-H7A 116.00  O2B-C7B-H7B 117.00 
C8A-C7A-H7A 116.00  C8B-C7B-H7B 117.00 
C8A-C9A-H9A2 118.00  C8B-C9B-H9B2 118.00 
C8A-C9A-H9A1 118.00  C8B-C9B-H9B1 118.00 
H9A1-C9A-H9A2 115.00  H9B1-C9B-H9B2 115.00 
C7A-C9A-H9A2 118.00  C7B-C9B-H9B2 118.00 
C7A-C9A-H9A1 118.00  C7B-C9B-H9B1 118.00 
C11A-C10A-H10A1 117.00  C11B-C10B-H10B1 118.00 
C8A-C10A-H10A1 117.00  C8B-C10B-H10B1 118.00 
C12A-C11A-H11A1 109.00  C12B-C11B-H11B1 109.00 
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C10A-C11A-H11A2 109.00  C10B-C11B-H11B2 109.00 
H11A1-C11A-H11A2 108.00  H11B1-C11B-H11B2 108.00 
C10A-C11A-H11A1 109.00  C10B-C11B-H11B1 109.00 
C12A-C11A-H11A2 109.00  C12B-C11B-H11B2 109.00 
C13A-C12A-H12A2 109.00  C13B-C12B-H12B2 109.00 
H12A1-C12A-H12A2 108.00  H12B1-C12B-H12B2 108.00 
C13A-C12A-H12A1 109.00  C13B-C12B-H12B1 109.00 
C11A-C12A-H12A1 109.00  C11B-C12B-H12B1 109.00 
C11A-C12A-H12A2 109.00  C11B-C12B-H12B2 109.00 
H13A1-C13A-H13A2 108.00  H13B1-C13B-H13B2 108.00 
C12A-C13A-H13A1 109.00  C12B-C13B-H13B1 109.00 
C14A-C13A-H13A1 109.00  C14B-C13B-H13B1 109.00 
C14A-C13A-H13A2 109.00  C14B-C13B-H13B2 109.00 
C12A-C13A-H13A2 109.00  C12B-C13B-H13B2 109.00 
C15A-C14A-H14A1 109.00  C15B-C14B-H14B1 109.00 
C13A-C14A-H14A2 109.00  C13B-C14B-H14B2 109.00 
H14A1-C14A-H14A2 108.00  H14B1-C14B-H14B2 108.00 
C13A-C14A-H14A1 109.00  C13B-C14B-H14B1 109.00 
C15A-C14A-H14A2 109.00  C15B-C14B-H14B2 109.00 
C14A-C15A-H15A1 109.00  C14B-C15B-H15B1 110.00 
H15A1-C15A-H15A2 108.00  H15B1-C15B-H15B2 108.00 
C14A-C15A-H15A1 109.00  C14B-C15B-H15B1 110.00 
O7A-C15A-H15A1 109.00  O7B-C15B-H15B1 110.00 
O7A-C15A-H15A2 109.00  O7B-C15B-H15B2 110.00 
 
Table S4: Torsion angles for compound KK1 (Å) 
Atoms Angle  Atoms Angle 
C5A-O1A-C1A-O2A -179.87  C5B-O1B-C1B-O2B 178.85 
C5A-O1A-C1A-C2A -61.73  C5B-O1B-C1B-C2B -63.51 
C1A-O1A-C5A-C4A 63.19  C1B-O1B-C5B-C4B 63.67 
C1A-O1A-C5A-C6A -171.92  C1B-O1B-C5B-C6B -172.64 
C7A-O2A-C1A-O1A -83.90  C7B-O2B-C1B-O1B -71.72 
C7A-O2A-C1A-C2A 156.31  C7B-O2B-C1B-C2B 169.00 
C1A-O2A-C7A-C8A -151.07  C1B-O2B-C7B-C8B -142.69 
C1A-O2A-C7A-C9A -83.27  C1B-O2B-C7B-C9B -74.98 
O1A-C1A-C2A-C3A 55.71  O1B-C1B-C2B-C3B 56.11 
O1A-C1A-C2A-O4A 174.88  O1B-C1B-C2B-O4B 176.34 
O2A-C1A-C2A-O4A -67.48  O2B-C1B-C2B-O4B -66.38 
O2A-C1A-C2A-C3A 173.36  O2B-C1B-C2B-C3B 173.39 
C1A-C2A-C3A-C4A -53.75  C1B-C2B-C3B-C4B -51.82 
O4A-C2A-C3A-O5A 64.58  O4B-C2B-C3B-O5B 66.78 
O4A-C2A-C3A-C4A -174.06  O4B-C2B-C3B-C4B -171.39 
C1A-C2A-C3A-O5A -175.11  C1B-C2B-C3B-O5B -173.66 
O5A-C3A-C4A-C5A 177.04  O5B-C3B-C4B-C5B 173.86 
C2A-C3A-C4A-O6A 176.08  C2B-C3B-C4B-O6B 172.69 
C2A-C3A-C4A-C5A 55.72  C2B-C3B-C4B-C5B 53.01 
O5A-C3A-C4A-O6A -62.59  O5B-C3B-C4B-O6B -66.45 
O6A-C4A-C5A-C6A 59.17  O6B-C4B-C5B-C6B 61.08 
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C3A-C4A-C5A-O1A -59.40  C3B-C4B-C5B-O1B -57.59 
O6A-C4A-C5A-O1A -179.13  O6B-C4B-C5B-O1B -178.71 
C3A-C4A-C5A-C6A 178.91  C3B-C4B-C5B-C6B -177.80 
O1A-C5A-C6A-O3A -58.97  O1B-C5B-C6B-O3B -58.22 
C4A-C5A-C6A-O3A 62.98  C4B-C5B-C6B-O3B 62.72 
O2A-C7A-C8A-C9A 106.13  O2B-C7B-C8B-C9B 108.03 
O2A-C7A-C8A-C10A -82.43  O2B-C7B-C8B-C10B -67.60 
C9A-C7A-C8A-C10A 171.44  C9B-C7B-C8B-C10B -175.62 
O2A-C7A-C9A-C8A -108.99  O2B-C7B-C9B-C8B -106.93 
C7A-C8A-C10A-C11A -170.39  C7B-C8B-C10B-C11B 177.14 
C9A-C8A-C10A-C11A -4.94  C9B-C8B-C10B-C11B 4.61 
C10A-C8A-C9A-C7A -171.52  C10B-C8B-C9B-C7B 175.62 
C8A-C10A-C11A-C12A 120.93  C8B-C10B-C11B-C12B 125.73 
C10A-C11A-C12A-C13A 170.84  C10B-C11B-C12B-C13B 175.96 
C11A-C12A-C13A-C14A -177.75  C11B-C12B-C13B-C14B -172.67 
C12A-C13A-C14A-C15A 172.73  C12B-C13B-C14B-C15B 178.63 
C13A-C14A-C15A-O7A -174.92  C13B-C14B-C15B-O7B -179.97 
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Figure S2: 1H NMR spectrum of compound KK1 (CD3OD, 600.13 MHz) 
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Figure S3: 13C NMR spectrum (ATP) of compound KK1 (CD3OD, 150.92 MHz) 
Supplementary Information 
 
S10 
 
 
 
Figure S4: (ge)-DQF-COSY spectrum of compound KK1 (CD3OD) 
 
 
 
Figure S5: TOCSY spectrum (100 ms MLEV-17 spinlock) of compound KK1 (CD3OD) 
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Figure S6: (ge)-HSQC spectrum (multiplicity edited) of compound KK1 (CD3OD) 
 
 
Figure S7: (ge)-HMBC spectrum of compound KK1 (CD3OD) 
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Figure S8: NOESY spectrum (800 ms mixing time) of compound KK1 (CD3OD) 
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Figure S9: Experimental (lower trace) and calculated (upper trace) 1H NMR spectra of compound KK1  
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KK5: (6E)-6[(2R)-2-(β-D-glucopyranosyloxy)cyclopropylidene]hexanoicacid 
(all NMR spectra show as impurity the plasticizer Di(2-ethylhexyl)-phthalate) 
 
Figure S10: 1H NMR spectrum of compound KK5 (CD3OD, 600.13 MHz) 
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Figure S11: Overlay 1H NMR spectra of compounds KK1 (upper trace) and KK5 (lower trace) 
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Figure S12: 13C NMR spectrum (ATP) of compound KK5 (CD3OD, 150.92 MHz) 
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Figure S13: (ge)-DQF-COSY spectrum of compound KK5 (CD3OD) 
 
 
 
Figure S14: (ge)-HSQC spectrum (multiplicity edited) of compound KK5 (CD3OD) 
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Figure S15: (ge)-HMBC spectrum of compound KK5 (CD3OD) 
 
 
 
Figure S16: NOESY spectrum (800 ms mixing time) of compound KK5 (CD3OD) 
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Figure S17: Structures of of compounds KK3, KK6 and KK7 
 
KK3: 4-O-β-D-glucopyranosyl-caffeic-acid 
KK6: 4-O-β-D-glucopyranosyl-p-trans-coumaric-acid 
KK7: methyl-α-fructofuranoside 
 
 
 
 
Table S5: 1H NMR (600.13 MHz) and 13C NMR (150.92 MHz) Data of KK3 and KK6 in CD3OD, KK7  
in CD3OD : CDCl3 = 1 : 1 ( in ppm; in parenthesis coupling constants in Hz) 
 
 KK3 KK 6 KK7 
 H    C H C H C 
1 4.853 d (7.5) 103.55 4.968 d (7.6) 101.86 3.718 d (12.1) 60.04 
    3.651 d (12.1)  
2 3.516 dd (7.5, 9.2) 74.80 3.472 m 74.83  108.61 
3 3.480 dd (9.2, 8.5) 77.55 3.472 m 77.94 4.024 d (4.0)  81.62 
4 3.413 dd (8.5, 9.7) 71.28 3.400 m 71.30 3.939 dd (5.9, 4.0)  77.93 
5 3.452 ddd (9.7, 2.2, 5.4) 78.41 3.472 m 78.23 3.879 ddd (5.9, 4.0, 2.9)  84.21 
6a 3.906 dd (12.1, 2.2) 62.40 3.900 dd (12.1, 2.2) 62.45 3.768 dd (12.1, 2.9)  61.84 
6b 3.720 dd (12.1, 5.4) 3.705 dd (12.1, 5.7) 3.641 dd (12.1, 4.0)  
1`  170.79  170.90 3.300 s 48.90 
2´ 6.319 d (15.9) 118.08 6.374 d (16.0)  117.96 
3’ 7.549 d (15.9) 145.91 7.616 d (16.0)  145.58 
4´  131.25  130.07 
5’ 7.103 d (2.1) 115.84 7.550 d (8.8)  130.68 
6’  148.54 7.122 d (8.8)  117.96 
7´  148.75  160.76 
8´ 7.203 d (8.4)  118.14 
9´ 7.039 dd (8.4, 2.1 122.08 
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Figure S18: (ge)-HSQC spectrum (multiplicity edited) of compound KK3 (CD3OD) 
 
 
 
 
Figure S19: (ge)-HSQC spectrum of compound KK6 (sample not pure; CD3OD) 
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Figure S20: (ge)-HSQC spectrum (multiplicity edited) of compound KK7 (sample not pure;  
CD3OD : CDCl3 = 1 : 1) 
 
 
 
 
 
Structure of compound XB – 2-deprenyl-rheediaxanthone B 
 
 
 
MS- analysis of compound XB: 
ESIMS m/z 329.0 [M + H]+; ESIMS2 (329.1 ) m/z 286.9 (21) [M – C3H6 + H]
+, 272.9 (100) [M – C4H8 
+ H]+, 248.9 (3); ESIMS m/z 327.0 [M - H]-; ESIMS2 (327.0 ) m/z 296.9 [M – CH2O - H]
- (100). 
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Multistage mass spectra (LC–ESI–IT-MSn) of 2-deprenylrheediaxanthone B: (A) positive ion mode 
MS1, (B) positive ion mode MS2 (329.1 ), (C) negative ion mode MS1, and (D) negative ion mode 
MS2 (327.0 ). 
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Figure S21: 13C NMR spectrum (ATP) of compound XB (CD3OD, 150.92 MHz) 
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Figure S22: 1H NMR spectrum of compound XB (CD3OD, 600.13 MHz)
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Figure S23: (ge)-HSQC spectrum (multiplicity edited) of compound XB (CD3OD) 
 
 
Figure S24: (ge)-HMBC spectrum of compound XB (CD3OD) 
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Figure S25: (ge)-DQF-COSY spectrum of compound XB (CD3OD) 
 
 
 
 
Figure S26: NOESY spectrum (800 ms mixing time) of compound XB (CD3OD)
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